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Staphylococcus (S.) aureus is a leading cause of hospital and community acquired 
infections. Strains of methicillin resistant S. aureus (MRSA) have emerged that are 
resistant to all but a few antibiotics, raising the specter of untreatable disease. 
Indicative of its medical importance, considerable data has been collected on S. 
aureus, including the whole genomic sequences of several strains with different 
resistance phenotypes, a diversity of transcriptome data, and a vast assortment of 
documented observations concerning the characteristics of mutants. These various 
types of data were analyzed to identify determinants of resistance to four types of 
clinically important antibacterial agents rifampin, β-lactams, vancomycin, and 
daptomycin that target respectively RNA polymerase, key cell wall synthesis 
enzymes, a fundamental cell wall precursor, and the cytoplasmic membrane. To 
elucidate regulatory networks, statistically over-represented patterns representing the 
binding sites of transcription factors were searched for in genomic sequences. To 
discover mechanisms of resistance, isogenic isolates displaying progressively 
increasing levels of resistance were sequenced using the method of whole genome 
shotgun sequencing. By consulting the large body of literature on S. aureus, it was 
possible to correlate observed genetic changes with transcriptome and phenotypic 
changes using various statistical methods. The identified determinants of resistance 
and their potentially complex pleitropic effects are discussed in some detail.            
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Chapter 1  
Introduction 
 
In natural history, examples abound of arms races: on land, the wolverine evolved a 
keen sense of smell that helps it to sniff out prey whereas the porcupine developed 
quills to discourage predators; in water, the alligator acquired a strong jaw that can 
crush quarry whereas the tortoise attained a hard shell for protection; and in soil, 
microbes have arisen that secrete chemical compounds that kill other microbes. Since 
natural history has been shaped by the coevolution of predators and their prey trying to 
outdo one another and by the competition of species for the same niche, it can be 
argued that virtually every kind of organism has at one time engaged in an arms race, 
with us humans being no exception. Indeed, we humans are today engaged in an 
escalating arms race, pitting the ingenuity of our species to develop antibiotics that kill 
bacterial pathogens against the tremendous capacity of these pathogens to evolve 
antibiotic resistance. One bacterial pathogen that has shown a remarkable ability to 
evolve antibiotic resistance is Staphylococcus (S.) aureus. Due to its clinical 
importance, S. aureus has been the subject of many studies, which have generated 
copious amounts of biological data. By mining this data, bioinformaticans can help to 
better understand the mechanisms of antibiotic resistance in S. aureus. 
 
1.1. The impact of antibiotics 
 
While it is generally a good idea to avoid such grandiose statements, it is often said 
that the development of antibiotics was the most important advancement in the history 
of medicine [1-3]. Before antibiotics, unstoppable bacterial disease would ravage 
whole nations. The development of the first medically important antibiotics   2 
represented a turning point, spawning whole industries and transforming public health 
across the globe.  
 
Over the eons, people have had to endure innumerable epidemics and pandemics 
caused by bacterial pathogens. It is estimated that 75 million people worldwide in the 
mid-late-14
th century died from the so called “Black Death”, thought to have been 
caused by Yersinia pestis. Included in this death toll is one to two thirds of the entire 
population of Europe [4]. Still, this figure pales in comparison with the more than one 
billion people worldwide in the 19
th and 20
th centuries that are reckoned to have died 
from Mycobacterium tuberculosis [5]. Nearly a million people in Russia from 1852-
1860 [6] and 5.5% of the population of Chicago in 1854 [7] died from Vibrio Cholera. 
An American in the 1800s had a 30% chance of dying from one of the bacterial 
diseases tuberculosis, pneumonia, and gastrointestinitis, which at the time were the 
three leading causes of mortality [8]. Moreover, even a simple cut or burn could be 
fatal if it became infected with Staphylococci or Streptococci.  
 
In the early-mid-20
th century, people’s prospects began to look up when the first 
medically important antibiotics were developed. Derived from the latin term “anti 
bios” meaning “against life”, the term antibiotic refers to any agent that kills or slows 
the growth of bacteria or fungi. Some medically important antibiotics are man-made 
synthesized compounds with no known analogs in Nature, but most are derivatives of 
natural products produced and secreted by microorganisms to kill or inhibit the growth 
of other competing microorganisms [8]. The first medically important antibiotic to be 
discovered, namely penicillin, is produced by a fungus Penicillium chrysogenum [9]. 
Though Alexander Fleming discovered penicillin in 1929, he was unable to purify 
significant quantities of the drug, and it was not until the early 1940s during World   3 
War II that penicillin came to be widely used when the mass production of the drug 
became a priority [9]. In World War I, it is estimated that about 15% of the war related 
fatalities were due to battle wounds infected by bacteria, mostly Staphylococci and 
Streptococci [9]. In World War II, the mass production and use of penicillin reduced 
the war related death rate due to wound infection to nearly zero [9]. Encouraged by the 
success of penicillin, laboratories raced to find other low molecular weight compounds 
with potent antibacterial activity. In the 1940s and 1950s, the antibiotics streptomycin, 
chloramphenicol, and tetracycline were isolated from a major group of antibiotic 
producing bacteria, the soil dwelling actinomycetes. Streptomycin was the first 
antibiotic effective against Mycobacterium tuberculosis [10]. Unlike penicillin and 
streptomycin which were narrow spectrum antibiotics, chloramphenicol [11] and 
tetracycline [12] proved to be broad spectrum antibiotics that were effective against a 
long list of bacterial pathogens. 
 
Not surprisingly, the production and sale of antibiotics evolved into a mammoth 
enterprise. In the mid-1900s, the bulk suppliers of antibiotics such as Pfzier, Merck, 
Eli Lilly, etc. enjoyed huge profits and joined the ranks of the world’s largest 
corporations, becoming part of what is today referred to as “big pharma” [13]. From 
1949 onwards, veterinarians experimented with antibiotics and found that low dosages 
of antibiotics could speed growth in healthy animals for reasons still debated today. 
Shortly thereafter, antibiotics came to be widely used as growth promoters in the 
agricultural livestock industry [14]. In recent times, antibiotic usage has reached 
staggering proportions. Each year in the 1980s in the USA, people consumed about 
200 million doses of antibiotics, and about half of the 20,000 tons of antibiotics 
produced were used in sub-therapeutic doses as growth promoters for farm animals 
[15]. In 2000, the worldwide sales of antibiotics topped 20 billions dollars [8].    4 
 
Looking back at the 20
th century, it is difficult to estimate the sheer number of 
people’s lives that have been saved by antibiotics. From 1900 to 1980, infectious 
disease morality fell by more than 20-fold from 797/100,000 to 36/100,000 in the 
developed world [8]. However, these numbers need to be interpreted carefully since 
they include not only bacterial and fungal infections but also viral infections, against 
which antibiotics are ineffective. Moreover, the declining death rate can be attributed 
to a myriad of improvements in public health. Today, pestilence continues to wreak 
havoc in the developing world due to a combination of factors, including lack of 
access to life saving medications and vaccinations as well as appalling sanitary 
conditions. What is clear is that antibiotics have had a profound impact on the quality 
of human life. Because of antibiotics, what were once terrifyingly deadly bacterial 
diseases are usually easily treatable. Gone are the days in the USA when the three 
main causes of death were the bacterial diseases tuberculosis, pneumonia, and 
gastrointestinitis. At the end of the 20
th century, only one of the top 10 causes of 
mortality in the USA was due to a bacterial infection, namely lower respiratory tract 
infections [8]. Today, affluent people with access to basic medications do not worry 
about dying from bacterial infections but rather heart disease or cancer. What is more, 
surgeons now attempt more dangerous operations without fear that the patient will 
develop a deadly Staphylococci or Streptococci infection, since such infections can 
usually be prevented with antibiotics. After transplant surgery, immunosuppressant 
drugs can be given to a patient to prevent organ rejection, and antibiotics can be used 
to prevent the bacterial infections that would otherwise develop in the patient as a 
result of his or her compromised immune system.   
 
   5 
1.2. The emergence of antibiotic resistance 
 
Such was the dramatic success of antibiotics that the US Surgeon General William 
Stewart proclaimed in 1969 that the war with pestilence was over and that it “was time 
to close the books on infectious disease.” [16] One thing Stewart did not account for is 
the incredible capacity of bacteria to adapt. As bacteria rapidly divide, mutants 
inevitably arise. Instead of eradicating bacterial disease, the massive use of antibiotics 
in humans and animals selected for antibiotic resistant mutants. Today, drug resistant 
bacterial infections have become common, limiting therapeutic options.  
 
In nutrient rich conditions, some bacteria can divide on the order of once every hour 
[17], quickly reaching enormous numbers. According to experts, it is plausible that 
many blood-borne infections are initiated by a single bacterium entering the blood and 
evading the immune system. In a human, a systematic blood-borne infection can 
consist of as many as 10
9 bacteria [personal communication with Professor Alexander 
Tomasz, Rockefeller University]. A bacterium dividing once per hour can grow into 
10
9 cells in log2(10
9) × 1 hr = 30 hr. Human nasal mucous can contain 10
3 to 10
6 
bacteria/ml [18] whereas cattle manure can contain as many as 10
10 bacteria per gram 
of dry weight [19]. 
 
In a growing population of bacteria, mutants can arise due to errors in DNA 
replication. The genome of a bacterium is typically on the order of L = 10
6 bases [20]. 
When a bacterium divides, the DNA replication machinery on average makes one 
mistake in 10
7 bases [8]. Thus, the probability  1 P  that a given base in the genome is 
mutated during a division is  1 P  = 
7 10
- . As a bacterium divides into N  = 
9 10  bacteria, 
the probability  2 P  that a given base in the genome will be mutated at least once is  2 P  =   6 
1 –
1
1 (1 )
N P
- -  = 1 –  ( ) 1 exp 1 N P - -      = 1 –  ( )
2 exp 10 - . (The approximation (1 )
b a +  
= exp( ) ab  for 
2 a  ≪ 1/b and a ≪ 1 is used, which can be derived by taking the 
logarithm of (1 )
b a +  and using the Taylor series expansion.) The probability  3 P  that 
every base in the genome will be mutated at least once is  3 P  =  2
L P  =  ( )
2 1 exp 10
L
  - -    
=   ( )
2 exp exp 10 L   -   =  ( )
6 2 exp 10 exp 10   -   = 1. In other words, a bacterium that 
goes on to divide into 10
9 bacteria is expected to produce mutants polymorphic at 
every locus. Some of the mutations may confer antibiotic resistance: sometimes, a 
single amino acid change in a protein can alter the protein’s binding affinity for an 
antibiotic, or alternatively, an amino acid change in an efflux pump may change the 
pump’s specificity so that it transports out a toxic antibiotic instead [8].  
 
In contrast to the typically single base changes that are produced by errors in DNA 
replication, substantial changes in the content of the genome of a bacterium can occur 
by the mechanism of lateral gene transfer, which involves the bacterium acquiring and 
incorporating into its genome DNA from other bacteria of the same or different 
species. Since most of the major classes of antibiotics used against bacteria were 
derived from natural products produced by microbes, bacteria in the environment 
provide a large reservoir of genes that confer antibiotic resistance. In cases where an 
antibiotic producing microbe is itself a bacterium, the microbe often has genes 
conferring antibiotic resistance so as to prevent its own suicide. When the antibiotic 
producing microbe is a non-bacterium, often the microbe has coevolved long enough 
with some type of bacterium so that the bacterium has had time to develop specialized 
antibiotic resistance genes. One bacterium may acquire from another bacterium any 
combination of genes that code for: enzymes that inactivate antibiotics, efflux pumps 
that transport out antibiotics, and/or proteins that can take over or circumvent the 
functions of proteins inhibited by antibiotics [8].   7 
 
Over time, the widespread use of antibiotics has led to the emergence of antibiotic 
resistant bacteria. Though an antibiotic may wipe out most of the bacteria in a large 
population, bacteria with mutations conferring resistance to the antibiotic survive and 
proliferate. After the first antibiotics were introduced into the clinic, it did not take 
long for bacteria resistant to the antibiotics to be observed in clinical specimen. Only a 
few years after penicillin became widely used, there were already reports in 1947 of 
penicillin resistant Staphylococcus (S.) aureus infections [21]. When streptomycin 
became available for the treatment of Mycobacterium tuberculosis (TB) in the mid-
late-1940s, it was immediately clear the drug was not a panacea. The drug would in 
many patients clear a TB infection for only a few months before the infection evolved 
resistance and returned with a vengeance [5]. Today, there are strains of S. aureus that 
have evolved resistance to all but a few antibiotics, raising the specter of untreatable S. 
aureus disease [21]. Moreover, there are strains of TB, Streptococci, Enterococci, 
Pseudomonai, etc. resistant to multiple antibiotics [22].   
 
Although it is difficult to gauge the extent of antibiotic resistance since monitoring is 
patchy at best, it is clear the problem is widespread. In the late 1990s, the Center for 
Disease Control and Prevention (CDC) conducted a meta-study of US hospitals [23]. 
The CDC estimated 70% of the bacteria that cause hospital-acquired infections in the 
USA are resistant to at least one of the antibiotics most commonly used to treat them.  
 
Calculations were done to assess the extra financial burden imposed on the US health 
care system due to complications in therapy stemming from antibiotic resistant 
hospital-acquired infections. The CDC came up with a sum of four billion dollars per 
annum but cautioned that the figure could be a gross underestimate.  T
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1.3. A timeline of antibiotic resistance in S. aureus 
 
Far from being idle, pharmaceutical companies have busy over the decades, 
developing and introducing antibiotics into the clinic. Frustratingly, the bacterium S. 
aureus has been able to evolve resistance to nearly all the antibiotics used against it 
[21, 24]. Table 1.1 lists the following: 11 classes of antibiotics used to treat S. aureus 
in the order they were introduced into the clinic, the first times S. aureus infections 
resistant to those antibiotics were reported, and the genetic mechanisms and 
prevalence of the different types of resistance. After a given antibiotic was first used, 
it can be seen that it took anywhere from a year to a decade for resistant isolates to 
emerge, with the singular exception of vancomycin. That it took more than 40 years 
for isolates of S. aureus resistant to vancomycin to appear may be due to the fact that 
vancomycin was scarcely used for the first 25 years. The mechanisms of resistance to 
different antibiotics vary and involve mutations in endogenous genes and also 
acquisition by lateral gene transfer of exogenous genes. 
 
1.4. Names of genes and proteins 
 
Table 1.1 illustrates a convention that will be used throughout. The name of a gene 
will be printed in italics (e.g. blaZ), and the name of a gene’s protein product will be 
capitalized and written in normal font (e.g. BlaZ). 
     
1.5. Measuring resistance: PAPs and MICs 
 
Figure 1.1 illustrates how the resistance of a sample of S. aureus bacteria to an 
antibiotic can be measured [39]. A population analysis profile (PAP) is computed by    12 
  
 
 
 
Antibiotic (mg/ml)
MIC
CFU
PAP
 
Figure 1.1: Measuring resistance to an antibiotic. In order to measure the 
resistance of a sample of S. aureus bacteria to an antibiotic, the bacteria can 
be cultured to a density of 10
10 bacteria/ml in tryptic soy broth at 37ºC using a 
rotating device to ensure vigorous aeration. The culture can then be plated on 
tryptic soy agar plates containing different concentrations of the antibiotic. The 
fraction of bacteria that survive on each plate can be measured by counting 
colony forming units (CFUs). A plot of the fraction of bacteria that survive 
versus the concentration of the antibiotic is called a population analysis profile 
(PAP). (Frequently, dilutions must be performed to obtain a countable number 
of CFUs. In such cases, suitable normalizations must be done to compute the 
PAP.) The concentration of antibiotic at which only 1% of the bacteria survive 
is called the minimum inhibitory concentration (MIC) of the antibiotic [39].   13 
determining the fraction of cultured bacteria that survive as a function of the 
concentration of the antibiotic. Often, resistance of the bacteria is expressed in terms 
of the minimum inhibitory concentration (MIC), defined as the concentration of 
antibiotic at which only 1% of the bacteria survive. 
     
1.6. Rifampin resistance 
 
Figure 1.2 illustrates the mode of action of the antibiotic rifampin and the mechanism 
of resistance to the antibiotic [33]. Perhaps the most important antibiotic today for 
treating TB, rifampin inhibits transcription by binding to the β-subunit RpoB of RNA 
polymerase. Mutations conferring resistance to rifampin map almost exclusively to 
RpoB. Hence,  rifampin resistance is a good example of a simple antibiotic resistance 
trait that involves mutations in only a single endogeneous gene. 
 
1.7. Resistance to cell wall synthesis inhibitors 
 
Figure 1.3 illustrates the bacterial cell wall, a major target of antibiotics [8]. The 
bacterial cell wall is a layer of peptidoglycan made from N-acetyl-glucosamine and 
muramyl- peptide moieties. In gram-positive bacteria like S. aureus, the cell wall is 
the outermost structure. In gram-negative bacteria like Escherichia coli, the cell wall 
is thinner and sandwiched between the cytoplasmic membrane and an outer membrane. 
Figure 1.4 illustrates the synthesis of peptidoglycan [8]. In S. aureus, the synthesis is 
carried out by four so called penicillin binding proteins (Pbps). The protein Pbp2 has 
trans-glycosylase activity and therefore helps in step (a) to synthesize the linear glycan 
strand. Pbp2 also has transpeptidase activity, as do the proteins Pbp1, Pbp3, and Pbp4. 
The four proteins help in step (b) to form the meshwork of peptide cross links [40].         14 
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Figure 1.2: Rifampin resistance. (a) Shown is a RNA polymerase (RNAP) 
transcribing DNA (blue and green) into RNA (red). (b) Rifampin (yellow filled 
circle) inhibits RNAP by binding deep within the main channel of RNAP and 
sterically preventing the RNA transcript from growing. (c) Rifampin attaches 
specifically to the β-subunit RpoB (blue) of RNAP. (d) In all bacteria, all 
mutations found to confer rifampin resistance map almost exclusively to RpoB. 
In a survey of >30 S. aureus isolates exhibiting rifampin resistance, >80% of 
mutations found to confer resistance mapped to the region aa 463-550 (green) 
of RpoB, called the rifampin resistance determining region (RRDR). The 
protein RpoB in S. aureus has a length of 1183 aa [33]. 15 
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Figure 1.3: The bacterial cell wall. The bacterial cell wall is a layer of 
peptidoglycan in which there can be embedded numerous proteins. In gram-
positive bacteria such as S. aureus, the cytosol is shielded by a cytoplasmic 
membrane and thick cell wall from the extracellular space. By comparison, 
gram-negative bacteria such as Escherichia coli have a thinner cell wall and 
an additional outer-membrane [8]. 
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Figure 1.4: Synthesis of peptidoglycan. The synthesis of the peptidoglycan 
layer in Figure 1.3 can be divided into two steps. (a) First, the N-acetyl-
glucosamine and muramyl-peptide moieties are cross-linked by trans-
glycosylase action to produce a linear glycan strand. (b) Then, the peptide 
strands are cross linked by transpeptidase action to produce the meshwork of 
peptide cross links (see Figure 1.3). The length and composition of the peptide 
strand varies from bacterial species to species. However, the last two amino 
acid residues are almost always D-Ala-D-Ala. Moreover, the formation of a 
peptide cross-link almost always involves the catalysis by the transpeptidase 
of a covalent bond between the third-last residue of the first peptide strand and 
the second-last D-Ala residue of the second peptide strand. In the process, the 
last D-ala residue of the second peptide strand is removed [8]. In S. aureus, 
peptidoglycan synthesis is carried out by four so called penicillin binding 
proteins (Pbps). The protein Pbp2 has both transglycosylase and 
transpeptidase activity, and the proteins Pbp1, Pbp3, and Pbp4 only have 
transpeptidase activity [40].17 
1.7.1. β-lactam resistance: MSSA, MRSA, heterogeneous and high 
homogeneous resistance, and auxiliary genes 
 
Figure 1.5 illustrates how β-lactams inhibit peptidoglycan synthesis by binding to and 
inhibiting transpeptidases [8]. β-lactams are a large class of antibiotics that includes 
penicillin and are the most widely used antibiotics in the clinic [8].  
 
Figure 1.6 illustrates the two known mechanisms of resistance to β-lactams in S. 
aureus [25]. Bacteria can acquire by lateral gene transfer the exogenous genes blaZ 
and/or mecA. The gene blaZ confers resistance to only a narrow range of β-lactams 
like penicillin, but the gene mecA confers resistance to all β-lactams, including 
methicillin. Hence, bacteria not carrying mecA are called methicillin susceptible S. 
aureus (MSSA) whereas bacteria carrying mecA are called methicillin resistant S. 
aureus (MRSA). 
 
Figure 1.7 illustrates the two regulatory systems known to regulate the expression of 
the genes blaZ and mecA [25]. They sense β-lactams and induce the transcription of 
blaZ and mecA. 
 
Figure 1.8 illustrates that the resistance levels of MRSA to β-lactams can vary wildly 
[25]. When a strain of MRSA produces a PAP like B, it is said to display 
heterogeneous resistance. When a strain of MRSA produces a PAP like C, it is said to 
display high homogeneous resistance. Rarely is the gene mecA different between 
MRSA displaying heterogeneous and high homogeneous resistance. Thus, high 
resistance must be conferred by unknown mutations in genes other than mecA [25]. 
Projects underway to identify these mutations are more than just academic exercises. 18 
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Figure 1.5: β-lactam inhibition of peptidoglycan synthesis. (a) β-lactams 
like penicillin bind to and inhibit transpeptidases, thus preventing the formation 
of the peptide cross links. (b) The weakened peptidoglycan layer leads to the 
death of the bacterium. Unrestrained osmotic pressure causes the bacterium 
to explode [8].19 
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Figure 1.6: Known mechanisms of β-lactam resistance in S. aureus. 
Bacteria can acquire the genes blaZ and/or mecA. BlaZ is an example of a β-
lactamase, which inactivates a β-lactam molecule by hydrolytically cleaving 
the molecule into two. BlaZ confers resistance to only a narrow range of β-
lactams since it inactivates only some β-lactams like penicillin and not β-
lactams like methicillin with bulky side chains that prevent cleavage. The gene 
mecA codes for a transpeptidase Pbp2' that has low binding affinity to and is 
therefore not inhibited by β-lactams. Pbp2' confers resistance to all β-lactams, 
including β-lactams like methicillin. Therefore, bacteria not carrying the gene 
mecA are called methicillin susceptible S. aureus (MSSA), and bacteria 
carrying mecA are called methicillin resistant S. aureus (MRSA) [25].   20 
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Figure 1.7: Known regulators of blaZ and mecA in S. aureus. Bacteria can 
carry the genes blaR1 and blaI, which code for a system that senses β-
lactams and induces the transcription of blaZ. In the absence of β-lactams, the 
inhibitor BlaI binds upstream and represses the transcription of blaZ. When 
present, β-lactam molecules bind to the extracellular domain of the 
transmembrane sensor BlaR1. This binding promotes the rapid autocatalytic 
cleavage of BlaR1 into two fragments. The free cytosolic fragment functions as 
a metalloprotease that cleaves and therefore inactivates the inhibitor BlaI, 
thereby alleviating the repression of blaZ. It is also observed that bacteria can 
carry the genes mecR1 and mecI, which code for a system exactly analogous 
to BlaR1 and BlaI that senses β-lactams and induces the transcription of 
mecA. Some cross talk between the two regulatory systems exists. Although 
BlaR1 can only inactivate BlaI and MecR1 can only inactivate MecI, BlaI 
represses mecA and MecI represses blaZ. Thus, inactivation of BlaR1 would 
lead to constitutive repression of the transcription of mecA [25].      21 
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Figure 1.8: Heterogeneous versus high homogeneous resistance in 
MRSA. The above figure illustrates three PAPs A, B, and C for the β-lactam 
methicillin. A population grown from an individual of a MSSA strain has a PAP 
that looks like A. Compared to MSSA, MRSA typically exhibit greater 
resistance. However, even MRSA with identical alleles of mecA can have 
widely different levels of resistance. A population grown from an individual of a 
MRSA strain frequently has a PAP like B. That is, only some of the bacteria 
are highly resistant. Depending on such factors as the strain used, the bacteria 
with high resistance can occur with a frequency f ranging from 10
-7 to 10
-3. 
When one of these bacteria with high-resistance is cultured, the new 
population usually has a PAP like C. Strains of MRSA producing PAPs like B 
are said to display heterogeneous resistance. Strains of MRSA producing 
PAPs like C are said to display high homogeneous resistance. Researchers 
have examined the gene mecA in various MRSA. Rarely is the gene different 
between MRSA displaying heterogeneous and high homogeneous resistance. 
Thus, high resistance must be conferred by unknown mutations in genes other 
then mecA. It is unclear what role if any the regulatory genes blaR1/blaI and 
mecR1/mecI may play [25].    
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Typically, a β-lactam antibiotic is administered to a patient in doses that ensure a 
blood serum concentration < 10  g/ml. Much higher concentrations can produce 
serious side effects that can endanger the life of the patient. The vast majority of 
strains of MRSA display heterogeneous resistance. When a patient with a MRSA 
infection is treated with a β-lactam, most of the bacteria are likely killed. The usual 
negative outcome of therapy is likely caused by the subpopulations of mutants arising 
at frequencies between 10
-7 to 10
-3 that are resistant to the β-lactam antibiotic up until 
concentrations on the order of 100  g/ml. These highly resistant mutants can survive 
therapy and proliferate, leading to an infection completely untreatable with β-lactams. 
Identifying the genetic determinants of high resistance in these mutants could lead to 
new drugs that target the determinants and lower the resistance, allowing β-lactam 
treatment to be effective.    
 
Figure 1.9 reinforces the idea that there are other genes besides mecA involved in high 
resistance to β-lactams. A strain COL of MRSA displaying high homogeneous 
resistance has been studied extensively. Mutants of COL displaying heterogeneous 
resistance have been isolated and characterized. The genes found to contain the 
mutations are called auxiliary genes and have very different functions [41-45]. It 
remains a mystery how all these auxiliary genes are involved in β-lactam resistance.     
 
1.7.2. Vancomycin resistance: VISA and VRSA 
 
Figure 1.10 shows how the antibiotic vancomycin inhibits peptidoglycan synthesis by 
binding to the terminal end of the muramyl-peptide moiety [8]. As can be seen in 
Table 1.1, only a few antibiotics – vancomycin, linezolid, and daptomycin – remain  
   23 
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Figure 1.9: Auxiliary genes in the MRSA strain COL important for high 
homogeneous resistance. COL is a strain of MRSA displaying high 
homogeneous resistance (see Figure 1.8). Mutagenesis studies in COL have 
produced mutants displaying heterogeneous resistance (Figure 1.8). Genes 
harboring the mutations have been identified and are called auxiliary genes. It 
is unclear how all these auxiliary genes with such diverse functions are related 
to β-lactam resistance [41-45].24 
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Figure 1.10: Vancomycin inhibition of peptidoglycan synthesis. (a) 
Vancomycin binds to the D-ala-D-ala terminus of the muramyl-peptide moiety 
(see Figure 1.4). The steric blockade posed by the antibiotic hampers trans-
glycosylase and -peptidase activity, thus preventing the synthesis of the long 
glycan strands and the formation of the peptide cross links. (b) The weakened 
peptidoglycan layer leads to the death of the bacterium. Unrestrained osmotic 
pressure causes the bacterium to explode [8].25 
widely effective against MRSA infections. Cases of isolates in clinical specimen 
resistant to any of these three antibiotics are still rare. Of the three antibiotics, 
vancomycin has by far been used the longest, proving itself time and time again since 
its introduction into the clinic in the 1950s. Therefore, vancomycin has become the 
mainstay of therapy against multi-drug resistant S. aureus infections. Linzolid and 
daptomycin are held in reserve in case an infection develops resistance to even 
vancomycin.  
 
Unfortunately, cases of vancomycin resistant S. aureus have been sporadically 
appearing in the clinic since the late 1990s, raising fears that vancomycin like so many 
other drugs before it will become ineffective against many strains of S. aureus. Two 
types of vancomycin resistance are observed, distinguished by the levels of resistance 
[21, 24]. Bacteria displaying the first type have MICs between 8-16  g/ml and are 
called vancomycin intermediate resistant S. aureus (VISA). Bacteria displaying the 
second type have MICs ranging from 32-5000  g/ml and are called complete 
vancomycin resistant S. aureus (VRSA). VISA appear to be much more prevalent, 
with only a few cases of VRSA having been reported in the clinic. Both types of 
resistance can result in treatment failure since the maximum attainable blood serum 
concentration of vancomycin in a patient is about 10  g/ml. Substantially greater 
concentrations can cause severe side effects that can kill the patient.   
 
The mechanisms of resistance in VISA are not well understood [46]. VISA can be 
generated in the laboratory by passaging cells through higher and higher 
concentrations of vancomcyin. The vancomycin MICs of the cells will gradually 
increase, from say 1 to 2 then to 4 and finally to 8  g/ml. Since in the sterile 
laboratory environment the cells cannot presumably acquire by lateral gene transfer   26 
exogenous genes from another type of bacteria, it is believed the cells acquire their 
resistance by mutations in endogenous genes. Since the cells’ resistance increases 
gradually in steps, it is believed that multiple mutations perhaps in several different 
genes need to occur [47].  
 
Figure 1.11 shows one characteristic common to most VISA – a thicker cell wall with 
fewer peptide cross links. It has been suggested that the mechanism of resistance may 
involve vancomycin molecules becoming trapped in the outermost regions of the 
thickened cell wall. Thus, the thicker cell wall would act as an impenetrable barrier, 
preventing vancomycin from reaching the trans-glycosylases and -peptidases bound to 
the cytoplasmic membrane [21]. 
 
Figure 1.12 shows the mechanism of resistance of VRSA. Unlike with VISA, the 
mechanism of resistance is known and involves acquisition by lateral gene transfer of 
the exogenous van gene cluster [21]. The gene cluster codes for proteins that modify 
the end of the muramyl-peptide moiety. The new end is different enough that it is an 
unsuitable substrate for vancomycin yet does not interfere with the trans-glycoslase 
and -peptidase activity.        
 
8. DAPTOMYCIN RESISTANCE 
 
The antibiotic daptomycin is believed to disrupt the cytoplasmic membrane and was 
only introduced into the clinic in 2003, specifically for the treatment of vancomycin 
resistant MRSA infections [48]. S. aureus mutants resistant to daptomycin have been 
generated in the laboratory by serial passage through higher and higher concentrations 
of daptomycin. The mutants were found to harbor mutations in the following genes:   27 
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Figure 1.11: Intermediate vancomycin resistance in S. aureus. Some 
bacteria have vancomycin MICs in the range 8-16  g/ml. These bacteria are 
called vancomycin intermiedate resistant S. aureus (VISA). The mechanisms 
of resistance to vancomycin in VISA are not well understood. Most VISA have 
a thicker cell wall with fewer peptide cross links and therefore more free D-Ala-
D-Ala termini. It has been proposed that the vancomycin molecules bind to the 
free D-Ala-D-Ala termini and become trapped in the outermost regions of the 
cell wall – far from the trans-glycosylases and -peptidases bound to the 
cytoplasmic membrane [21]. 
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Figure 1.12: Complete vancomycin resistance in S. aureus. Some bacteria 
have vancomycin MICs > 32 g/ml. These bacteria are called complete 
vancomycin resistant S. aureus (VRSA). (a) Resistance to vancomycin in 
VRSA is conferred by the van gene cluster, which codes for enzymes that 
convert the last two amino acid residues in the muramyl-peptide from D-Ala-D-
Ala to D-Ala-lactate. (b) Though the new D-Ala-lactate terminus is an 
unsuitable substrate for vancomycin, it does not interfere with the trans-
glycoslase and -peptidase reactions [21].   29 
 mprF coding for an enzyme involved in the synthesis of a membrane phospolipid; 
yycF and yycG coding for a two component system believed to regulate cell membrane 
composition and cell wall homeostasis; and finally rpoB and rpoC coding for subunits 
of RNA polymerase [35]. More research is required to determine how each of these 
genes may be involved in resistance to daptomycin. 
 
The introduction of daptomycin was seen as providing a much needed therapeutic 
option for vancomycin resistant MRSA infections. The launch of daptomycin was in 
fact the most profitable launch in dollar terms of an intravenous antibiotic in US 
history [49]. Unexpectedly, one study found that many VISA isolates are resistant to 
daptomycin, calling into question the long term effectiveness of the drug [50]. Isolates 
resistant to daptomycin are defined as having MICs ≥ 2  g/ml by the Clinical and 
Laboratory Standards Institute [50]. Presently, there is insufficient safety data for 
blood serum concentrations of daptomycin much greater than 2  g/ml in patients. 
Greater than 80% of the VISA isolates from clinical specimen were found to have 
daptomycin MICs ≥ 2  g/ml [50]. Inexplicably, many of these VISA were likely never 
treated with daptomycin, suggesting that VISA are intrinsically resistant to 
daptomycin. Thus far, the VRSA isolates that have been tested do not seem to have 
this intrinsic mechanism of resistance and are all susceptible to daptomycin.  
 
9. The specter of widespread untreatable S. aureus disease 
 
Today, MRSA are endemic in many hospitals, where their existence is ensured by the 
enormous selective pressures imposed by the massive use of antibiotics. Surveys in 
the late 1990s indicate that in the USA and Europe MRSA cause about 25% of all S. 
aureus infections in hospitalized patients [30, 51]. As can be seen in Table 1.1, many    30 
Table 1.2: An estimation of the number of deaths per year in the USA due 
to S. aureus infections in hospitalized patients. A survey was done in 1995 
of S. aureus infections in hospitalized patients in 13 New York Metropolitan 
area counties (Bronx, Dutchess, Kings, Manhattan, Nassau, Orange, Putnam, 
Queens, Richmond, Rockland, Suffolk, Ulster, and Westchester) [52]. The 
counties have a combined population of about 10,000,000. In 1995 in the 13 
counties, it was estimated that 1400 people died from S. aureus disease. 
Estimates were also produced of the number of cases of different types of S. 
aureus infection (infections of the lung, blood, surgical site, heart, and bone). 
These numbers can be extrapolated to the entire USA, with a population of 
about 300 million. Given the mortality rates of the different types of S. aureus 
infection [private communication with professor Alexander Tomasz, 
Rockefeller University], about 200,000 deaths per year due to infections in 
hospitalized patients could be expected USA-wide should an untreatable S. 
aureus strain become widespread.   
Type of 
infection 
Mortality rate 
(%) if 
untreated 
Number of cases 
in New York 
Metropolitan 
area in 1995
a 
Predicted cases  
USA-wide
b 
Predicted 
deaths  
USA-wide if 
untreatable
c 
deaths due to S. aureus disease  1400  41,000   
lung 
(pneumonia)  50  3600  108,000  54,000 
blood  70  4400  132,000  92,400 
surgical site  20  2300  69,000  13,800 
heart  100  550  16,500  16,500 
bone  30  2000  60,000  18,000 
         
Number of deaths should an untreatable S. aureus strain become widespread  194,700
d 
a.  Figures in this column are number of cases in 1995 in the 13 New York Metropolitan area 
counties. 
b.  Figures in this column are number of cases predicted USA-wide by extrapolation (multiplying 
number of cases in column 3 by 300/10). 
c.  Number of deaths predicted USA-wide due to each type of infection if untreatable (obtained 
my multiplying number of cases USA-wide in fourth column by mortality rates in second 
column) 
d.  Sum of figures directly above entry. 
 
 
MRSA infections are resistant to multiple antibiotics besides β-lactams. One MRSA 
strain isolated in 1994 was found to be resistant to all the antibiotics in Table 1.1 
printed in red – that is all the antibiotics save for vancomycin, linezolid, and  
daptomycin. This strain is believed to have originated in Brazil but has since spread 
worldwide [38]. Ominously, there have even been isolated reports of MRSA infections    31 
resistant to one and sometimes two of the antibiotics vancomycin, linezolid, and 
daptomycin [50, 53, 54]. That these reports are still rare offers little comfort, for 
resistant strains can spread quickly. When penicillin was introduced into the clinic in 
the early 1940s, the vast majority of S. aureus isolates were susceptible to the 
antibiotic. By 1948, 50% of the S. aureus isolates in the hospital were resistant to the 
drug [24]. 
 
The prospect of widespread untreatable S. aureus disease is frightening. Besides 
causing superficial skin infections, S. aureus can cause invasive infections of the lung, 
blood, heart, etc. There are few nation-wide surveys of the number of deaths due to S. 
aureus disease. Perhaps one of the most detailed surveys of S. aureus infections was a 
study in 1995 of 13 New York Metropolitan area counties. As detailed in Table 1.2,  
the results of this study can be extrapolated to the entire USA. It can be estimated that 
there are roughly 40,000 deaths per year in the USA due to S. aureus infections in 
hospitalized patients. Should an untreatable S. aureus infection become widespread, 
the number could balloon to 200,000. 
 
10. Data 
 
Because antibiotic resistant S. aureus infections pose such a serious threat, much data 
has been generated on S. aureus. Table 1.3 shows the different strains of S. aureus 
whose genomes have been sequenced. The strains include MSSA, MRSA displaying 
heterogeneous and high homogeneous resistance, and VISA. Table 1.4 lists examples 
of transcriptome studies that have been done using microarray chips to measure the 
levels of transcription of genes genome-wide in S. aureus cells under different 
conditions.   32 
 
Table 1.3: Strains of S. aureus whose genomes have been sequenced. 
The strains have been grouped according to their relatedness as assessed by 
the strains’ MLSTs. The MLST of a strain is a sequence of seven integers 
identifying the alleles found in the strain of the seven essential house keeping 
genes arcc, aroe, glpf, gmk, pta, tpi, and yqil.        
Strain  Type of resistance 
Year sequence 
was published  MLST  Ref. 
COL  high homogeneous MRSA  2005  3, 3, 1, 1, 4, 4, 16  [55] 
8325  MSSA  published only 
on internet  3, 3, 1, 1, 4, 4, 3  [56] 
USA300  heterogeneous MRSA  2006  3, 3, 1, 1, 4, 4, 3  [57] 
MW2  heterogeneous MRSA  2002  1, 1, 1, 1, 1, 1, 1  [58] 
476  MSSA  2004  1, 1, 1, 1, 1, 1, 1  [59] 
N315  heterogeneous MRSA  2001  1, 4, 1, 4, 12, 1, 10  [60] 
Mu50  heterogeneous MRSA 
VISA  2001  1, 4, 1, 4, 12, 1, 10  [60] 
JH1  heterogeneous MRSA  discussed herein  1, 4, 1, 4, 12, 1, 28   
JH9  heterogeneous MRSA 
VISA  discussed herein  1, 4, 1, 4, 12, 1, 28   
252  heterogeneous MRSA  2004  2, 2, 2, 2, 6, 3, 2  [59] 
  
 
 
Table 1.4: Examples of transcriptome studies in S. aureus. Many studies 
in S. aureus have been done using microarray chips to determine the levels of 
transcription of genes genome wide in cells harboring mutations or cells 
exposed to different conditions. Some examples are listed here.   
Study  Reference 
Cells exposed to antibiotics targeting cell wall synthesis 
compared cells before and after exposure to sub-lethal concentrations of β-
lactam antibiotic and vancomyicn 
[61, 62] 
Auxiliary genes 
compared wild-type MRSA COL displaying high homogeneous resistance to 
a mutant of COL with loss of function mutations in the auxiliary gene murF 
displaying heterogeneous resistance  
manuscript in 
preparation 
Mutants with increased levels of resistance 
compared vancomycin susceptible JH1 to VISA JH9  [63] 
Mutants with loss of function mutations in key regulators of cell wall synthesis 
compared wild-type cells to mutants with loss of function mutations in the 
vraSR locus coding for a major regulator of cell wall synthesis  [62] 
Mutants with loss of function mutations in master regulators of virulence 
compared wild-type cells to mutants with loss of function mutations in the 
agr locus coding for a master regulator of virulence  [64]   33 
11. Outline of thesis 
 
This thesis will discuss various analysis carried out on the data on S. aureus in order to 
identify mechanisms of antibiotic resistance. The data analysis posed several 
challenges, due to the sheer size of the data sets and the random and systematic errors 
inherent in biological measurements. The genomic sequence of a typical S. aureus 
strain is about 3 million bases long and can contain random errors. A single 
transcriptome study using a microarray chip may produce a list of hundreds of 
differentially expressed genes. The list can contain artifacts arising from the method 
used to prepare the cells and/or errors in the design of the micoarray chip. Ultimately, 
analysis of such data requires computational and statistical approaches. In the next two 
chapters, such methods will figure prominently as two inter-related projects are 
discussed: the identification of bind sites of transcription factors and the tracking of 
the in vivo microevolution of a multi-drug resistant MRSA infection in a terminally ill 
patient.  
 
The first of these two projects was carried out to elucidate the complex networks 
underlying the regulation of transcription. In a bacterial cell, elaborate sensory 
mechanisms exist that detect internal and external changes and respond by altering 
gene expression. Transcriptome studies have revealed that a single mutation 
conferring antibiotic resistance can often effect the transcription of hundreds of genes. 
Understanding how a genetic change leads to a new phenotype sometimes requires 
determining which transcription factors regulate which genes. Towards this end, an 
algorithm was devised and implemented for identifying binding sites of transcription 
factors by searching for statistically over represented motifs in genomic sequences.  
   34 
The second project involved examining the genomic sequences of a very closely 
related series of isolates extracted over the course of 13 weeks from a terminally ill 
patient with a MRSA infection that evolved VISA-type vancomycin resistance as well 
as rifampin, β-lactam, and daptomycin resistance. The lessons learnt from the first 
project proved invaluable. It was possible to correlate the genetic changes with the 
transcriptome data. The isolates chosen for analysis were so closely related that they 
differed by only a few dozen base changes, making it possible to infer the precise 
mechanisms of resistance.      35 
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Chapter 2  
Genome Wide Identification of Regulatory Motifs 
 
2.1. Introduction  
 
Bacterial genome annotation has generally been confined to the prediction of 
sequences encoding proteins and prominent families of RNA genes. The predicted 
ORF's are grouped into categories by comparing them (e.g. using BLAST) to hand  
curated proteins or motifs with already characterized functions. Information about 
protein interactions can be extracted by finding how genes group into operons [1] and 
searching for homologs to protein domains that reside on distinct proteins in one 
species and are joined into a single protein in another [2, 3]. 
 
The comparison between the genomes of the model metazoans (fly, worm, and plant) 
with the human genome has confirmed the widely held belief of evolutionary and 
developmental biologists that much of the diversity of life stems from changes in 
regulation and not the creation of novel proteins. For bacteria, there is much more 
horizontal gene transfer, and it is an unresolved question of how regulation of these 
genes is coordinated with the host. When it is realized that even for E. coli less than 
20% of the operons have been thoroughly examined upstream for regulatory motifs 
and less than 1/4 of the 300 or more putative DNA binding proteins have known sites, 
it is apparent that the automatic methods for inferring regulatory motifs must approach 
those used for inferring protein coding sequences and function if the full potential of 
the 'genomic revolution' is to be realized. 
   42 
The inference of improbably frequent motifs from a collection of sequences is a 
recognized branch of bioinformatics. Algorithms can be categorized by the search 
strategy used to find a motif and the model used to assess the probability of the 
frequency of the motif's occurrence. Most algorithms operate on the regulatory 
sequences of clusters of genes with related function and return one or a few motifs [4-
10]. The probability of the frequency of occurrence of a given motif in the set of 
regulatory sequences is usually assessed based on the contrast between the set of 
sequences and the rest of the genome. When the genomes of other related species are 
available, motif predictions can by interspecies comparisons sometimes be made on a 
gene by gene basis [11-14]. Computational methods, though imperfect, are an 
essential step in interpreting genome wide experiments and doing a preliminary screen 
for targets that merit further laboratory investigation. 
 
In this article, we extend a strategy originally applied to E. coli [15] that considers the 
entire genome at once and finds all improbably frequent motifs in parallel. It uses an 
exhaustive search, so it misses nothing within the category of motifs it searches for.  
Probability is assessed internally since there is no plausible set of sequences to 
compare against. This approach has the obvious merits of presuming nothing about 
regulons, being quick to implement, and using all the available sequences that may 
share regulatory motifs.  It has the obvious demerits of not using the protein 
annotations or information about co-expression such as available from microarray 
experiments.  Instead, these resources are used to check the validity of the putative 
regulons predicted from the sequence alone. 
 
In bacteria, a regulatory protein often recognizes and binds to a class of similar dimers, 
where a dimer W1NxW2 consists of two specific words W1,2 separated by x non-specific   43 
bases. If a dimer is observed to occur n times in a set of sequences, a p-score can be 
assigned to the frequency n by computing the probability of observing n or more 
instances of the dimer under a null model that assumes the instances of the words W1,2 
are distributed in the sequences at random. For the p-score to be considered significant, 
it must fall below an appropriately chosen threshold. Since many regulatory proteins 
bind to dimers with identical or reverse complementary words W1,2, these classes of 
dimers are given special consideration, and a different threshold is used than in the 
general case. Because secondary structure motifs also have dimer form, dimers with 
significant p-scores do not always represent protein binding sites, e.g. the T-box [16].  
 
Essential to the success of our strategy is the way in which we cluster over-represented 
dimers, derive weight matrices, and infer regulons. Dimers are clustered into distinct 
groups based on sequence similarity. Weight matrices for the clusters are derived from 
the actual sequences matched by the dimers and scored over the regions upstream  
of the operons to predict sites. The set of operons immediately downstream of the 
matches to a particular weight matrix are inferred to be a regulon. We find in 
“Results” that the number of predicted regulons as well as the number of operons per 
predicted regulon is in line with expectations. For only a sixth of our clusters of 
dimers could evidence for function be deduced from the available information for B. 
subtilis. We validated these clusters by comparing their weight matrix matches with 
known regulatory sites, examining the operons composing their regulons for common 
function (either manually using the detailed gene annotations or automatically using 
the COG categories), and inspecting their weight matrix matches for positional biases 
(with respect to translation start or predicted σ
A sites). 
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2.2. Algorithm 
 
Our algorithm for identifying regulatory elements in prokaryote genomes is an 
extension of [15] and consists of the following steps: 
1.  Identify operons and extract upstream sequences. 
2.  Enumerate statistically over-represented dimers of the form W1NxW2 in 
upstream sequences. 
3.  Cluster the dimers into similar groups. 
4.  Construct for each cluster a weight matrix, derived from the matches in the 
upstream regions to the cluster's dimers. 
5.  Predict regulatory elements by using standard information theory to score the 
upstream sequences against the weight matrices. 
For B. subtilis, the rate limiting steps 2 and 3 take ~1/2 and ~3 hr respectively to 
execute on a 500 MHz Pentium II workstation. Our predicted regulatory sites can be 
viewed at the URL http://www.physics.rockefeller.edu/~mwangi/. 
 
2.2.1. Putative operons and upstream sequences   
 
We group adjacent ORF's on the same strand into putative operons if (a) the two 
ORF's are separated by no more than m bases or (b) the two ORF's are both not 
hypothetical, are separated by no more than n bases, and have names differing only in 
their last letters, which would suggest that the ORF's protein products have related 
functions. Tests involving E. coli K12 suggest that the optimal values of m and n are m 
= 32 and n = 130. At these values, we correctly predict ~70% of the ~400 operons in E. 
coli K12 listed in RegulonDB [17] as having some supporting experimental evidence. 
To construct the set of upstream sequences most likely to contain regulatory elements,   45 
we extract from immediately upstream of the translation start sites of our predicted 
operons a maximum of 300 bases, limited so as not to include any coding sequence 
(ORF) on either strand. The upper limit of 300 is chosen because it includes almost all 
the known regulatory sites in E. coli K12 [18]. Using the REPuter program [19], we 
discard all exact repeats of length 16 or more bases from the upstream contiguous 
sequences to eliminate potential insertion sequences and transposons. From the set of 
fragments generated by the removal of the repeats, we discard any fragment with less 
than 50 bases to obtain our final set of upstream sequences. Of the 471289 bases of 
upstream sequence in B. subtilis, 98.3% remained after the removal of the repeats, and 
95.9% remained after imposing the minimum fragment length of 50. 
 
2.2.2. Enumeration of dimers 
 
We search in the upstream sequences for statistically over-represented dimers of the 
form W1NxW2 with word strings W1 and W2 of a, c, g, and t of lengths 4-5 and a 
spacing x in the range 3-30. When we include words with length 3 or less, we find it 
virtually impossible to cluster the over-represented dimers, probably because dimers 
with short word lengths occur frequently in the whole genome and can be part of 
regulatory elements recognized by different transcription factors. When we use words 
with length 6 or greater, the large sample space of dimers searched for necessitates 
that we be exceedingly stringent with our thresholds for significance, so only the most 
improbably infrequent motifs are detected. Since the conserved portions of the 
consensus sequences of known regulatory elements are rarely observed to be separated 
by more than ~20 bases [20], it is natural to constrain x to the interval 3-30. To 
enumerate the dimers, we tabulate the positions of all words W in our set U of 
upstream sequences in a three dimensional table, the entries of which are indexed by   46 
the string W and the sequence S in U that contains the occurrence of W. We then use 
the table to count the number of occurrences n(D) of the dimer D = W1NxW2 in U. 
Denoting the length of a word or dimer M as L(M), the expected number of 
occurrences of D under the null hypothesis that the occurrences of W1 and W2 are 
uncorrelated is 
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A dimer is considered over-represented if  
  1/ D P N <   (2.3) 
where ND is the number of dimers considered, that is (4
4+4
5)
2 • 31 ~ 50,000,000. 
Because the binding sites of transcription factors are frequently symmetric (e.g. 
acctN5acct) or reverse complement symmetric (e.g. ccctN5aggg) [20], we score these 
separately using ND = (4
4+4
5) • 31 ~ 40,000. Under our null model, no dimer would 
satisfy Eq. 2.3 by chance. However, our null model is inaccurate for sequences 
consisting of long stretches of the same nucleotide (A or T being the most common 
cases in practice) since a sequence like AAAAAANxTTTTTT can for x < y contain 
multiple instances of the dimer AAAANyTTTT displaced relative to each other by one 
base. In contradiction to our null model, the occurrences of the words AAAA and 
TTTT are manifestly correlated, leading to extra instances of the dimer 
AAAANyTTTT and an over-estimation of the significance of the frequency of the 
dimer's occurrence. To circumvent the problem, we ignore all words that consist of   47 
only the same nucleotide and so miss motifs like AAAAN5TTTT recognized by 
ComK. It is however important to note that the frequency of occurrence of a dimer 
like TAAAAN5TTTTA is properly assessed since the problem is not the abundance of 
any particular nucleotide in a dimer but the translational symmetry that results when 
each word is a continuous uninterrupted string of the same nucleotide. We therefore 
believe that our statistical model is misrepresenting a negligible number of motifs 
even in the poly A/T rich genome of B. subtilis.  
 
2.2.3. Clustering of dimers   
 
Since many of our over-represented dimers represent different but overlapping 
versions of the conserved cores of the binding sites of the same factor, it is necessary 
for us to cluster our over-represented dimers into distinct groups. For example, the 
following two dimers 
 ttgaNNNNNNNNNNNNNNNNNNNNataat 
  tgccNNNNNNNNNNNNNNNNNNtata 
in B. subtilis should belong to the same group since they are both related to the 
consensus sequence TTGACAN17TATAAT recognized by the sigma factor σ
A [21].  
 
To cluster our dimers, we first compute for each pair of dimers D1 and D2 a pairwise 
similarity score S(D1, D2). We define the score of an alignment of D1 and D2 to be a 
sum over the pairs of overlapping bases: matches are scored as +1, mismatches as -1, 
and N paired with anything scores as 0. We define S(D1, D2) to be the maximum score 
produced by all possible alignments between D1 and D2 subject to the constraint that 
the left (and similarly right) words in the two dimers must partially overlap by at least   48 
2 bases. When the aforementioned constraint cannot be satisfied, we define S(D1, D2) 
= 0. Hence, for the above two dimers, S(D1, D2)  = 5 - 1. 
 
Define a pairwise dis-similarity score between D1 and D2 as D(D1, D2) = [max D1,D2 
S(D1, D2)] - S(D1, D2). Now, define a graph G0 = (V, E0) with vertices V representing 
our dimers and edges E0 having lengths D(D1, D2). In such a graph, highly similar 
dimers would tend to form spatially compact clusters. In practice, these compact 
clusters tend to be connected by long chains of edges since through a series of 
substitutions, insertions, and deletions a dimer D can be transformed into a highly dis-
similar dimer D'. Because of these long chains of edges, many clustering algorithms 
have difficulty properly delineating the compact clusters. For example, as the 
agglomerative algorithm CAST [22] constructs clusters starting with our individual 
dimers, it fails to merge many highly similar groups together, probably because the 
algorithm has a difficult time deciding which groups the dimers on the long chains of 
edges belong to. In the divisive SPC algorithm [23], our dimers are represented as 
spins in a Pott's model, and clusters are mapped out using a spin-spin correlation 
function. As the temperature is raised, the increase in thermal energy disrupts the 
correlation between many of the dimers in the compact clusters before it disrupts the 
correlations over the long chains of edges between the clusters, leading to many highly 
similar groups often each consisting of one dimer. We devised an algorithm, the 
weakest-link-clustering (WLC) algorithm, to specifically seek out and severe the long 
chains of edges to generate compact clusters.   
 
Starting with G0 = (V, E0), our WLC algorithm in each iteration generates from a 
graph Gi-1 = (V, Ei-1) a new graph Gi = (V, Ei). Our clusters of dimers are defined as 
the connected components of the current graph Gi. To generate Gi, we compute all the   49 
shortest finite paths in Gi-1 between all pairs of dimers D1, D2 Î V. Multiple paths may 
run across a given edge (D1, D2) Î Ei-1. Let P(D1, D2) be the mean length of these 
paths. The weakest link in Gi-1 is defined as the edge (D1, D2) Î Ei-1, D1 ¹  D2, at 
which P(D1, D2) is a maximum. When P(D1, D2) is a maximum at multiple edges, then 
the edge to be designated the weakest link is chosen at random. Irrespective of the 
exact edge chosen to be the weakest link, the edge will undoubtedly be part of one of 
the aforementioned long chains of edges in G0. To generate compact clusters of dimers, 
our algorithm severs the weakest link in Gi-1 to produce Gi.  
 
Define the intra-cluster affinity A(C) of a connected component C = (Vc, Ec) as 
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Note that the sum of similarity scores S(D1, D2) in the numerator is performed over all 
pairs of dimers in C regardless of whether or not the dimers are currently connected by 
an edge in C. A(C) is therefore the average pairwise similarity score of dimers in C. 
Every time two new connected components C1 and C2 are formed by severing a 
weakest link in a connected component P, our algorithm computes the ratio 
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of the mean of the intra-cluster affinities of the child clusters C1 and C2 to the intra-
cluster affinity of the parent cluster P. Hence, our algorithm produces a series of R 
values until the trivial state of every dimer being in its own cluster is reached.  
 
The optimal number of clusters can be inferred from a plot of R versus the number of 
clusters, e.g. Figure 2.1. R declines rapidly as the highly non-compact clusters are 
severed and plateaus when a succession of clusters is encountered that exhibit the 
same degree of compactness from parent to children. R can then increase, e.g. around 50 
 
 
Figure 2.1: WLC Algorithm. Choosing the correct number of clusters. The 
ratio R (Eq. 2.5) of the mean child to parent intra-cluster affinities versus the 
number of clusters for B. subtilis generated by our WLC algorithm. As weakest 
links are severed, the number of clusters increases from 29 to 732. Note the 
stabilization at and around 350 clusters, the optimal cluster number. 
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370 clusters in Figure 2.1, when formerly compact clusters are fragmented into yet 
better children. To make our clusters as generic as possible, we choose the cluster 
number to be the in the first plateau in R. 
 
2.2.4. Weight matrices 
 
For each cluster of dimers generated by our WLC algorithm, we extract from our 
upstream sequences all unique segments that match any dimer. Using a multiple 
alignment of the dimers in the cluster, we align the segments and pad each to the left 
and right with up to ~5 bases from the genome to create a column of equal length 
segments. We compute a matrix  , i n a  that gives the number of occurrences of the base 
α in the i
th column of the alignment. We prune the matrix  , i n a  by performing a chi-
squared test over a window of length lc = 3 columns running over the length of the 
matrix. For a given position of the window, we compute the probability [24] that the 
observed matrix entries were obtained by sampling the background distribution of 
frequencies 
0
a f , 
0
c f , 
0
g f , and 
0
t f  of the bases a, c, g, and t respectively in our 
upstream sequences. When the probability exceeds 1%, we block out the middle 
column in the window and do not use it to score sequences against the matrix. 
Although the outer low significance columns are eliminated from the matrix, the inner 
blocked out columns are retained to preserve the spacing. The final matrix typically 
has a dimeric pattern, but monomeric, trimeric, and even more complex patterns are 
occasionally observed.  
  
To predict regulatory sites, we in accordance with a scoring scheme by Berg and von 
Hippel [25] first convert the pruned matrix  , i n a  to a weight or surrogate binding 
energy matrix  , i w a . For an unblocked column i,  , i w a  =  ( )
0
10 , log i f f a a  where  , i f a  =   52 
, , ( 1) ( 1) i i n n a a a + + ∑  is the relative frequency of the base α in the i
th column with a 
pseudo count of 1 added due to the Bayesian estimate. For a blocked column i,  , i w a  = 
0.  
 
The consensus sequence for a weight matrix is computed according to the prescription 
outlined in [26]. Denote the total number of counts  , i n a a ∑  recorded in the i
th column 
of the matrix  , i n a  by N. If  , i n a /N > 0.5 for some base α and  , i n a  > 2  , i n b  for all bases β 
¹ α, then the i
th site in the sequence is assigned the consensus α. Otherwise, if 
( , i n a + , i n b )/N  > 0.75 for some pair of bases α and β, then the site is assigned the co-
consensus [α / β]. If neither criterion is satisfied or if the column i was blocked out 
because it did not satisfy the chi-squared test, the site is assigned a N. 
 
2.2.5. Predicting regulatory sites 
 
The score of a sequence b1 b2… bl to a weight matrix  , i w a  is defined by the sum s = 
, 1 i
l
i b i w
= ∑ , which correlates with the binding affinity of the factor to the DNA 
sequence [25]. When a weight matrix is scored over many distinct segments, the 
histogram of scores s can usually be approximated by some normal distribution N(s; m, 
σ) with mean m and variance σ
2. Hence, we characterize a weight matrix by the mean 
ms and variance 
2
s s  of the scores of the matrix to the N defining segments used to 
compute the matrix and by the mean m and variance σ
2 of the scores of the matrix 
against all the distinct segments of length l in our upstream sequences. The more 
separated N(s; ms, σs) and N(s; m, σ) are, the better the matrix can distinguish potential 
sites from background sequences. The sites predicted by a weight matrix are those 
with a score larger than a cutoff s0. The false positive rate is given by 
0
( ; , )
s
N s m s
¥
∫  and   53 
the false negative rate by 
0
( ; , )
s
s s N s m s
-¥ ∫ . Since a decrease in the false positive rate can 
only occur at the expense of an increase in the false negative rate, care must be taken 
in choosing s0. We choose s0 to be max{ms – zselfσs, m + zbackσ}, with the two 
parameters zself and zback, called the critical self and background z-scores respectively, 
typically having the values 1 and 3 to ensure a false positive hit rate no greater than 
0.2%.  
 
2.2.6. Running time 
 
The rate limiting steps of our algorithm are the exhaustive search for and the 
clustering of the over-represented dimers. The exhaustive search executes in 
( ) D U D O N L L +  time where  D N  is the number of dimers searched for,  U L  is the 
combined length of the upstream sequences, and  D L  is the sum of the different word 
lengths considered (e.g. 9 if word lengths 4 and 5 are considered). To reach the trivial 
state that every dimer is in its own cluster, our current implementation of our WLC 
algorithm executes in  ( )
2 3
2 log O E V V E V +  time on the graph G = (V, E) and 
uses a breadth first search to identify the connected components and Dijkstra's 
algorithm to compute the shortest paths between all over-represented dimers. The 
stated running time of our WLC algorithm however should be interpreted as an 
upperbound that can in certain instances be a gross overestimate depending on the 
precise topology of the graph G.  
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2.2.7. Web site 
 
Our website http://www.physics.rockefeller.edu/~mwangi/ presently lists our 
regulatory site predictions for B. subtilis and several other species. For each, we list: 
1.  the regulon defined by each weight matrix with the operons' annotations, 
2.  each upstream region with the predicted regulatory sites, 
3.  all matrices with significant number of multiple matches in a upstream region, 
4.  pairs of our matrices that frequently co-occur in the same upstream region, 
5.  the observed and expected distributions of positions of a matrix's matches 
relative to translation start, 
6.  the observed and expected distributions of positions of a matrix's matches 
relative to our best primary sigma factor binding site predictions, 
7.  input files for the DNA sequence viewer and annotation tool ARTEMIS [27].   
 
2.3. Results 
 
2.3.1. Nomenclature 
 
To simplify terminology, we will use the term 'operon' in what follows to denote our 
putative operons predicted as described in “Putative operons and upstream sequences”.  
Since a particular weight matrix is thought to represent sites uniquely recognized by 
some transcription factor, the term 'regulon' will be used for the group of operons 
having a match to the matrix directly upstream, i.e. direct targets of the factor. 
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Table 2.1: The top 10 most significant dimers (column 1). Dimers 
searched for had word lengths 4-5 and a spacer 3-30. Coding sequence was 
not considered. Listed are the number of occurrences in the dataset (column 
2) and the statistical significance  10 log P -  (column 3), with P calculated from 
Eq. 2.2. 
Dimer  Number observed  Significance 
ttgaN20ataat  48  21.1 
gccgcN11gcggc  10  15.9 
ggtggN3cgcg  10  14.6 
ttgaN19tata  70  14.5 
gaaacN16cgta  17  14.4 
ttgaN21taat  58  13.8 
agggtN4ccgcg  8  13.7 
gccgcN12cggc  12  13.7 
ttgaN23ataa  75  13.6 
ttgacN19ataat  18  13.6 
 
2.3.2. Overview 
 
We applied our algorithm to the well studied gram positive bacteria B. subtilis.  
We grouped the prokaryote's 4100 ORF's into 2729 putative operons and found after 
the removal of poly a/t patterns 732 over-represented dimers with both words between 
4-5 in length and a spacer between 3 and 30. In the list of our 10 most significant 
dimers in Table 2.1, the four dimers ttgaN20ataat, ttgaN19tata, ttgaN21taat, and 
ttgacN19ataat all correspond to the consensus sequence TTGACAN17TATAAT 
recognized by the primary sigma factor σ
A [21], the two dimers ggtggN3cgcg and 
agggtN4ccgcg correspond to the T-box [28] with a known consensus sequence 
AANNAGGGTGGTACCGCGNN involved in the alternate transcription termination 
regulation of the aminoacyl-tRNA synthetases, and the consensus sequence 
TGAAACN16CGTA recognized by the antimicrobial resistance sigma factor σ
W [21] 
is represented by the dimer gaaacN16cgta. Figure 2.1 shows the ratio R (Eq. 2.5) of the 
mean child to parent intra-cluster affinity versus the number of clusters when we  
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Table 2.2: 52 unique biologically significant weight matrices. Listed are 
the matrix's identifier (column 1), consensus sequence (column 2), regulon 
size (column 3), and annotation (column 4). The matrices are sub-divided into 
categories according to the means by which they were identified: by 
comparison to documented regulatory mechanisms, by inspecting the operons 
in a matrix's regulon for related functions, and by examining the matrix's 
matches for positional biases. If a matrix was identified by several means, all 
listings for the matrix except the first in the top-most category are marked with 
pluses. Where applicable, the statistical significance  10 log P -  is reported in (), 
and entries in a category are sorted according to significance.    
Weight 
matrix  Consensus sequence  Regulon 
size  Annotation 
Documented regulatory mechanisms 
DBTBS database [29] 
Sigma factors [21] 
WM1  N7TTGAN19TATAATAN6  1141  σ
A, housekeeping 
WM118  [G/T]GTTTAN13[A/C]GGGAA[G/T]  8  σ
B, general stress response 
WM11  NTGAAACNTTTN12CGTAT[A/T]  16  σ
W, antimicrobial resistance 
WM212  TGGCA[C/T]N4CTTGCAT  5  σ
L, levanase and amino acid 
Miscellaneous 
WM2  AANNAGGGTGGTACCGCGNN  24 
T-box, alternate transcription 
termination regulation of 
aminoacyl-tRNA synthetases 
[28] 
WM22  [A/T]AAN[A/C]GAACNN[A/T]NGTTC
NNTTN  29  LexA, SOS response [30] 
WM71  NT[A/T]TGTAN10ACA[A/T]AN  111 
TnrA pleiotropic regulator 
involved in global nitrogen 
regulation [31] 
WM317  [A/T]TGTAA[A/G]CG[C/T]TT[A/T]N[
A/T]  54  CcpA, carbon catabolite 
repression [32] 
Two-component response regulators [33, 34] 
WM298  NTAATN20ATTAN  27  YccG-YccH (3.4) 
WM259  TGCGN10CGCA  5  YclK-YclJ (3.3) 
Novel predictions 
Regulons whose operons have highly related functions 
Identified by detailed manual inspection 
WM171  TCGCN11GCGA  2  Sec-dependent protein 
machinery export [35] 
WM116  AATTC[A/T]N28[A/T]GAATT  4  Cell lysis 
WM266  TCCACAN3CCACA  3  Extracellular proteins 
WM69  TATCTN4[A/T]TCGAGA  5  Transport 
WM233  NCGGAN3TCCGG  7  Antimicrobial resistance 
WM290  NTTGAN16TGTTAN3T  18  DNA synthesis and repair 
WM47  A[A/T]AGAGN18CTCTTT[C/T]N  27  DNA synthesis and repair 
WM124  NTTAC[A/T]N6TTACN  17  Transport 
Identified using COG functional categories 
+WM2  AANNAGGGTGGTACCGCGNN  24  T-box, translation, ribosomal 
structure, and biogenesis (12) 
+WM317  [A/T]TGTAA[A/G]CG[C/T]TT[A/T]N[
A/T]  54  CcpA, carbohydrate transport 
and metabolism (6.5), energy   57 
Table 2.2 (Continued) 
      production and conversion 
(3.0) 
WM130  N4TTCAN14[A/T]N4TGAAAN  38 
Posttranslational modification, 
protein turnover, and 
chaperones (4.2) 
+WM1  N7TTGAN19TATAATAN6  1141  σ
A, transcription (3.3) 
+WM212  TGGCA[C/T]N4CTTGCAT  5  σ
L, energy production and 
conversion (3.1) 
WM255  NCTGAAN26TTCAGN  3  Cell motility and secretion 
(2.9) 
 +WM22  [A/T]AAN[A/C]GAACNN[A/T]NGTTC
NNTTN  29  LexA, DNA replication, 
recombination, and repair (2.6) 
WM39  [A/G]NNTGCTN30AGCAN  21 
Secondary metabolites 
biosynthesis transport, and 
catabolism (2.5) 
WM228  NGCAGAN13TCTGCN  3 
Secondary metabolites 
biosynthesis transport, and 
catabolism (2.5) 
WM283  AGCTCN13GAGCTT  3  Translation, ribosomal 
structure, and biogenesis (2.4) 
WM80  NGTTTN29AAACN  86  Energy production and 
conversion (2.3) 
WM223  NATTTN28AAATN  69  Transcription (2.3) 
WM16  NCCGGC[C/T]N6GCCGGN[G/T]TTTT  27  Signal transduction 
mechanisms (2.3) 
WM17  [A/G]NCGGCN8[A/C]NGCCGN  40  Cell motility and secretion 
(2.3) 
WM23  [A/T]CGAAN27TTCG[A/T]  25  Amino acid transport and 
metabolism (2.2) 
WM221  NGCCGN29CGGCN  6  Amino acid transport and 
metabolism (2.2) 
WM119  NAATAN9TATTN  62  Cell envelope biogenesis, outer 
membrane (2.1) 
+WM304  AGTGTN15ACACT  4  Inorganic ion transport and 
metabolism (2.1) 
WM46  NTATAN17AAAGGAG[A/G]N  109  DNA replication, 
recombination, and repair (2.1) 
WM75  [G/T]N3CTACN9GN12CTACA  5 
Secondary metabolites 
biosynthesis transport, and 
catabolism (2.0) 
WM31  NTGTTN5AACAN  58  Carbohydrate transport and 
metabolism (2.0) 
Positions of binding sites are highly biased with respect to σ
A sites. 
+WM46  NTATAN17AAAGGAG[A/G]N  109  Repressor (17) 
WM21  AANCCGN15CGGNTTTTTT  128  Activator (7.9) 
WM33  NAAGC[A/T]GN12C[A/T]GCTTN  96  Activator (4.7) 
WM50  NNGCTTTTTTTATTN  152  Activator (3.6) 
WM173  NAAAGN[A/G]NGGAAN4  35  Repressor (3.0) 
WM169  NAAAGN3GTGAN  40  Repressor (2.9) 
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WM13  [A/G][A/C][A/G]CCC[G/T]…[G/T]N9G
GG[C/T][G/T]TT[A/T]T   21  Activator (2.8) 
WM180  [A/T]AGAGN5AGAGN  15  Repressor (2.6) 
WM58  NAAAGANAN15TCTTTTN  42  Activator (2.6) 
WM79  NTTCT[A/T]N4TTCTN  67  Activator (2.5) 
WM84  AN3AACATN3GGAGGN  19  Repressor (2.4) 
WM7  NAAAGN19[G/T]CTTTN3  90  Activator (2.3) 
+WM17  [A/G]NCGGCN8[A/C]NGCCGN  40  Activator (2.1) 
Absolute positions of binding sites are highly biased. 
+WM46  NTATAN17AAAGGAG[A/G]N  109  (61) 
+WM1  N7TTGAN19TATAATAN6  1141  σ
A (16) 
+WM169  NAAAGN3GTGAN  40  (10) 
+WM21  AANCCGN15CGGNTTTTTT  128  (6.3) 
+WM2  AANNAGGGTGGTACCGCGNN  24  T-box (4.8) 
+WM16  NCCGGC[C/T]N6GCCGGN[G/T]TTTT  27  (4.1) 
+WM13  [A/G][A/C][A/G]CCC[G/T]...  21  (3.9) 
+WM58  NAAAGANAN15TCTTTTN  42  (3.4) 
+WM11  NTGAAACNTTTN12CGTAT[A/T]  16  σ
W (3.1) 
+WM17  [A/G]NCGGCN8[A/C]NGCCGN  40  (3.0) 
WM25  NNGTTTN17GG[A/T]A[A/T]  59  (3.0) 
WM37  NAAGC[A/T]N19GCTTT  25  (3.0) 
WM14    N3CGGCN11GCCGN3  197  Tends to co-occur with T-box 
(3.0) 
WM143  NCCTCN24TTATN  25  (2.8) 
WM185  NAACCN15GGTTNNTT  15  (2.7) 
+WM47  A[A/T]AGAGN18CTCTTT[C/T]N  27  (2.6) 
+WM33  NAAGC[A/T]GN12C[A/T]GCTTN  96  (2.1) 
WM28  [A/G]AAAGCN21[A/G]GCTT[C/T]TT  30  (2.0) 
Unusually high number of matches in a single promoter 
WM34  NCACA[A/T]N[A/T]TGTGN  17 
Three repeats overlap dnaA 
boxes TTATCCACA [36], 
may inhibit chromosome 
replication, (7.8) 
 
clustered the 732 over-represented dimers. There was a plausible plateau at 350 
clusters, 97 of which contained 2 or more dimers. We found that 317 of the 350 
clusters matched 3 or more sequences and converted these clusters to weight matrices 
for further study. Of the 317 matrices, we were able to identify 52, listed in Table 2.2, 
that met at least one of our criteria for significance. Of the 52 matrices, 10 represent 
experimentally characterized regulatory factors, 30 have regulons that contain a 
disproportionate number of operons with related functions, and 32 have matches 
exhibiting some positional bias. A total of 28 of the matrices listed in Table 2.2 were   59 
derived from a cluster of two or more dimers. To further demonstrate our algorithm, 
we also searched for longer symmetric dimers with word lengths 6 that could overlap 
coding sequence and applied our algorithm to the subset of sequences upstream of 
operons identified to be co-expressed in various studies. 
 
2.3.3. Regulon sizes 
 
To validate our methods, we began with a collection of transcription factors with 
experimentally characterized recognition sites collected in the DBTBS database [29] 
and by Helmann [37]. We restricted our attention to the 34 factors each with at least 
two sites, giving 600 sites in total. In the histograms of regulon sizes in Figure 2.2, 
size is reported in terms of number of operons. In (a), a regulon of a factor is defined 
as the set of our predicted operons that have immediately upstream a site documented 
in the DBTBS database to be recognized by the factor. Similarly, a regulon of a weight 
matrix in (b) or (c) consists of the operons that have immediately upstream a match to 
the matrix. A matrix in (b) for a factor was computed from the sites listed in the 
DBTBS database for the factor. For factors like σ
A and DegU that recognize dimers 
with variable spacing x, we computed separately a matrix for each spacing x. The 
matrices in (c) are our 317 matrices derived from our clusters of over-represented 
dimers. As noted in the caption, a number of matrices have regulons containing more 
than 400 operons. Some of these matrices, like those for σ
G and σ
K , were derived 
from experimental sites exhibiting little consensus. Others represent factors like 
ComK that recognize ubiquitous motifs like AAAAN5TTTT, which may not all be 
functional. An exception is the matrix for the factor SpoOA with 824 operons in its 
regulon. Spo0A is the master regulator of sporulation and may have many targets [38]. 
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Figure 2.2: Histogram of regulon sizes. A regulon for a factor in (a) is 
defined as the set of our predicted operons that have immediately upstream a 
site documented in the DBTBS database to be recognized by the factor. A 
regulon for a weight matrix in (b) and (c) is defined as the set of our predicted 
operons that have immediately upstream a match to the matrix. The matrices 
in (b) were derived from the experimental verified sites in the DBTBS database. 
The matrices in (c) were derived from our clusters of over-represented dimers. 
The several regulons in (b) (σ
A, σ
G, σ
K, ComK, GltC, GltR, Hpr, LevR, and 
Spo0A) and the three regulons in (c) with more than 400 members are 
discussed further in the text. 61 
 
The expressions in “Predicting regulatory sites” for the rates of false negative and 
positive predictions for a weight matrix's matches assumed a Gaussian distribution of 
values. We used the 600 DBTBS sites to test the expressions by computing for each 
factor's weight matrix in Figure 2.2(b) the percentage of its sites and the percentage of 
sites annotated for another factor that the weight matrix matched. The false negative 
rate can be deduced from the former percentage, and the false positive rate is given 
directly by the latter. The results agree well with the Gaussian assumption. 
 
More than half of the regulons for our matrices in Figure 2.2(c) contain 10 or fewer 
operons. The five largest regulons with sizes 1141, 903, 518, 320, and 281 belong to 
the matrices WM1, WM5, WM29, WM4, and WM90 with consensus sequences 
N7TTGAN19TATAATAN6, N5[A/T]TTT[A/T]N5AAAT[A/T][A/T]N5, 
NAAATTAN6[A/T]N4TAATTTNN, N4[A/T]AAATT[A/T]N6A[A/T]TT[A/T]N5, and 
N[C/T]TTAC[A/T]N16GTAA[A/G]NN respectively. Since WM1 represents the 
primary sigma factor σ
A, it is not surprising that its regulon contains nearly half of all 
our predicted operons. The matrices WM5, WM29, and WM4, representing ubiquitous 
poly a/t patterns, may correspond to UAS and UP elements [39]. The matrices that 
correlate well with the known factors σ
B, σ
W, T box, σ
L, LexA, TnrA, and CcpA (see 
next section) have regulons containing 8, 16, 24, 5, 29, 111, and 54 of our operons 
respectively. It is clear from our literature search that we underestimate the number of 
operons directly targeted by σ
B and σ
W. To date, at least 35 operons have been shown 
experimentally to be transcribed from σ
B dependent promoters [40]. Moreover, 
various genetic and reverse genetic approaches and array technologies suggest that 
over 200 genes are σ
B dependent, although some indirectly [41]. Using consensus 
search, run-off transcription followed by macroarray analysis, and transcriptional   62 
profiling, [42] identified 30 σ
W dependent promoters. Our underestimates of the σ
B 
and σ
W regulons can be attributed to the high specificity of our weight matrices and 
highlight a weakness in our algorithm. Our σ
B matrix was derived from a cluster of 
only one dimer, and our σ
W matrix was derived from a cluster of 7 dimers with no 
mismatches. Although the factors' recognition consensuses are very well reflected by 
the dimers in these clusters, no dimers representing allowed variations to these 
consensuses in both sequence and spacer met our criterion for over-representation, so 
our σ
B and σ
W clusters and hence their derivative matrices were too specific and 
matched only the strongest of sites. To remedy this weakness, we would have to 
search not for over-represented dimers but over-represented classes of dimers with 
mismatches and variable spacers. Notwithstanding this, the sizes of our other matrix 
regulons compare favorably with those documented in the literature. Of the 21 
aminoacyl-tRNA synthetase operons, 14 are known to be regulated by the T-box [16]. 
Reference [21] estimates that the σ
L regulon contains 6 operons, and according to [30], 
some 20 operons are direct targets of LexA. We could not find any recent estimates of 
the sizes of the TnrA and CcpA regulons. Both factors are believed to regulate many 
genes [31, 43], and CcpA according to the DBTBS database is believed to directly 
target at least 34 sites. Excluding WM5, WM29, and WM4, our 317 matrices predict 
on average 3.5 sites per upstream region. On our web site, we mark simultaneously all 
predictions from our 317 matrices and the matrices derived from the experimental 
sites. 
 
2.3.4. Weight matrices correlating with known factors 
 
To correlate our 317 weight matrices with known factors, we scored them over the 600 
DBTBS and Helmann sites. The number e of sites for a factor f expected to match a    63 
matrix w is 
  ( )
1
1
s N
i w w
i
e l l p
=
= - + ∑   (2.6) 
where Ns is the number of sites listed for the factor, li is the length of the i
th site si, lw is 
the number of columns in w, and pw is the probability that a randomly chosen segment 
of length lw will match w. The probability P(w,f) of observing by chance that n of the 
sites si bound by f contain a segment that matches w is then given by the Poisson 
distribution. For P(w,f) to be significant, we insisted that it be less than 10
-4, roughly 
the inverse of the total number of matrices times factors being compared. 
 
If P(w,f) happened to meet this cutoff, we manually checked that it was the most 
conserved positions in the experimental sites for a factor that matched our matrix. By 
these criteria, we could correlate at least one of our matrices with one of seven factors 
(σ
A, σ
B, σ
W, σ
L, LexA, TnrA, and CcpA) in our collection of 34 factors, a 21% success 
rate. We missed the factors ComA, CtsR, Fnr, HrcA, RocR, YqhN, and Zur even 
though these factors are quite specific. In most cases, it is because the dimers that are 
part of the conserved core of the binding sites of the factor did not satisfy criterion Eq. 
2.3. When we only considered dimers with word lengths 4, the number of dimers 
considered decreased ~16-fold in the general case (~4-fold in the symmetric cases), 
and we found that under the new less stringent criteria given by Eq. 2.3 that at least 
one of our matrices correlated with one of nine factors (σ
A, σ
B, σ
W, LexA, CcpA, 
ComA, Fnr, GltC, and GltR) or ~26% of the factors in our collection. Unfortunately, 
we missed the factors σ
L and TnrA since their representative dimers all contain length 
5 words.  
 
For σ
A, we can compare our predictions with those of Reference [44]. Using a hidden    64 
Markov model (HMM) fitted to known σ
A sites that allowed for variable spacing 
between the -35 and -10 elements, [44] predicted 881 σ
A sites in our upstream 
sequences, 625 with a spacer 17 captured by our weight matrix WM1. Our matrix 
WM1 has 1580 matches upstream of 1141 operons, of which 413 agree with one of 
the 625 from [44]. Moreover, WM1 matched with no training 109 out of the 132 sites 
listed in [37]. It is unclear if we are seriously over-predicting since [44] estimates that 
their HMM misses 30% of real sites, and some of our WM1 matches could represent 
other spacings, which would be expected to yield a disproportionately large number of 
false positives. Our prediction that ~40% of our operons directly depend on the 
dominant sigma factor does not seem excessive. Our WM1 matches also have a very 
strong positional bias (see below). 
 
Noticeably absent from our list are matrices that represent the very specific HrcA and 
Fur factors. HrcA binds to the CIRCE elements TTAGCACTCN9GAGTGCTAA [45] 
directly upstream of the genes hrcA and groES. Although Fur recognizes the 15 bp 
consensus TGAtAATNATTaTCA, many of the 20 operons known to be targeted by 
Fur are regulated by two overlapping Fur sites with the classic 19 bp consensus  
GATAATGATNATCATTATC [46]. One of the two CIRCE elements (that upstream 
of the groE operon) overlaps coding sequence and so was not in our search space of 
upstream sequences. We examined all dimers with word lengths 4-5 and spacing 1-11 
that matched the given 15 and 19 bp Fur consensuses. The most significant dimer 
taatNNttatc occurred 15 times in our search space of upstream sequences with a 
probability  10 log P -  = 3.6. Although the Fur sites display a high degree of 
conservation along their length, it appears that due to variations at individual sites no 
dimer met our criterion for over-representation. For example, the dimer tgataN5tatca 
only occurs twice in the 21 known Fur sites listed in Figure 2.4 in [46] because of   65 
variations at the fourth and twelfth sites highlighted in lowercase in the consensus 
TGAtAATNATTaTCA. This illustrates a known shortcoming of our method, which 
ignores dimers that, though not significant individually, are significant as a cluster. 
Because words like taat and ttatc occur frequently, note that the significance of the 
occurrence of the dimer taatNNttatc is much lower than might be expected. Under a 
null model ignoring nucleotide correlations, the dimer taatNNttatc would in our search 
space of ~0.5 Mb be expected to be seen ~1/4
9 • 500000 ~ 2 times. Hence, the 
probability of seeing the dimer 15 times would by Poisson statistics be ~2
15/15! • 
2 e
-  
~ 10
-9. 
 
Observing that both the HrcA and Fur consensuses are long and reverse complement 
symmetric, we decided to search for over-represented symmetric and reverse 
complement symmetric dimers with word lengths 6 and spacers 1-30. We also 
augmented our search space to 300 bp upstream of each operon irrespective of 
whether this includes coding sequence. We clustered the 64 dimers we found into 35 
clusters. Our third largest cluster had two dimers gcactcN9gagtgc and tagcacN13gtgcta 
that matched the CIRCE element and an additional two dimers acacgcN7gcgtg and 
aagctcN13gagctt that may define a broader recognition consensus for HrcA. There 
were no plausible matches to the Fur consensuses. 
 
2.3.5. Known sets of coregulated genes 
 
Drawing from microarray studies, known regulons, CHip-CHip studies, etc., we 
compiled 39 sets, each containing genes believed to be targeted by some factor either 
directly or indirectly. The list of factors considered includes seven sigma factors (D, E, 
F, G, K, and X [21] and H [47]), the two-component systems DegU, ComA, and PhoP   66 
[33], 24 other two-component systems [34], AbrB [29], Fur [46], PucR [48], and PurR 
[49]. In what follows, we work with our operons predicted as discussed in “Putative 
operons and upstream sequences”. If in a set a gene in one of our operons is listed to 
be a target of a factor, then the entire operon is considered to be a target. For each of 
our 39 sets except those for the sigma factors, we asked which if any of our weight 
matrices had a regulon containing a disproportionate number of the set's operons. A 
weight matrix identified in this way could correspond either to the master factor 
believed to co-regulate the set's genes or some downstream factor activated later in the 
regulatory cascade. The probability that one of our regulons and one of the 32 sets 
considered share n operons by chance can be assessed using Poisson statistics. A 
probability cutoff of < 10
-4 is used appropriate to our sample size of  32•317. None of 
our weight matrices were found to have a regulon containing a disproportionate 
number of the targets listed in a set. (Of the 3 (18) operons identified as being 
regulated by the two-component system YccG-YccH (YclK-YclJ), 2 (2) were 
contained in the regulon for our matrix WM298 (WM259) with a size 27 (5) for a 
significance of ~10
-4 (~10
-3). We report these two-component systems in Table 2.2 
because we think they might be real.)  
 
To see why we did so poorly, we examined in more detail the 69 operons listed in the 
microarray study [33] to be targeted by DegU. Only 2 of these operons could be found 
among the 13 listed in the DBTBS database to be part of the DegU regulon. This 
suggests that the microarray study produced a considerable number of false negatives. 
It is possible that many of the targets listed in the study are indirect targets controlled 
by a cascade of regulatory factors and that no single factor directly binds to enough 
sites for its recognition consensus to be identifiable in our whole genome wide 
analysis.   67 
For 13 of the factors we considered (sigma D, E, F, G, X, and H, DegU, PhoP, AbrB, 
Fur, PucR, and PurR), the recognition consensuses are known. For each factor, we 
applied our algorithm to the regions upstream of the operons listed in our sets to be 
coregulated by the factor. Since for each of these factors only 5-70 operons are listed 
to be targets, we had to search for only length 2-3 words in order to have reasonable 
counts. For 2/5 of the factors, at least one of our three topmost significant dimers 
matched the known consensus. For gene sets this small, other methods however may 
be preferable (see Discussion). 
 
2.3.6. Regulons identified by operon functions 
 
A detailed manual examination reveals that the constituent operons of many of the 
regulons of our 317 weight matrices have highly related functions. For instance, the 
two operons prsA and sipA in the regulon for WM171 are both part of the Sec-
dependent protein export machinery [35]. In addition, the regulon for WM304 of size 
four contains at least three transporters, and the regulons for WM290 and WM47 
contain a disproportionate number of genes involved in DNA synthesis and repair.  
 
To attach a putative function to our 317 matrices automatically, we made use of ~20 
COG functional categories assigned to the ORF's in the protein table (PTT) file for B. 
subtilis [50]. We defined the category of one of our operons to be the category of the 
first gene and inspected each of our matrix regulons for over represented categories by 
using Poisson statistics to assess the number of operons belonging to any category. For 
significance, we used a probability threshold of 0.01, roughly the inverse of the 
number of regulons considered. (The probability threshold 0.001, corresponding to the 
inverse of the number of regulon-category pairs considered, would be too stringent   68 
since the over-representation of a particular category in one of our regulons often 
excludes the over-representation of another category.) The 21 of our matrices whose 
regulons contain an over-represented category are listed in Table 2.2 along with their 
significance scores. For a category to be over-represented in a given matrix regulon, 
note that the majority of the operons in the regulon need not belong to the category, 
just a disproportionately large number. Since many of the genes in B. subtilis have yet 
to be assigned a COG and since many regulons might contain operons belonging to a 
diverse set of categories, this form of automatic functional scoring is rather haphazard. 
Indeed, only one of the matrices WM304 that we identified manually (using the more 
extensive information available at http://genolist.pasteur.fr/SubtiList/ [51]) came up in 
our automatic screen. When we searched the regulons consisting of our operons 
immediately downstream of the experimental verified sites listed in the DBTBS 
database and by Helmann, the regulons for 5 out of the 11 sigma factors and 6 out of 
the 23 other transcription factors contained an over-represented category. 
 
2.3.7. Weight matrices with positional bias 
 
When we score our matrices over the whole genome, the matches to some of our 
matrices exhibit clear positional biases. Not only do many of these matches prefer to 
fall in non-coding as opposed to coding sequence, which can be expected since the 
matrices themselves are derived from non-coding sequence, but the matches tend to 
cluster into various intervals upstream of the translation starts. Of particular interest 
are the positions of the matches to our matrix WM1 representing σ
A, for these matches 
define the transcription start sites and thus can be used to determine whether a putative 
site is bound to by either an activator or a repressor. We defined a regulatory subset R 
of the non-coding sequence to be the regions upstream of the translation starts of   69 
divergently transcribed operons. Hence, for each divergent pair of operons, there are 
two sequences in R. We restricted the sequences to be each a maximum of 300 bases, 
and when the inter-operon distance was < 600 bases, we included the middle 
overlapping segment (with the appropriate orientation) in both sequences. Because the 
σ
A matrix is far from reverse complement symmetric, this ostensible double counting 
is not a problem. For comparison, we defined an analogous non-regulatory subset NR 
of the non-coding sequence to be the sequences downstream of the translation stop 
codons of pairs of convergently transcribed operons. Although the numbers of 
segments in the two sets are nearly equal, there are 175500 independent ways of 
placing a WM1 match in R versus 49500 in NR. Hence, the regions between divergent 
operons are longer than between convergent operons. Still, there are 806 matches to 
WM1 in R versus 99 in NR. Hence, the density of matches is 2.2 greater in the 
regulatory set.  
 
In addition to the greater number of matches, the actual distribution of matches in the 
regulatory set deviated more from random (see Figure 2.3). For each set, we defined 
the random distribution as that expected if each position for a WM1 match in the 
sequences was equally likely. We then normalized the distribution so that the total 
number of matches was equal to that observed and binned the counts to obtain the 
histogram in Figure 2.3. The deviation between the actual and random distributions 
was scored with the Kolmogorov Smirnov test. For the interval [-70, -40), there is a 5x 
greater probability of occurrence of a WM1 match in R versus NR and 6x greater than 
for coding sequence (after accounting for the different number of samples). We also 
looked at all analogous sequences between tandemly transcribed operons, comparing 
the conventional upstream regulatory region of the downstream operon (R) with the 
same size region immediately downstream of the upstream operon (NR). We scored 70 
 
 
Figure 2.3: Matches to our σ
A weight matrix WM1 exhibit a clear 
positional bias. Histograms of positions of the matches to our σ
A weight 
matrix WM1 between (a) divergent and (b) convergent operons. In (a), 
positions are measured relative to translation start. In (b), positions are 
measured relative to the downstream end of the region. In either case, the first 
upstream base is assigned the position -1. The expected distribution, under 
the null hypothesis that the matches are uniformly distributed in their upstream 
regions, is denoted by *. Probability P of the observed distribution under the 
null hypothesis is reported as the significance score  10 log P - .  71 
WM1 over the latter region in the opposite sense to transcription to distinguish from 
perhaps distant sites regulating the downstream operon. Once again, the WM1 
matches exhibited a clear positional bias for matching segments in the regulatory set, 
in particular the [-70, -40) interval. However, the difference between the two sets was 
less substantial: there was only a 3x greater probability of occurrence of a WM1 match 
in R versus NR in the interval [-70, -40). 
 
We tested the matches to the remainder of our 317 matrices for positional biases. For 
each matrix, we compared the distribution of the matrix's matches in our search space 
of upstream regions defined in “Algorithm” with a random distribution defined as the 
distribution expected if each position for a match were equally likely. Eighteen 
matrices had biased distributions at a significance level P < 0.01 as assessed by the 
Kolmogorov Smirnov test. The six most significant distributions discounting WM1 
are shown in Figure 2.4. The matches for one of the 18 matrices, WM14, tend to occur 
in the same upstream sequences as the T-box [16]. The c/g richness and the reverse 
complement symmetry of WM14's consensus N3CGGCN11GCCGN3 suggest that the 
motif is capable of forming a stem loop structure that may interact with the alternate 
structures formed by the T-box. 
              
A more ambitious test, since it relies on the quality of our σ
A predictions, distinguishes 
matrices representing activators and repressors by their matches' positions relative to 
the σ
A predictions. The position of a matrix match relative to a WM1 match in the 
same upstream region in our search space is measured center to center. The position -1 
indicates that the center of the matrix match is 1 base upstream of the center of the 
WM1 match. Relative to the center of the σ
70 site in E. coli, the centers of activator 
sites are concentrated upstream in the -20 to -70 interval, and the centers of repressor  72 
 
 
Figure 2.4: Other weight matrices with matches exhibiting a clear 
positional bias. Histograms of positions of the matches in all upstream 
sequences to the six non-σ
A weight matrices with the most position biased 
matches, using the same conventions as Figure 2.3.73 
sites tend to fall downstream of the -20 position [18]. At a significance level P < 0.01, 
the matches of 13 matrices (excluding those representing σ
A) exhibited biases relative 
to our WM1 matches (see Table 2.2). The six most significant cases are shown in 
Figure 2.5, and only WM46 appears to be a repressor. In the case of WM46, the 
positional bias may come simply from the similarity of the 5' end of WM46, TATA, 
with the 3' end of WM1 with consensus N7TTGAN19TATAATAN6. Nevertheless, if 
WM46 represents an actual factor, it would act as a repressor. 
 
The matches to WM22 did not exhibit a positional bias with respect to our WM1 
matches, even though WM22 is a good representative of the canonical repressor LexA 
(of the 35 matches to WM22, 18 agreed with one of the 30 experimentally verified 
LexA sites in [30]). In our set of upstream sequences, only 9 of the 35 WM22 matches 
have a WM1 match to compare with in the same sequence, suggesting that the σ
A 
recognition sites are weak for LexA regulated genes. When a comparison can be made, 
the centers of the WM22 matches tend to fall upstream of the WM1 matches, which is 
consistent with the observation that LexA sometimes prevents transcription initiation 
by binding upstream of the RNA polymerase binding element to inhibit the interaction 
of the RNA polymerase α-subunit with the a/t rich UP element. A histogram of the 
positions, again measured center to center, of the 30 experimentally verified LexA 
sites relative to the known sigma site has the most weight in the upstream interval [-40, 
-20). 
 
We also checked the weight matrices derived from the experimentally verified 
recognition sites for the 23 non-sigma factors in the DBTBS database. No matrix had 
matches exhibiting a positional bias with respect to our WM1 matches at a 
significance level P < 0.01. In a number of cases (e.g. AraR, RocR, CtsR, and HrcA),    74 
 
 
Figure 2.5: Weight matrices with matches exhibiting a clear positional 
bias relative to σ
A. Histograms of positions of the matches to weight matrices 
relative to the best matches to the σ
A weight matrix WM1. The position of a 
weight matrix match relative to a WM1 match is measured center to center. 
The position -1 indicates that the center of the matrix match is 1 base 
upstream of the center of the WM1 match. Plots for the six weight matrices 
with the most positionally biased matches are shown using the same 
conventions as Figure 2.3.   75 
the total number of matches is small and thus does not define a significant distribution; 
in other cases (e.g. CcpA, DegU, Spo0A, and TnrA), the regulators act as both 
activators and repressors; finally, for the factors with more than 400 matches in Figure 
2.2(b), we expect that many of the matches are false positives for reasons stated above. 
 
2.3.8. Other applications 
 
Pathogenicity islands (PAI's) [52] transferred between bacteria present interesting 
cases for study, for it is not clear if and how the PAI's are coordinately regulated with 
the host genome. Any cross regulation that exists may not have any profound 
significance but could occur by chance and not be deleterious. A well studied case is 
the PAI SPI-1 in S. typhimurium LT2 [53], which encodes two transcription factors 
HilA and InvF [54] that regulate genes within the island. When we applied our 
algorithm to the entire S. typhimurium LT2 genome, we did find a marginal match to 
the HilA recognition consensus but the statistics were poor. There were numerous 
matrices though that recognized sites within and outside the island, suggesting that the 
pathogenicity genes are coregulated with the remainder of the genome. We also ran 
our algorithm on just the SPI-1 island itself but found nothing over-represented that 
matched the known HilA and InvF recognition consensuses.  
 
2.4. Discussion 
 
There are a number of motif finding algorithms (Consensus [4], Gibbs [5], MEME [6]) 
that construct a weight matrix directly and are suitable for locating similar patterns in 
groups of tens of operons. They are thus the best tools for which to process gene 
clusters obtained from microarrays. (For bacterial applications, their sensitivity is   76 
much improved if they fit to dimer patterns with symmetry.) They evaluate 
significance by reference to a model of random bases (which is far from the truth, 
even if poly A/T sequences are excluded) and may not converge to the optimal pattern. 
They also do not use information from beyond the genes being analyzed. Reference 
[7] search for over-represented monomers of length 6 in a target set. Significance is 
assessed by contrasting the counts in the target set to the counts genome wide. They 
are then faced with an assembly problem for the various 6-mers that scored significant 
and the possibility that a degenerate pattern is significant even when none of the words 
that overlap it are. 
 
There are a number of algorithms that exploit the dimer symmetry of bacterial motifs 
[8-10]. They differ in how they assign significance. Reference [8] searches for dimers 
of world length 3 in a subset of sequences and assesses the frequency of occurrence by 
either contrasting the subset with the genome or using actual word counts and 
computing a probability from Poisson statistics based on the spacing, as we do. They 
do not attempt to cluster the word pairs thereby obtained nor do they attempt genome 
wide applications. Reference [9] compute significance from a Markov Model applied 
to the entire dimer. They score degenerate patterns defined by IUPAC symbols and 
resolve overlapping motifs with a greedy algorithm [55].  
 
Our algorithm is a direct extension of [15], who worked with E.coli. Our principal 
technical innovations involved the clustering of the dimers, the construction of weight 
matrices from sites, and the detailed manner in which we validated our predictions 
using the available B. subtilis information. When applied to E. coli, our clustering 
procedure gave about half the number of clusters as in the earlier paper (if clusters 
containing one dimer are counted) and generally reduced the number of nearly   77 
equivalent weight matrices. When we computed weight matrices, we did not use low 
information matrix columns in subsequent scans with the matrix across the genome. 
This eliminated a certain amount of noise and generally gave us putative regulons of 
comparable size to the more sophisticated inference method developed  by [56]. 
 
When we compared our results with the DBTBS and Helmann databases, we hit a 
smaller fraction (~21%) of the known recognition sites than in the parallel study for E. 
coli, probably because for many factors only a few sites with a poorly defined 
consensus are listed. We did do better with sigma sites, and our most significant 
dimers corresponded to the consensus recognized by σ
A, the functional homologue of 
the primary sigma factor σ
70 in E. coli. Although σ
A and σ
70 recognize the same 
consensus, failure to recover the σ
70 matrix in [15] was not due to difference in 
method but rather the inherent greater variability of the E. coli sites. In contrast to 
some weight matrix scans in E. coli that generalized from experimental sites, e.g. [20], 
most of our dimers generated matrices (with the exception of the poly A/T dimers) 
that gave very reasonable regulon sizes. Our surrogate σ
A matrix, WM1, had a regulon 
of size 1141 and matched 109 out of 132 experimental sites documented by Helmann 
with the same spacing. Evidence that a matrix represents an actual regulatory factor 
could be deduced for a total of 52 of our 317 weight matrices using either matches to 
known sites, correlations in operons' functions, or biases in matches' positions. For 
comparison, the B. subtilis genome is predicted to encode for 200 DNA binding 
proteins [57]. Some of our predictions may correspond to translation control motifs, 
which sometimes operate though conserved stems in the mRNA. We tended to set our 
significance thresholds high so as to minimize false positives. For these reasons, we 
missed specific factors such as ComA, CtsR, and Fnr. In counting dimers, we insisted 
that any prediction have a probability 10
-7 of occurring by chance given our statistical   78 
model, i.e. there is about one random prediction among the set of 10
7 dimers we 
searched through. A less stringent cutoff could be used for symmetric and reverse 
complement symmetric dimers since there are fewer cases to examine.  
 
The most serious shortcoming of our algorithm is that it enumerates and scores ACGT 
words rather than more degenerate patterns. Thus a fairly specific pattern such as the 
Fur box TGAtAATNATTaTCA, with a variable site in the center of each word, does 
not yield any single dimer that passes our cutoffs for significance. Another 
shortcoming is our relatively crude method of predicting operons. A more 
sophisticated method could be used, like the ones outlined in [58] and [59]. A more 
fundamental problem is that a transcription factor can distinguish its preferred binding 
sites in the genome even when it is impossible to discern these sites by searching for 
statistical over-representation [60]. Interspecies comparisons are an obvious source of 
additional sequence information, and one can envision a generalization of our 
counting procedure to handle multiple genomes. Other extensions would use sequence 
information along with expression or annotation data to assign higher weight to 
marginal sites falling within a cofunctional gene group.79 
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Chapter 3 
Tracking in Vivo Evolution of Multidrug Resistance 
in Staphylococcus aureus by Whole Genome Sequencing 
 
3.1. Introduction 
 
Staphylococcus aureus has remained one of the most frequent causes of human 
disease both in hospitals and the community including infections of the skin and also 
potentially life threatening afflictions such as septicemia, heart valve infections, and 
toxic shock syndrome. The spectacular adaptive capacity of this pathogen resulted in 
the emergence and worldwide spread of lineages that acquired resistance to the 
majority of available antimicrobial agents. The choice of therapy against such 
multidrug resistant S. aureus (MRSA) strains has been narrowed to the glycopeptides 
antibiotic vancomycin which has become the mainstay of therapy worldwide.  
Therefore, it is a major concern that MRSA strains with reduced susceptibility to 
vancomycin began to appear in clinical specimen since the late 1990s raising the 
specter of untreatable staphylococcal disease [1].  In most of these so-called VISA 
isolates (for vancomycin intermediate resistant Staphylococcus aureus), the decrease 
in drug susceptibility, as expressed by the modest increase in the minimal inhibitory 
concentration (MIC) of vancomycin, is sufficient to cause complications in therapy 
and treatment failure [2-4].   
 
The genetic basis of VISA-type resistance to vancomycin is unknown; unlike the most 
recently described and currently still rare VRSA isolates which carry the Tn1546-
linked resistance mechanism [5, 6], the VISA type isolates do not seem to carry   86 
acquired genetic elements related to drug resistance: their reduced susceptibility to 
vancomycin appears to be based on an adaptive process.  
 
Examination of VISA type isolates recovered from many parts of the world showed a 
number of different phenotypic alterations including changes in cell morphology and 
composition and turnover of cell wall [7, 8]. Nevertheless, in most of these studies, 
associating these altered properties with the mechanism of resistance has remained 
problematic because of the lack of availability of an isogenic vancomycin susceptible 
“parental” isolate that could be used as a valid comparison.  For instance, comparing 
the sequences of the first clinical VISA isolate MU50 [9] to the genetically related 
vancomycin susceptible strain N315, identified over 174 ORFs that carried non-
synonymous changes.  However, MRSA strain N315 was isolated 15 years earlier than 
strain Mu50 and from different patients.  Thus, it is not clear how many of the 174 
mutations are related to the mechanism of drug resistance versus the different 
evolutionary history of the strains. 
 
Recently, we obtained a series of MRSA isolates from a patient X with congenital 
heart disease who had a bacteremic S. aureus infection against which extensive 
vancomycin therapy was instituted and eventually failed [10].  Prior to vancomycin, 
the patient also received a single dose of rifampin and a course of therapy with the  
 
beta-lactam antibiotic imipenem during early periods of the hospitalization.  After 
over 2 months of therapy, the patient died.  The serial isolates, (beginning with JH1 
obtained at hospital admission) recovered at various times after the beginning of 
chemotherapy with vancomycin, were compared for antibiotic resistance profiles, 
physiological and biochemical properties [8], and gene expression profiles [11]. The   87 
first isolate JH1 was susceptible to vancomycin (MIC = 1 mg/ml) and rifampin (MIC = 
0.01 mg/ml). The last isolate JH9 was resistant to rifampin (MIC = 16 mg/ml) and 
showed decreased susceptibility to vancomycin (MIC = 8 mg/ml).  Surprisingly, the 
last JH isolates also showed over 100 fold increase in the MIC for daptomycin (from 
0.01 up to 1.0 mg/ml), in spite of the fact that this agent was not used in the therapy. 
This is a troubling development since daptomycin most recently received FDA 
approval, specifically against MRSA with reduced susceptibility to vancomycin.   
 
Comparison of the fully drug susceptible isolate JH1 with the vancomycin resistant 
isolate JH9 by several genetic typing techniques indicated that the two strains were 
isogenic [8, 11].  The JH lineage was also related – although more remotely –  to the 
fully sequenced MRSA strain N315 [11, 12].   
 
The availability of these isolates offered a unique opportunity to better understand the 
genetic basis of VISA type vancomycin resistance by whole genome shotgun 
sequencing. 
 
3.2. Whole genome shotgun sequencing of JH1 and JH9   
 
For each isolate, the reads were assembled into 60-80 contigs representing the 
chromosome and a complete 30kb plasmid.  The N315 genome and the paired end 
reads bridging contigs were used to order the contigs and estimate the lengths of the 
gaps separating them (see Methods).  We used information available from N315 rather 
than the related VISA type MU50 for the genome assembly for the following reasons.  
Three-way alignments of orthologus regions from the N315, MU50 and JH1 
chromosomes were constructed and 50 isolated point mutations between N315 and   88 
MU50 were examined genome wide.  The sequence of JH1 was found in about 3 out 
of every 4 cases to agree with N315 rather than MU50.    
 
The sizes of the chromosomes of JH1 and JH9 were each estimated to be about 2.9Mb, 
a figure that includes the unknown sequence in the gaps, most of which are <1kb in 
length.  Only 1.5% and 2.3% of the chromosomal sequence for respectively JH1 and 
JH9 is predicted to fall into gaps.     
 
3.3. Intergenomic comparisons  
 
To enumerate polymorphisms, we multi-aligned the N315 genome, the JH1 and JH9 
assemblies, and the JH1 and JH9 reads. To identify large differences, we carefully 
verified the entire machine alignment by eye.  For smaller mutations, we formulated a 
Bayesian probabilistic model (BPM) to identify high quality bases and called 
nucleotide differences (ND’s) column by column in the alignment. The BPM 
considered the coverage and Phred quality values [13] of the JH1 and JH9 reads 
(Methods). 
 
When we compared N315 (isolated in 1982) and the high quality sequences of JH1 
(isolated in 2000), we found 17 insertions and deletions larger than 1 kb and a point 
mutation rate of about 1:5000 nucleotides (Figure 3.1).  No transpositions > 10kb and 
no inversions were observed between N315 and either of the JH isolates.  It is 
expected that all ND’s that were reported are bona fide mutations or are due to 
sequencing errors in N315 but not JH1 (Methods).  
 
When we compared JH1 and JH9, there was sufficient coverage to call polymorphisms    89 
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Figure 3.1: (a) Differences found between N315 and JH1 chromosomes. 
Shown is a schematic of the 2,967,572 column alignment of the N315 and JH1 
chromosomes. The positions of detected differences are marked: █ = insertion 
in JH1 relative to N315; █ = deletion in JH1 relative to N315; and | = a 
nucleotide substitution. The insertions and deletions range in size from 1 bp 
(shortest of bands) to >40,000 bp (longest of bands). Three replacements 
involving distantly related or non-homologous sequence produced dense 
clusters of polymorphisms (aqua). The largest replacement involved the 
swapping of a ~40,000 bp phage-like element in N315 with an element in JH1 
with only 70% bp identity. Excluding the three regions of replacement, we 
detected 82 insertions and deletions and 445 nucleotide substitutions 
chromosome-wide. Included in this list are insertions in JH1 of three >40,000 
bp phage-like elements and a deletion in JH1 of a 15,659 bp pathogenicity 
island (orange). (b) JH1 plasmid. The 30,429 JH1 plasmid is composed of 
segments bearing >99% identity to either the 24,653 bp N315 plasmid or the 
25,107 bp Mu50 plasmid. The single segment with similarity to the N315 
plasmid spans almost half the plasmid (black). Four segments are similar to 
the transposable element tnpE on the Mu50 plasmid (brown). Additionally, 
three other segments are similar to the Mu50 plasmid (grey). The remaining 
segments have homology to neither the N315 nor Mu50 plasmids and encode 
for ORFs of unknown function (white)  90 
with an expected error (both false positive and negative) of less than one per genome 
in 94% of the chromosomes and 100% of the plasmids. In the remaining low coverage 
regions and gaps, we found only single base changes that are very likely to be due to 
read errors and no evidence of any larger changes (Methods). To minimize the number 
of undetected ND’s between JH1 and JH9, liberal thresholds were set in our BPM.  
PCR sequencing was done to check the predicted ND’s and to rule out marginal cases. 
In total, we confirmed 33 point mutations between JH1 and JH9, 31 of which are on 
the chromosome and two on the plasmid. Due to failure of the PCR sequencing 
method, we could not validate two single nucleotide deletions in JH9 on the 
chromosome. Our list of 33 confirmed mutations and two unconfirmed deletions (see 
Table 3.1) is expected to be nearly exhaustive. Including regions of low coverage and 
gaps, the number of unreported ND’s between JH1 and JH9 is expected to be ≤ 2 on 
the chromosome and zero on the plasmid (Methods). 
 
3.4. Sequential appearance of mutations  
 
The availability of additional blood stream isolates recovered from the patient at 
different times after initiation of the vancomycin therapy (Table 3.1) allowed us to test 
the time of appearance of the 33 confirmed point mutations in these intermittent 
strains by PCR sequencing.  Also available were a single isolate JH14 recovered 
posthumously from the heart valve of the patient and an additional fully vancomycin 
susceptible isolate JH15 which was recovered from the nares of a healthy contact [10].  
The results (Table 3.1) allow several conclusions. (i) The isolate JH1 and the isogenic 
and vancomycin susceptible contact isolate JH15 have the same resistance and allelic 
profiles. (ii) Once a mutation appeared in JH2, it was found to be retained in 
subsequent blood isolates (with the single exception of the mutation in SA1249). Thus   91 
Table 3.1:  Stepwise appearance of 35 point mutations as a function of 
the date of recovery of the isolate from the patient X. See Table 3.2 for a 
more detailed description of each of the 35 point mutations. Note that only two 
loci contain multiple point mutations: rpoB with four and prsA with two. Also 
available was a fully vancomycin susceptible isolate JH15 that was recovered 
from the nares of a healthy contact. It had resistance and allelic profiles 
identical to those of JH1.  
Daptomycin  0.01  0.05  0.05  1.0  1.0  1.0 
Rifampin  0.012  16  16  16  16  16 
Oxacillin (a β-lactam)  0.75  25  0.75  1.5  0.75  1.5 
MIC (µg/ml) 
Vancomycin  1.0  3.0  6.0  8.0  8.0  8.0 
 
Isolate  JH1  JH2  JH5  JH6  JH9  JH14 
Isolation date in year 2000 (month/day)  7/20  9/20  10/01  10/06  10/13  10/17 
Locus
a  Type of 
mutation
b 
Blood  Heart 
 33 confirmed point mutations 
on plasmid in SAP011(blaR1)  FS  ▲                
SA0500(rpoB)  NS (4)    ■  ■  ■  ■  ■ 
SA0501(rpoC)  NS    ■  ■  ■  ■  ■ 
SA1129 (protein with RNA binding domain?)  NS    ■  ■  ■  ■  ■ 
SA1702(in vraSR operon)  NS    ■  ■  ■  ■  ■ 
SA1249 (in murG operon?)  FS      ■  □  ■  □ 
SA0019(yycH)  TR        ■  ■  ■ 
between divergent SAS014 and 
SA0411(ndhF)  INT        ■  ■  ■ 
SA0582 (Na
+/H
+ antiport?)  S        ■  ■  ■ 
SA0980(iron acquistion gene isdE)  NS        ■  ■  ■ 
SA1659(gene prsA encoding chaprone that 
assists in post-translocational folding)  FS        ■  ■  ■ 
SA1843(agrC)  FS        ■  ■  ■ 
SA2094(malic/Na
+-lactate antiporter?)  NS        ■  ■  ■ 
between divergent SA2125 and SA2126  INT        ■  ■  ■ 
SA2320(sugar specific permease?)  S        ■  ■  ■ 
on plasmid between convergent SAP007 and 
SAP008  INT          ■   
SA0171(fdh)  FS          ■   
SA0617(vraG)  NS          ■   
12 other point mutations in JH9 only (see below) 
SA0215 NS  SA0388(set12 exotoxin) S  between divergent SA0526 and SA0527(nagB) INT 
upstream of SA0558 INT  SA0185 NS  SA1147 NS  SA1510(gapB) S  SA1659(prsA) NS  
SA2091 S  SA2119 S  upstream of SA2232(pyrimidine biosynthesis?) INT  SAtRNA34(tRNA-Tyr) INT 
Two unconfirmed single nucleotide deletions that could not be PCR sequenced 
between convergent SA2015 and SA2016(rpsI) INT  Deletion occurred in run of adenines, with initial length of 
14 bp. Sequence reactions would not extend past run. 
in multi-copy IS1811 transposable element 
downstream of SA0617(vraG) FS  Unique PCR primers could not be designed. 
 (a). N315 identifier for gene followed by description in parenthesis. Unless otherwise stated, locus is on 
chromosome. (b). (NS): Non-Synonymous substitution; (S): Synonymous substitution; (FS): Frameshift; (TR): 
Truncation of ORF; (INT): In intergenic sequence; (RED): In run of identical nucleotides initially ≥ 6 bp. 
Solid symbols (▲■)  indicate a mutation.  Empty symbols (  □) indicate reversion of a previously identified 
mutation.  
T
a
b
l
e
 
3
.
2
:
 
A
 
s
u
m
m
a
r
y
 
o
f
 
t
h
e
 
3
5
 
p
o
i
n
t
 
m
u
t
a
t
i
o
n
s
 
f
o
u
n
d
 
b
e
t
w
e
e
n
 
J
H
1
 
a
n
d
 
J
H
9
.
 
A
 
n
u
m
e
r
i
c
a
l
 
i
d
e
n
t
i
f
i
e
r
 
i
s
 
a
s
s
i
g
n
e
d
 
t
o
 
e
a
c
h
 
m
u
t
a
t
i
o
n
 
i
n
 
t
h
e
 
c
o
l
u
m
n
 
“
#
”
.
 
A
n
 
i
d
e
n
t
i
f
i
e
r
 
i
s
 
p
r
i
n
t
e
d
 
i
n
 
r
e
d
 
i
f
 
t
h
e
 
m
u
t
a
t
i
o
n
 
i
s
 
a
n
 
i
n
s
e
r
t
i
o
n
 
o
r
 
d
e
l
e
t
i
o
n
 
i
n
 
a
 
r
u
n
 
o
f
 
i
d
e
n
t
i
c
a
l
 
n
u
c
l
e
o
t
i
d
e
s
 
o
f
 
l
e
n
g
t
h
 
≥
 
6
 
n
u
c
l
e
o
t
i
d
e
s
 
(
e
.
g
.
 
t
t
t
t
t
t
t
)
.
 
T
h
e
 
l
o
c
u
s
 
h
a
r
b
o
r
i
n
g
 
t
h
e
 
m
u
t
a
t
i
o
n
 
i
s
 
l
i
s
t
e
d
 
i
n
 
t
h
e
 
c
o
l
u
m
n
 
“
L
o
c
u
s
”
 
a
n
d
 
i
s
 
o
n
 
t
h
e
 
c
h
r
o
m
o
s
o
m
e
 
u
n
l
e
s
s
 
o
t
h
e
r
w
i
s
e
 
i
n
d
i
c
a
t
e
d
.
 
A
 
b
o
x
 
i
s
 
s
h
a
d
e
d
 
g
r
e
y
 
t
o
 
i
n
d
i
c
a
t
e
 
t
h
a
t
 
t
h
e
 
l
o
c
u
s
 
i
s
 
o
n
 
t
h
e
 
p
l
a
s
m
i
d
.
 
T
h
e
 
l
o
c
i
 
h
a
r
b
o
r
i
n
g
 
t
h
e
 
m
u
t
a
t
i
o
n
s
 
w
e
r
e
 
P
C
R
 
s
e
q
u
e
n
c
e
d
 
i
n
 
a
l
l
 
i
s
o
l
a
t
e
s
.
 
T
h
e
 
b
o
x
 
f
o
r
 
a
n
 
i
s
o
l
a
t
e
 
i
s
 
s
h
a
d
e
d
 
i
n
 
g
r
e
y
 
i
f
 
t
h
e
 
m
u
t
a
t
i
o
n
 
w
a
s
 
f
o
u
n
d
 
i
n
 
t
h
e
 
i
s
o
l
a
t
e
.
 
T
h
e
 
t
w
o
 
l
o
c
i
 
h
a
r
b
o
r
i
n
g
 
m
u
t
a
t
i
o
n
s
 
3
4
 
a
n
d
 
3
5
 
c
o
u
l
d
 
n
o
t
 
b
e
 
P
C
R
 
s
e
q
u
e
n
c
e
d
.
 
T
h
e
 
s
e
q
u
e
n
c
i
n
g
 
r
e
a
c
t
i
o
n
s
 
w
o
u
l
d
 
n
o
t
 
e
x
t
e
n
d
 
p
a
s
t
 
t
h
e
 
r
u
n
 
o
f
 
A
’
s
 
c
o
n
t
a
i
n
i
n
g
 
m
u
t
a
t
i
o
n
 
3
4
,
 
a
n
d
 
u
n
i
q
u
e
 
P
C
R
 
p
r
i
m
e
r
s
 
c
o
u
l
d
 
n
o
t
 
b
e
 
d
e
s
i
g
n
e
d
 
t
o
 
a
m
p
l
i
f
y
 
t
h
e
 
r
e
g
i
o
n
 
c
o
n
t
a
i
n
i
n
g
 
m
u
t
a
t
i
o
n
 
3
5
 
i
n
 
t
h
e
 
I
S
1
8
1
1
 
i
n
s
e
r
t
i
o
n
 
s
e
q
u
e
n
c
e
 
w
i
t
h
 
m
u
l
t
i
p
l
e
 
c
o
p
i
e
s
 
i
n
 
t
h
e
 
c
h
r
o
m
o
s
o
m
e
.
 
A
 
l
o
c
u
s
 
m
a
r
k
e
d
 
w
i
t
h
 
a
s
t
e
r
i
s
k
s
 
w
a
s
 
a
l
s
o
 
f
o
u
n
d
 
t
o
 
b
e
 
m
u
t
a
t
e
d
 
i
n
 
M
u
5
0
 
(
s
e
e
 
t
e
x
t
 
b
e
l
o
w
 
t
h
e
 
t
a
b
l
e
)
.
 
A
s
 
a
 
g
u
i
d
e
 
t
o
 
t
h
e
 
l
i
t
e
r
a
t
u
r
e
 
o
n
 
a
 
p
a
r
t
i
c
u
l
a
r
 
l
o
c
u
s
,
 
r
e
f
e
r
e
n
c
e
s
 
i
n
 
p
a
r
e
n
t
h
e
s
e
s
 
a
r
e
 
g
i
v
e
n
.
 
#
 
L
o
c
u
s
 
 
F
u
n
c
t
i
o
n
 
P
o
l
y
m
o
r
p
h
i
s
m
(
s
)
 
N
3
1
5
 
J
H
1
 
J
H
2
 
J
H
5
 
J
H
6
 
J
H
9
 
 
J
H
1
4
 
J
H
1
5
 
(
a
)
 
C
o
n
f
i
r
m
e
d
 
b
y
 
P
C
R
 
s
e
q
u
e
n
c
i
n
g
 
(
I
)
 
L
o
c
i
 
p
r
e
v
i
o
u
s
l
y
 
i
m
p
l
i
c
a
t
e
d
 
i
n
 
r
e
s
i
s
t
a
n
c
e
 
t
o
 
b
o
t
h
 
v
a
n
c
o
m
y
c
i
n
 
a
n
d
 
β
-
l
a
c
t
a
m
s
 
1
 
S
A
1
7
0
2
*
 
i
n
 
o
p
e
r
o
n
 
w
i
t
h
 
g
e
n
e
s
 
v
r
a
S
R
,
 
w
h
i
c
h
 
e
n
c
o
d
e
 
f
o
r
 
a
 
r
e
g
u
l
a
t
o
r
 
o
f
 
c
e
l
l
 
w
a
l
l
 
s
y
n
t
h
e
s
i
s
 
g
e
n
e
s
 
[
1
4
-
1
6
]
 
A
a
 
c
h
a
n
g
e
 
H
1
6
4
R
 
 
 
 
 
 
 
 
 
2
 
b
e
t
w
e
e
n
 
d
i
v
e
r
g
e
n
t
 
O
R
F
s
 
S
A
0
5
2
6
 
a
n
d
 
S
A
0
5
2
7
(
n
a
g
B
)
 
N
a
g
B
 
i
s
o
m
e
r
i
z
e
s
 
g
l
u
c
o
s
a
m
i
n
e
-
6
-
P
 
t
o
 
f
r
u
c
t
o
s
e
-
6
-
P
 
[
1
7
]
.
 
n
u
c
l
e
o
t
i
d
e
 
c
h
a
n
g
e
 
g
→
a
 
1
0
7
 
a
n
d
 
1
7
2
 
b
p
 
u
p
s
t
r
e
a
m
 
o
f
 
S
A
0
5
2
6
 
a
n
d
 
n
a
g
B
 
r
e
s
p
e
c
t
i
v
e
l
y
 
 
 
 
 
 
 
 
 
(
I
I
)
 
L
o
c
i
 
p
r
e
v
i
o
u
s
l
y
 
i
m
p
l
i
c
a
t
e
d
 
i
n
 
r
e
s
i
s
t
a
n
c
e
 
t
o
 
v
a
n
c
o
m
y
c
i
n
 
3
 
S
A
0
6
1
7
(
v
r
a
G
)
 
p
e
r
m
e
a
s
e
 
o
f
 
a
n
 
A
B
C
 
t
r
a
n
s
p
o
r
t
e
r
 
[
1
6
]
 
A
a
 
c
h
a
n
g
e
 
A
5
8
0
V
 
 
 
 
 
 
 
 
 
4
 
S
A
1
8
4
3
(
a
g
r
C
)
*
*
 
A
g
r
 
q
o
r
u
m
 
s
e
n
s
i
n
g
 
s
y
s
t
e
m
 
r
e
g
u
l
a
t
i
n
g
 
t
h
e
 
e
x
p
r
e
s
s
i
o
n
 
o
f
 
v
i
r
u
l
e
n
c
e
 
a
n
d
 
s
u
r
f
a
c
e
 
p
r
o
t
e
i
n
s
 
[
1
8
-
2
6
]
 
D
e
l
e
t
i
o
n
 
o
f
 
t
 
i
n
 
a
t
t
t
t
t
t
t
a
 
f
r
a
m
e
s
h
i
f
t
e
d
 
l
a
s
t
 
7
0
%
 
o
f
 
g
e
n
e
.
 
 
 
 
 
 
 
 
 
(
I
I
I
)
 
L
o
c
i
 
i
n
v
o
l
v
e
d
 
i
n
 
r
e
s
i
s
t
a
n
c
e
 
t
o
 
β
-
l
a
c
t
a
m
s
 
5
 
S
A
P
0
1
1
(
b
l
a
R
1
)
 
(
o
n
 
p
l
a
s
m
i
d
)
 
r
e
g
u
l
a
t
i
o
n
 
o
f
 
β
-
l
a
c
t
a
m
a
s
e
 
g
e
n
e
 
b
l
a
Z
 
a
n
d
 
b
r
o
a
d
 
s
p
e
c
t
r
u
m
 
β
-
l
a
c
t
a
m
 
r
e
s
i
s
t
a
n
c
e
 
g
e
n
e
 
m
e
c
A
 
[
2
7
-
2
9
]
 
D
e
l
e
t
i
o
n
 
o
f
 
a
 
i
n
 
t
a
a
a
a
a
a
a
a
t
 
f
r
a
m
e
s
h
i
f
t
e
d
 
l
a
s
t
 
7
0
%
 
o
f
 
g
e
n
e
.
 
 
 
 
 
 
 
 
 
(
I
V
)
 
L
o
c
i
 
i
n
v
o
l
v
e
d
 
i
n
 
r
e
s
i
s
t
a
n
c
e
 
t
o
 
r
i
f
a
m
p
i
n
 
a
n
d
 
p
r
e
v
i
o
u
s
l
y
 
i
m
p
l
i
c
a
t
e
d
 
i
n
 
r
e
s
i
s
t
a
n
c
e
 
t
o
 
d
a
p
t
o
m
y
c
i
n
 
6
 
A
a
 
c
h
a
n
g
e
 
D
4
7
1
Y
 
 
 
 
 
 
 
 
 
7
 
A
a
 
c
h
a
n
g
e
 
A
4
7
3
S
 
 
 
 
 
 
 
 
 
8
 
A
a
 
c
h
a
n
g
e
 
A
4
7
7
S
 
 
 
 
 
 
 
 
 
9
 
S
A
0
5
0
0
(
r
p
o
B
)
*
*
*
 
β
-
s
u
b
u
n
i
t
 
o
f
 
R
N
A
 
p
o
l
y
m
e
r
a
s
e
 
[
3
0
-
3
7
]
 
A
a
 
c
h
a
n
g
e
 
E
4
7
8
D
 
 
 
 
 
 
 
 
 
(
V
)
 
L
o
c
i
 
p
r
e
v
i
o
u
s
l
y
 
i
m
p
l
i
c
a
t
e
d
 
i
n
 
r
e
s
i
s
t
a
n
c
e
 
t
o
 
d
a
p
t
o
m
y
c
i
n
 
1
0
 
S
A
0
0
1
9
(
y
y
c
H
)
 
s
i
m
i
l
a
r
 
t
o
 
Y
y
c
H
 
i
n
 
B
.
 
s
u
b
t
i
l
i
s
,
 
p
o
s
s
i
b
l
y
 
i
n
v
o
l
v
e
d
 
i
n
 
r
e
g
u
l
a
t
i
o
n
 
o
f
 
l
y
t
M
 
a
n
d
 
t
e
i
c
h
o
i
c
 
a
c
i
d
 
b
i
o
s
y
n
t
h
e
s
i
s
 
g
e
n
e
s
 
[
3
3
,
 
3
8
-
4
1
]
 
N
u
c
l
e
o
t
i
d
e
 
c
h
a
n
g
e
 
g
→
a
 
c
o
n
v
e
r
t
e
d
 
3
6
t
h
 
c
o
d
o
n
 
t
o
 
s
t
o
p
 
c
o
d
o
n
,
 
p
o
s
s
i
b
l
y
 
t
r
u
n
c
a
t
i
n
g
 
p
r
o
t
e
i
n
 
t
o
 
1
0
%
 
o
f
 
i
t
s
 
l
e
n
g
t
h
.
 
 
 
 
 
 
 
 
 
 
92  
T
a
b
l
e
 
3
.
2
 
(
C
o
n
t
i
n
u
e
d
)
 
1
1
 
S
A
0
5
0
1
(
r
p
o
C
)
 
β
'
-
s
u
b
u
n
i
t
 
o
f
 
R
N
A
 
p
o
l
y
m
e
r
a
s
e
 
[
3
3
,
 
4
2
]
 
A
a
 
c
h
a
n
g
e
 
E
8
5
4
K
 
p
l
a
u
s
i
b
l
y
 
m
a
p
s
 
t
o
 
o
u
t
e
r
 
r
i
m
 
o
f
 
s
e
c
o
n
d
a
r
y
 
c
h
a
n
n
e
l
 
[
4
2
]
.
 
 
 
 
 
 
 
 
 
(
V
I
)
 
L
o
c
i
 
i
n
v
o
l
v
e
d
 
i
n
 
p
o
s
t
-
t
r
a
n
s
l
o
c
a
t
i
o
n
a
l
 
f
o
l
d
i
n
g
 
 
1
2
 
D
e
l
e
t
i
o
n
 
o
f
 
a
 
i
n
 
c
a
a
a
a
a
a
a
t
 
i
n
 
2
6
8
t
h
 
c
o
d
o
n
 
f
r
a
m
e
s
h
i
f
t
e
d
 
l
a
s
t
 
1
5
%
 
o
f
 
g
e
n
e
.
 
 
 
 
 
 
 
 
 
1
3
 
S
A
1
6
5
9
(
p
r
s
A
)
 
c
h
a
p
e
r
o
n
e
 
t
h
a
t
 
a
s
s
i
s
t
s
 
p
o
s
t
-
t
r
a
n
s
l
o
c
a
t
i
o
n
a
l
 
f
o
l
d
i
n
g
 
o
f
 
p
r
o
t
e
i
n
s
 
a
t
 
t
h
e
 
c
y
t
o
p
l
a
s
m
i
c
/
c
e
l
l
 
w
a
l
l
 
i
n
t
e
r
f
a
c
e
 
[
4
3
-
4
7
]
 
A
a
 
c
h
a
n
g
e
 
E
1
1
4
Q
 
 
 
 
 
 
 
 
 
(
V
I
I
)
 
O
t
h
e
r
 
O
R
F
s
 
w
i
t
h
 
n
o
n
s
y
n
o
n
y
m
o
u
s
 
c
o
d
i
n
g
 
d
i
f
f
e
r
e
n
c
e
s
 
1
4
 
S
A
0
1
7
1
(
f
d
h
)
 
m
a
t
c
h
e
s
 
f
a
m
i
l
y
 
o
f
 
D
-
i
s
o
m
e
r
 
s
p
e
c
i
f
i
c
 
2
-
h
y
d
r
o
x
y
a
c
i
d
 
d
e
h
y
d
r
o
g
e
n
a
s
e
s
 
 
D
e
l
e
t
i
o
n
 
o
f
 
n
u
c
l
e
o
t
i
d
e
 
p
o
s
s
i
b
l
y
 
f
r
a
m
e
s
h
i
f
t
e
d
 
9
8
%
 
o
f
 
g
e
n
e
.
 
 
 
 
 
 
 
 
 
 
1
5
 
S
A
0
1
8
5
 
l
i
k
e
l
y
 
i
n
 
o
p
e
r
o
n
 
w
i
t
h
 
t
w
o
 
O
R
F
s
 
e
n
c
o
d
i
n
g
 
c
o
m
p
o
n
e
n
t
s
 
o
f
 
t
h
e
 
p
h
o
s
p
h
o
e
n
o
l
p
y
r
u
v
a
t
e
:
:
s
u
g
a
r
 
p
h
o
s
p
h
o
t
r
a
n
s
f
e
r
a
s
e
 
s
y
s
t
e
m
 
A
a
 
c
h
a
n
g
e
 
A
2
5
D
 
 
 
 
 
 
 
 
 
1
6
 
S
A
0
2
1
5
 
l
i
k
e
l
y
 
i
n
 
o
p
e
r
o
n
 
w
i
t
h
 
a
n
 
O
R
F
 
s
i
m
i
l
a
r
 
t
o
 
p
e
r
i
p
l
a
s
m
i
c
-
i
r
o
n
 
b
i
n
d
i
n
g
 
p
r
o
t
e
i
n
 
B
i
t
C
 
i
n
 
B
.
 
h
y
o
d
y
n
s
e
n
t
e
r
i
a
e
 
[
4
8
]
 
A
a
 
c
h
a
n
g
e
 
D
1
9
7
G
 
 
 
 
 
 
 
 
 
1
7
 
S
A
0
9
8
0
(
i
s
d
E
)
 
p
a
s
s
a
g
e
 
o
f
 
h
e
m
e
-
i
r
o
n
 
t
o
 
c
y
t
o
p
l
a
s
m
 
d
u
r
i
n
g
 
p
a
t
h
o
g
e
n
e
s
i
s
 
[
4
9
-
5
1
]
 
A
a
 
c
h
a
n
g
e
 
A
8
4
V
 
 
 
 
 
 
 
 
 
1
8
 
S
A
1
1
2
9
 
c
o
n
t
a
i
n
s
 
m
a
t
c
h
 
t
o
 
R
N
A
 
b
i
n
d
i
n
g
 
m
o
t
i
f
 
A
a
 
c
h
a
n
g
e
 
D
2
9
6
Y
 
 
 
 
 
 
 
 
 
1
9
 
S
A
1
1
4
7
 
c
o
n
t
a
i
n
s
 
m
a
t
c
h
 
t
o
 
f
a
m
i
l
y
 
o
f
 
r
e
s
t
r
i
c
t
i
o
n
 
e
n
d
o
n
u
c
l
e
a
s
e
s
 
A
a
 
c
h
a
n
g
e
 
T
9
A
 
 
 
 
 
 
 
 
 
2
0
 
S
A
1
2
4
9
 
p
o
s
s
i
b
l
y
 
i
n
 
a
n
 
o
p
e
r
o
n
 
w
i
t
h
 
c
e
l
l
 
w
a
l
l
 
s
y
n
t
h
e
s
i
s
 
g
e
n
e
 
m
u
r
G
 
D
e
l
e
t
i
o
n
 
o
f
 
c
 
i
n
 
t
c
c
c
c
c
c
c
c
c
a
 
p
o
s
s
i
b
l
y
 
f
r
a
m
e
s
h
i
f
t
e
d
 
8
0
%
 
o
f
 
g
e
n
e
.
 
 
 
 
 
 
 
 
 
2
1
 
S
A
2
0
9
4
 
s
i
m
i
l
a
r
 
t
o
 
t
h
e
 
m
a
l
i
c
/
N
a
+
-
l
a
c
t
a
t
e
 
a
n
t
i
p
o
r
t
e
r
 
M
l
e
N
 
i
n
 
B
.
 
s
u
b
t
i
l
i
s
 
[
5
2
]
 
A
a
 
c
h
a
n
g
e
 
A
9
4
T
 
 
 
 
 
 
 
 
 
(
V
I
I
I
)
 
R
e
g
i
o
n
s
 
e
n
c
o
d
i
n
g
 
n
o
n
-
m
R
N
A
’
s
 
2
2
 
S
A
t
R
N
A
3
4
 
t
R
N
A
-
T
y
r
 
i
n
s
e
r
t
i
o
n
 
o
f
 
g
 
i
n
 
a
g
g
g
g
g
g
c
 
 
 
 
 
 
 
 
 
 
(
I
X
)
 
O
t
h
e
r
 
i
n
t
e
r
g
e
n
i
c
 
r
e
g
i
o
n
s
 
b
e
t
w
e
e
n
 
d
i
v
e
r
g
e
n
t
l
y
 
a
n
d
 
t
a
n
d
e
m
l
y
 
t
r
a
n
s
c
r
i
b
e
d
 
O
R
F
s
 
2
3
 
b
e
t
w
e
e
n
 
d
i
v
e
r
g
e
n
t
 
O
R
F
s
 
S
A
S
0
1
4
 
a
n
d
 
S
A
0
4
1
1
(
n
d
h
F
)
 
N
d
h
F
 
i
s
 
t
h
e
 
F
-
s
u
b
u
n
i
t
 
o
f
 
N
A
D
H
 
d
e
h
y
d
r
o
g
e
n
a
s
e
.
 
d
e
l
e
t
i
o
n
 
o
f
 
t
 
i
n
 
a
t
t
t
t
t
t
t
c
 
5
7
9
 
a
n
d
 
4
5
2
 
b
p
 
u
p
s
t
r
e
a
m
 
o
f
 
S
A
S
0
1
4
 
a
n
d
 
S
A
0
4
1
1
 
r
e
s
p
e
c
t
i
v
e
l
y
 
 
 
 
 
 
 
 
 
2
4
 
b
e
t
w
e
e
n
 
t
a
n
d
e
m
 
O
R
F
s
 
S
A
0
5
5
7
 
a
n
d
 
S
A
0
5
5
8
 
S
A
0
5
5
7
 
m
a
t
c
h
e
s
 
f
a
m
i
l
y
 
c
o
n
s
i
s
t
i
n
g
 
o
f
 
a
 
n
u
m
b
e
r
 
o
f
 
m
o
n
o
m
e
r
i
c
 
N
A
D
P
H
-
d
e
p
e
n
d
e
n
t
 
o
x
i
d
o
r
e
d
u
c
t
a
s
e
s
.
 
t
→
c
 
3
2
1
 
b
p
 
u
p
s
t
r
e
a
m
 
o
f
 
S
A
0
5
5
8
 
a
n
d
 
1
2
5
 
b
p
 
d
o
w
n
s
t
r
e
a
m
 
o
f
 
S
A
0
5
5
7
 
 
 
 
 
 
 
 
 
2
5
 
b
e
t
w
e
e
n
 
d
i
v
e
r
g
e
n
t
 
O
R
F
s
 
S
A
2
1
2
5
 
a
n
d
 
S
A
2
1
2
6
 
S
A
2
1
2
5
 
m
a
t
c
h
e
s
 
f
a
m
i
l
y
 
c
o
n
s
i
s
t
i
n
g
 
o
f
 
a
r
g
i
n
a
s
e
s
,
 
a
g
m
a
t
i
n
a
s
e
s
,
 
a
n
d
 
f
o
r
m
i
m
i
n
o
g
l
u
t
a
m
a
s
e
s
.
 
 
t
→
c
 
i
n
 
a
 
p
o
t
e
n
t
i
a
l
 
s
i
g
m
a
-
A
 
s
i
t
e
 
2
3
7
 
a
n
d
 
5
3
 
b
p
 
u
p
s
t
r
e
a
m
 
o
f
 
S
A
2
1
2
5
 
a
n
d
 
S
A
2
1
2
6
 
r
e
s
p
e
c
t
i
v
e
l
y
.
 
S
A
2
1
2
6
 
i
s
 
u
n
d
e
r
e
x
p
r
e
s
s
e
d
 
b
y
 
1
3
-
f
o
l
d
 
i
n
 
J
H
9
 
c
o
m
p
a
r
e
d
 
t
o
 
J
H
1
 
[
1
1
]
.
 
 
 
 
 
 
 
 
 
 
93  
T
a
b
l
e
 
3
.
2
 
(
C
o
n
t
i
n
u
e
d
)
 
2
6
 
B
e
t
w
e
e
n
 
t
a
n
d
e
m
 
O
R
F
s
 
S
A
2
2
3
2
 
a
n
d
 
S
A
2
2
3
3
 
S
A
2
2
3
2
 
m
a
t
c
h
e
s
 
f
a
m
i
l
y
 
o
f
 
r
e
d
u
c
t
a
s
e
s
 
i
n
v
o
l
v
e
d
 
i
n
 
t
h
e
 
a
l
t
e
r
n
a
t
i
v
e
 
p
y
r
i
m
i
d
i
n
e
 
b
i
o
s
y
n
t
h
e
t
i
c
 
p
a
t
h
w
a
y
.
 
S
A
2
2
3
3
 
h
a
s
 
s
i
m
i
l
a
r
i
t
y
 
t
o
 
m
e
t
h
y
l
e
n
o
m
y
c
i
n
 
A
 
r
e
s
i
s
t
a
n
c
e
 
p
r
o
t
e
i
n
 
M
m
r
 
i
n
 
 
B
.
 
s
u
b
t
i
l
i
s
.
 
t
→
c
 
1
4
4
 
b
p
 
u
p
s
t
r
e
a
m
 
o
f
 
S
A
2
2
3
2
 
a
n
d
 
8
2
 
b
p
 
d
o
w
n
s
t
r
e
a
m
 
o
f
 
S
A
2
2
3
3
 
 
 
 
 
 
 
 
 
(
X
)
 
O
R
F
s
 
w
i
t
h
 
s
y
n
y
n
o
n
y
m
o
u
s
 
c
o
d
i
n
g
 
d
i
f
f
e
r
e
n
c
e
s
 
2
7
 
S
A
0
3
8
8
(
s
e
t
1
2
)
 
e
x
o
t
o
x
i
n
 
t
→
c
 
i
n
 
2
2
1
s
t
 
c
o
d
o
n
 
 
 
 
 
 
 
 
 
2
8
 
S
A
0
5
8
2
 
s
i
m
i
l
a
r
 
t
o
 
N
a
+
/
H
+
 
a
n
t
i
p
o
r
t
e
r
 
s
u
b
u
n
i
t
 
M
r
p
E
 
i
n
 
B
.
 
s
u
b
t
i
l
i
s
 
[
5
3
]
 
t
→
c
 
i
n
 
3
0
t
h
 
c
o
d
o
n
 
 
 
 
 
 
 
 
 
2
9
 
S
A
1
5
1
0
(
g
a
p
B
)
 
g
l
y
c
e
r
a
l
d
e
h
y
d
e
-
3
-
p
h
o
s
p
h
a
t
e
 
d
e
h
y
d
r
o
g
e
n
a
s
e
,
 
g
l
u
c
o
n
e
o
g
e
n
e
s
i
s
 
a
→
g
 
i
n
 
2
0
3
r
d
 
c
o
d
o
n
 
 
 
 
 
 
 
 
 
3
0
 
S
A
2
0
9
1
 
u
n
k
n
o
w
n
 
t
→
c
 
i
n
 
2
3
0
t
h
 
c
o
d
o
n
 
 
 
 
 
 
 
 
 
3
1
 
S
A
2
1
1
9
 
m
a
t
c
h
e
s
 
f
a
m
i
l
y
 
o
f
 
d
e
h
y
d
r
o
g
e
n
a
s
e
s
 
t
→
c
 
i
n
 
2
4
7
t
h
 
c
o
d
o
n
 
 
 
 
 
 
 
 
 
3
2
 
S
A
2
3
2
0
(
p
f
o
R
)
 
c
o
n
t
a
i
n
s
 
m
a
t
c
h
 
t
o
 
a
 
d
o
m
a
i
n
 
o
f
 
a
 
s
u
g
a
r
 
s
p
e
c
i
f
i
c
 
p
e
r
m
e
a
s
e
 
a
→
g
 
i
n
 
1
6
8
t
h
 
c
o
d
o
n
 
 
 
 
 
 
 
 
 
(
X
I
)
 
I
n
t
e
r
g
e
n
i
c
 
r
e
g
i
o
n
s
 
b
e
t
w
e
e
n
 
c
o
n
v
e
r
g
e
n
t
l
y
 
t
r
a
n
s
c
r
i
b
e
d
 
O
R
F
s
 
3
3
 
b
e
t
w
e
e
n
 
c
o
n
v
e
r
g
e
n
t
 
O
R
F
s
 
S
A
P
0
0
7
 
a
n
d
 
S
A
P
0
0
8
 
(
o
n
 
p
l
a
s
m
i
d
)
 
S
A
P
0
0
8
 
m
a
t
c
h
e
s
 
a
 
f
a
m
i
l
y
 
o
f
 
a
l
c
o
h
o
l
 
d
e
h
y
d
r
o
g
e
n
a
s
e
s
.
 
d
e
l
e
t
i
o
n
 
o
f
 
a
 
i
n
 
g
a
a
a
a
a
a
t
 
3
5
 
a
n
d
 
1
3
7
 
b
p
 
d
o
w
n
s
t
r
e
a
m
 
o
f
 
S
A
P
0
0
7
 
a
n
d
 
S
A
P
0
0
8
 
r
e
s
p
e
c
t
i
v
e
l
y
 
 
 
 
 
 
 
 
 
(
b
)
 
U
n
c
o
n
f
i
r
m
e
d
 
3
4
 
b
e
t
w
e
e
n
 
c
o
n
v
e
r
g
e
n
t
 
O
R
F
s
 
S
A
2
0
1
5
 
a
n
d
 
S
A
2
0
1
6
(
r
p
s
I
)
 
R
p
s
I
 
i
s
 
t
h
e
 
3
0
S
 
s
u
b
u
n
i
t
 
o
f
 
r
i
b
o
s
o
m
a
l
 
p
r
o
t
e
i
n
 
S
9
.
 
p
u
t
a
t
i
v
e
 
d
e
l
e
t
i
o
n
 
i
n
 
J
H
9
 
o
f
 
a
 
i
n
 
c
a
a
a
a
a
a
a
a
a
a
a
a
a
a
g
 
2
6
 
a
n
d
 
1
5
0
 
b
p
 
d
o
w
n
s
t
r
e
a
m
 
o
f
 
S
A
2
0
1
5
 
a
n
d
 
S
A
2
1
0
6
 
r
e
s
p
e
c
t
i
v
e
l
y
 
N
O
T
 
D
E
T
E
R
M
I
N
E
D
 
3
5
 
i
n
 
I
S
1
8
1
1
 
t
r
a
n
s
p
o
s
a
b
l
e
 
e
l
e
m
e
n
t
 
7
2
 
b
p
 
d
o
w
n
s
t
r
e
a
m
 
o
f
 
S
A
0
6
1
7
(
v
r
a
G
)
 
V
r
a
G
 
i
s
 
a
 
p
e
r
m
e
a
s
e
 
o
f
 
a
n
 
A
B
C
 
t
r
a
n
s
p
o
r
t
e
r
 
p
r
e
v
i
o
u
s
l
y
 
i
m
p
l
i
c
a
t
e
d
 
i
n
 
v
a
n
c
o
m
y
c
i
n
 
r
e
s
i
s
t
a
n
c
e
.
 
S
e
e
 
p
a
r
t
 
(
a
)
.
 
p
u
t
a
t
i
v
e
 
d
e
l
e
t
i
o
n
 
i
n
 
J
H
9
 
o
f
 
a
n
 
a
 
N
O
T
 
D
E
T
E
R
M
I
N
E
D
 
*
I
n
 
M
u
5
0
,
 
V
r
a
S
 
h
a
r
b
o
r
s
 
t
h
e
 
a
m
i
n
o
 
a
c
i
d
 
s
u
b
s
t
i
t
u
t
i
o
n
 
I
5
N
.
 
*
*
I
n
 
M
u
5
0
,
 
t
h
e
 
g
e
n
e
 
a
g
r
A
 
w
i
t
h
 
a
 
w
i
l
d
-
t
y
p
e
 
l
e
n
g
t
h
 
o
f
 
7
1
7
 
n
u
c
l
e
o
t
i
d
e
s
 
i
s
 
m
u
t
a
t
e
d
.
 
A
n
 
i
n
s
e
r
t
i
o
n
 
o
f
 
t
w
o
 
a
d
e
n
i
n
e
s
 
o
c
c
u
r
r
e
d
 
i
n
 
a
 
r
u
n
 
o
f
 
s
e
v
e
n
 
a
d
e
n
i
n
e
s
 
s
t
a
r
t
i
n
g
 
a
t
 
n
u
c
l
e
o
t
i
d
e
 
7
0
6
,
 
a
n
d
 
a
n
 
i
n
s
e
r
t
i
o
n
 
o
f
 
o
n
e
 
a
d
e
n
i
n
e
 
o
c
c
u
r
r
e
d
 
b
e
t
w
e
e
n
 
n
u
c
l
e
o
t
i
d
e
s
 
7
1
4
 
a
n
d
 
7
1
5
.
 
U
l
t
i
m
a
t
e
l
y
,
 
t
h
e
 
l
e
n
g
t
h
 
o
f
 
A
g
r
A
 
w
a
s
 
u
n
a
l
t
e
r
e
d
,
 
a
n
d
 
o
n
l
y
 
t
h
e
 
l
a
s
t
 
2
3
8
t
h
 
a
m
i
n
o
 
a
c
i
d
 
i
n
 
A
g
r
A
 
w
a
s
 
c
h
a
n
g
e
d
 
f
r
o
m
 
I
 
t
o
 
K
.
 
T
h
o
u
g
h
 
m
o
d
e
s
t
,
 
t
h
e
 
c
h
a
n
g
e
 
m
a
y
 
h
a
v
e
 
a
 
p
h
e
n
o
t
y
p
i
c
 
e
f
f
e
c
t
 
f
o
r
 
t
h
e
 
f
o
l
l
o
w
i
n
g
 
r
e
a
s
o
n
s
.
 
M
u
5
0
 
i
s
 
d
e
f
i
c
i
e
n
t
 
i
n
 
A
g
r
 
f
u
n
c
t
i
o
n
,
 
a
s
 
d
e
m
o
n
s
t
r
a
t
e
d
 
b
y
 
i
t
s
 
i
n
a
b
i
l
i
t
y
 
t
o
 
p
r
o
d
u
c
e
 
δ
−
h
e
m
o
l
y
s
i
n
 
[
2
5
]
.
 
T
h
e
 
s
t
r
a
i
n
 
R
N
4
2
2
0
 
h
a
r
b
o
r
s
 
i
n
 
a
g
r
A
 
a
n
 
i
n
s
e
r
t
i
o
n
 
o
f
 
o
n
e
 
a
d
e
n
i
n
e
 
i
n
 
t
h
e
 
r
u
n
 
o
f
 
s
e
v
e
n
 
a
d
e
n
i
n
e
s
 
s
t
a
r
t
i
n
g
 
a
t
 
n
u
c
l
e
o
t
i
d
e
 
7
0
6
.
 
T
h
e
 
r
e
s
u
l
t
i
n
g
 
f
r
a
m
e
s
h
i
f
t
 
o
n
l
y
 
c
a
u
s
e
d
 
t
h
e
 
2
3
8
t
h
 
a
m
i
n
o
 
a
c
i
d
 
i
n
 
A
g
r
A
 
t
o
 
c
h
a
n
g
e
 
f
r
o
m
 
I
 
t
o
 
N
 
a
n
d
 
t
h
e
 
a
d
d
i
t
i
o
n
 
o
f
 
t
h
r
e
e
 
r
e
s
i
d
u
e
s
 
I
,
 
I
,
 
a
n
d
 
R
 
t
o
 
t
h
e
 
C
−
t
e
r
m
i
n
u
s
.
 
N
e
v
e
r
t
h
e
l
e
s
s
,
 
t
h
e
 
f
r
a
m
e
s
h
i
f
t
 
w
a
s
 
s
h
o
w
n
 
t
o
 
b
e
 
r
e
s
p
o
n
s
i
b
l
e
 
f
o
r
 
a
 
2
−
3
 
h
r
 
d
e
l
a
y
 
i
n
 
a
g
r
 
a
c
t
i
v
a
t
i
o
n
 
t
h
a
t
 
r
e
s
u
l
t
s
 
i
n
 
t
h
e
 
f
a
i
l
u
r
e
 
t
o
 
t
r
a
n
s
l
a
t
e
 
t
h
e
 
α
−
 
a
n
d
 
δ
−
h
e
m
o
l
y
s
i
n
s
 
[
2
6
]
.
 
*
*
*
I
n
 
M
u
5
0
,
 
R
p
o
B
 
h
a
r
b
o
r
s
 
t
h
e
 
a
m
i
n
o
 
a
c
i
d
 
s
u
b
s
t
i
t
u
t
i
o
n
 
H
4
8
1
Y
,
 
w
h
i
c
h
 
w
a
s
 
s
h
o
w
n
 
t
o
 
c
o
n
f
e
r
 
r
i
f
a
m
p
i
n
 
r
e
s
i
s
t
a
n
c
e
 
[
3
0
]
.
 
 
 
 
 
94   95 
the mutations appeared in a sequential order in the successive blood isolates recovered 
after initiation of the therapy, in parallel with the increasing vancomycin MIC values.  
(iii) The pattern of mutations suggests that the heart valve infection must have been 
established prior to the emergence of JH9, in parallel with the blood stream isolate 
JH6. (iv) Isolates JH6, JH9 and JH14 had identical – reduced – vancomycin 
susceptibilities (MIC = 8  g/ml), and carried a common set of mutations in 15 genes.  
However, the last blood stream isolate JH9 also carried point mutations in an 
additional 15 genetic determinants (Table 3.1).  These additional mutations carried
only in isolate JH9 may represent genetic changes that reflect some unknown selective 
pressure generated in the in vivo environment of the terminally ill bacteremic host.   
 
3.5. Point mutations as potential resistance determinants   
 
Between JH1 and JH2, the vancomycin, oxacillin (a β-lactam), and rifampin MIC’s 
increase respectively from 1, 0.75, and 0.012 µg/ml (in JH1) to 3.0, 25, and 16 µg/ml 
(in JH2).  Accompanying the increases in MIC’s are genetic changes that include: an 
amino acid change H164R in SA1702; the reversal of the frameshift in blaR1; and 
four amino acid changes D471Y, A473S, A477S, and E478D in RpoB (Table 3.1).  
 
While the effect of the amino acid change in the protein SA1702 of unknown function 
can only be guessed, the gene SA1702 is in a common operon with the genes vraS and 
vraR, which encode respectively for the sensor VraS and response regulator VraR of a 
two component system (TCS). Upregulation of vraR has been previously shown to 
increase the vancomycin MIC by 4-fold in one vancomycin susceptible strain [16], 
and increased transcription of vraS and vraR in JH9 over JH1 was observed in a study 
with DNA microarrays [11].   96 
 
In JH1 and JH15, the deletion of an adenine in a string of eight adenines in the 
plasmid frame shifted 70% of blaR1. The transmembrane sensor BlaR1 and its 
cognate cytosolic repressor BlaI are part of a signaling pathway known to sense β-
lactams and induce the expression of the β-lactamase gene blaZ and the broad 
spectrum β-lactam resistance gene mecA. The inactivation of BlaR1 would be 
expected to lead to the BlaI mediated constitutive repression of blaZ and mecA [28]. 
Hence, it is no surprise that a frameshift in blaR1 has previously been shown to 
abolish β-lactam resistance [29]. The reversal of the frameshift in blaR1 may therefore 
be responsible for the increase in oxacillin resistance in JH2.  Interestingly, in 
subsequent isolates the oxacillin resistance drops (beginning with JH5) and remains 
low as the vancomycin resistance increases. Such an inverse relationship between 
oxacillin and vancomycin resistance has been demonstrated in vitro [54] but the 
mechanism is not known.   
 
It is very likely that the four amino acid changes in the β−subunit RpoB of RNA 
polyermase (RNAP) are related to the increase in rifampin resistance. The change 
D471Y has alone been shown to confer rifampin resistance, and all four changes occur 
in the region aa 463-550, found to harbor most mutations responsible for rifampin 
resistance [30].  
 
The observation that the frameshift in SA1249 may have reverted twice between JH5, 
JH6, and JH9 is perhaps not surprising since the mutation is a deletion of a cystine in a 
string of nine cystines. Due to slippage of the DNA polymerase, a homopolymeric 
tract can rapidly increase or decrease in length [55]. In our list of 33 confirmed point 
mutations, changes in runs of identical nucleotides are in fact statistically over-  97 
represented. Our 33 point mutations include 1 bp expansions or contractions of seven 
distinct homopolymeric segments, all initially ≥ 6 bp (P-score = 10
−6). Since rapid 
changes in phenotype have been previously associated with variable length simple 
repeats (e.g. phase variation in Bordetella pertussis) [56], it is tempting to speculate 
that runs of identical nucleotides in S. aureus can promote quick switching between 
resistant phenotypes. In particular, the VISA phenotype has been noted to be unstable 
[57].  
 
Between JH5 and JH6, the vancomycin MIC increases from 6 to 8 µg/ml. In the same 
period, a deletion of a thymine in a string of seven thymines occurs that frameshifts 
the last 70% of agrC. Involved in quorum sensing, the agr locus regulates many 
virulence and cell surface genes. Loss of the locus was proposed to be associated with 
the VISA phenotype [25].  
 
Between JH5 and JH6, a substitution also occurs that introduces a premature stop 
codon in yycH, truncating the gene to 10% of its original length. The gene yycH is in a 
gene cluster with the genes yycG and yycF, which encode respectively for the sensor 
kinase YycG and response regulator YycF of a TCS. In Bacillus subtilis, deletion of 
the yycH ortholog results in upregulation of genes controlled by the yycF ortholog [58]. 
In S. aureus, the regulator YycF was shown to bind upstream of the gene lytM, 
encoding for the glycyl-glycine endopeptidase [38]. Hence, loss of yycH might be 
expected to lead to upregulation of lytM, and indeed, transcriptome profiling has 
previously shown that the expression of lytM is fivefold greater in JH9 compared to 
JH1[11]. Vancomycin blocks access of LytM to its cell wall substrate [39], and the 
upregulation of lytM may be a response to this inhibition. Curiously however, JH9 was 
shown to have decreased cell wall turnover and susceptibility to autolysis, which may   98 
be related to an abnormality and/or over-production of teichoic acids [8] and not to the 
inhibitory effect of vancomycin [39].   
 
When the loci in Table 3.1 were examined in the VISA strain Mu50 (which is also 
resistant to rifampin),  mutations were found in the vraSR operon, agr locus, and 
RpoB, where the single amino acid change H481Y was shown to confer rifampin 
resistance [30]. 
 
3.6. Decreased susceptibility to daptomycin  
 
Interestingly, the gene rpoC (encoding for the β'−subunit of RNAP) and the yyc gene 
cluster are both found to be mutated in the late JH isolates. These loci were two of 
several loci found genome-wide in another study to be mutated in laboratory generated 
daptomycin resistant S. aureus mutants [33]. This prompted us to determine the 
daptomycin MIC’s of the JH isolates. Though the patient X is not known to have been 
treated with daptomycin [59], increase in the daptomycin MIC value was observed 
among the JH isolates.  The daptomycin MIC of JH1 (0.01  g/ml) increased to 0.05 
 g/ml in JH2 through JH5 followed by a sharp increase to 1  g/ml in JH6 and all 
subsequent isolates – in the direction of the current clinical breakpoint of daptomycin 
resistance (2  g/ml). The increases in the daptomycin MIC’s occurred in parallel with 
the mutations in rpoC and yycH. Decreased susceptibility to daptomycin was already 
observed among some VISA isolates [60]. 
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3.7. Mutations in 31 genes and the extensive alterations in gene 
expression profiles in vancomycin resistant Staphylococcus aureus   
 
Although only 35 point mutations in 31 loci are observed, prior transcriptome  
profiling work found 224 ORFs to be differentially expressed by two-fold or more 
between JH1 and JH9 [11]. We assessed the overlap between this list of 224 ORFs and 
each of the lists of 48, 244, and 32 ORFs found in prior work to be controlled by 
respectively VraR [15], positive regulators of the agr locus[19-21], and YycF [38]. In 
each case, the overlap was statistically significant (respective P-scores = 10
-11, 10
-2, 
10
-2), suggesting that many of the mRNA expression changes between JH1 and JH9 
are due to the mutations in the vraSR operon, agrC, and yycH. Additionally, non-
synonymous substitutions in rpoB conferring rifampin resistance in Bacillus subtilis 
have been shown to have pleitropic effects on growth, competence, sporulation, and 
germination [34]. 
 
3.8. Genetic changes and the vancomycin resistant phenotype   
 
Our discovery of an ordered series of mutations leading to a level of VISA type 
vancomycin resistance that can compromise therapy provides a short list of mutations 
that should enable us to design experiments to reconstruct the vancomycin resistant 
phenotype in susceptible strains of S. aureus.  Polygenetic traits are very hard to trace 
by association studies and even expression array data may be hard to interpret when 
regulators with pleiotropic functions are involved. Our short list of mutant loci can 
easily be screened in other VISA strains to determine their prevalence.  
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With many new inexpensive differential sequencing technologies [61] on the horizon, 
subsequent clinical studies could collect more samples to temporally resolve the 
appearance of single mutations and the population structure of the bacteria as has been 
done for HIV [62].  The spread of strains among patients could be followed as well as 
the emergence of virulent strains. 
 
3.9. Methods 
 
3.9.1. Organization 
 
In Section 3.9.3 called “Overview”, we provide a succinct 7 page summary of our 
methods. In the subsequent sections, we elaborate on various topics, sometimes 
explaining terminology that may not be familiar to everyone. If you while reading 
Section 3.9.3 are interested in learning more details about a particular topic, you need 
not read the entire treatise and can just skip to the appropriate section. The numbers in 
brackets (e.g. [63], [66, 67], [68], etc.) do not refer to sections but rather to the 
references listed at the end of the text. 
 
3.9.2. Definition of “ND” 
 
The term “ND” (for nucleotide difference) is used to refer to any difference between 
two sequences in a single column in the alignment of the two sequences. The term ND 
refers not only to bona fide mutations but sequencing and assembly errors. A ND can 
involve an insertion, deletion, or substitution. When isolated, it can be a point 
mutation. However, it can also be part of a run of ND’s arising due to a larger 
mutation. For example, a run of 1000 ND’s would be produced by a single insertion of   101 
a 1000 nucleotides long element. We use the term “real ND” to refer to a ND that 
arose due to a bona fide mutation as opposed to a sequencing or assembly error. 
 
3.9.3. Overview 
 
Available for download. (a) Raw and trimmed JH1 and JH9 reads with base specific 
Phred quality values. (b) Complete JH1 and JH9 plasmid sequences. (c) Full multi-
alignment of JH1, JH9, and N315 chromosomal sequences and trimmed JH1 and JH9 
reads with site specific Phred quality values. (d) Various programs.   
 
Multi-alignment programs used. clustalw [63]. dialign [64]. MGA, which is capable 
of globally multi-aligning closely related whole bacterial chromosomes [65]. 
The .align file outputted by MGA is particularly useful, since it is a succinct summary 
of all the differences between the sequences in the MGA global multi-alignment.   
  
Sequencing and de novo assembly of the JH1 and JH9 genomes and mapping of 
the JH1 and JH9 reads onto respectively the JH1 and JH9 contigs. Unless 
explicitly stated otherwise, the following applies to each of JH1 and JH9: The whole 
genome shotgun sequencing [66, 67] was done by the Joint Genomes Institute [68]. 
Each base call in each read was assigned its own Phred quality value [13]. The reads 
were trimmed for both vector and quality using a specialized trimming pipeline. The 
mean coverage of the trimmed reads was estimated to be 8.5-9.5X. The de novo 
assembly of the trimmed reads was done using the Celera assembler [69]. 
Independently of the assembler, a mapping of the reads onto the contigs was generated 
using the q-gram technique [70]. As is standard, some minimal editing was done to 
remove contigs arising from containment sequence. During this editing, <2% of the   102 
contig sequence was eliminated. The contigs that were discarded included contigs with 
>99% nucleotide identity to the sequenced E. coli K12 and human genomes. For JH1 
and JH9, there remained 62 and 79 contigs respectively.    
 
Determination of the JH1 and JH9 plasmid and chromosomal sequence and 
ordering of the JH1 and JH9 contigs using N315. Previously, it was shown by 
MLST typing that the JH isolates are closely related to the sequenced S. aureus strains 
N315 and Mu50 [10]. When we used MGA to multi-align several randomly chosen 
large JH1 contigs with the complete N315 and Mu50 genomic sequences, it became 
clear that JH1 is more related to N315 than Mu50. From the multi-alignments, the 
point mutation rate between JH1 and N315 was crudely estimated to be 1:5000 bp. 
Unless explicitly stated otherwise, the following applies to each of JH1 and JH9: All 
the JH contigs were blasted against the N315 plasmid and chromosomal sequence. 
One JH contig was found to be a complete plasmid sequence. This contig exhibited 
high homology to the N315 plasmid and was circular. The remaining JH contigs were 
found to contain chromosomal sequence. The contigs could be ordered by position 
using read pairs bridging the contigs and the high homology to the N315 chromosome. 
No change in synteny between the JH and N315 chromosomes was observed, apart 
from several transpositions involving elements <10,000 bp. For each of JH1 and JH9, 
we therefore identified a complete plasmid sequence and produced an ordered set of 
contigs containing chromosomal sequence. 
 
Identification and subsequent experimental verification of the mutations between 
the JH1 and JH9 plasmids. The program clustalw was used to align the complete 
JH1 and JH9 plasmid sequences. The two sequences were found to differ over their 
entire lengths by only 3 isolated ND’s. PCR sequencing confirmed that two of the   103 
ND’s were bona fide point mutations and showed that the other was a sequencing 
error.    
 
Preliminary construction of the MAC. For each of JH1 and JH9, we concatenated in  
order the contigs containing chromosomal sequence, making sure to always place 
between two consecutive contigs a X to mark the contig gap. For each of JH1 and JH9, 
we therefore generated a single long chromosomal sequence punctuated with X’s. We 
used MGA to construct a multi-alignment (referred to herein as the MAC) of these 
JH1 and JH9 chromosomal sequences and the N315 chromosomal sequence. 
 
Estimation of the sizes of the JH1 and JH9 contig gaps, the ruling out of large 
differences between JH1 and JH9 in the contig gaps, and the editing of the MAC. 
The .align file outputted by MGA was used to very carefully examine by eye the entire 
MAC. A JH1 or JH9 contig gap could be identified as an indel adjacent to a X. With 
the exception of several JH1 and JH9 contig gaps in new sequence specific to the JH 
lineage, the size of each gap could be inferred from the length of the corresponding 
region in N315. For 70-80% of the JH1 and JH9 contig gaps, the size of the gap could 
also be estimated from read pairs spanning the gap. Ultimately, the size of every JH1 
and JH9 contig gap could be estimated from N315 and/or read pairs. While a size 
estimate from N315 is a single number, a size estimate from read pairs is a normally 
distributed random variable, with a mean and a standard deviation (STD). When all 
the estimates from N315 and all the means of the estimates from the read pairs were 
examined in both JH1 and JH9, it was found that >80% of the values were <1000 
nucleotides and all were <10,000 nucleotides. When all the STD’s of the estimates 
from the read pairs were examined in both JH1 and JH9, it was found that >80% of the 
values were <1000 nucleotides and all were <4000 nucleotides. In all but one case, the   104 
mean of the size estimate of a contig gap in one JH strain computed from read pairs 
agreed to within three STD’s with the lengths of the corresponding regions in N315 
and the other JH strain. In most cases, the agreement was in fact to within one or two 
STD’s. In the single exceptional case in which the disagreement exceeded three STD’s, 
the sequence in the gap in the JH1 was PCR sequenced to show that it was identical to 
the corresponding sequence in N315 and JH9. Wherever there was an indication of a 
large difference between JH1 and JH9 in a contig gap, the difference was ruled out 
experimentally (e.g. by PCR sequencing). Using the estimates of the sizes of the JH1 
and JH9 contig gaps, the MAC was edited. Each X marking a JH1 or JH9 contig gap 
was replaced by a string of N’s with a length equal to the estimate of the size of the 
contig gap from N315 where applicable or the mean of the estimate from the read 
pairs otherwise. Then, MGA was used to recompute the MAC, and the .align file 
produced by MGA was used to carefully scrutinize the MAC by eye and fix the 
infrequent alignment errors manually. The JH1 and JH9 chromosomes are each 
estimated to be about 2,900,000 bp long, a figure which includes the contig gaps. The 
JH1 and JH9 contig gaps are estimated to contain a mere 1.5 and 2.3% respectively of 
the JH1 and JH9 chromosomal sequence. 
 
Construction of the MACR. We produced a full multi-alignment (referred herein to 
as the MACR) of the JH1, JH9, and N315 chromosomal sequences and the JH1 and 
JH9 reads. The program clustalw was used to construct piecewise the MACR from the 
MAC and the mapping of the JH1 and JH9 reads onto respectively the JH1 and JH9 
contigs. The final MACR had a length of about 3,000,000 columns. In the MACR, an 
indel in a read was assigned the Phred quality value of the previous base in the read. 
To identify alignment errors in the MACR, we searched for and manually examined 
columns in which the symbol in a contig sequence disagreed with a symbol in a read   105 
with a high Phred quality value. Alignment errors were found to occur at a rate of only 
about 1:200,000 columns, with no error spanning more than several columns. 
 
Preliminary manual comparison of the JH1, JH9, and N315 chromosomal 
sequences. Using the .align file outputted by MGA, we carefully examined by eye the 
entire MAC. Differences between the JH1, JH9, and N315 chromosomal sequences 
were noted. Considered was the sequence interior to the JH1 and JH9 contigs, which 
are estimated to contain 98.5% and 97.7% respectively of the JH1 and JH9 
chromosomal sequence. There were hundreds of large and small differences between 
JH1 and N315, including indels >40,000 nucleotides long. The only differences 
between JH1 and JH9 were isolated ND’s, with the exception of some indels 2-20 
nucleotides long and clusters of ND’s. The indels 2-20 nucleotides long and clusters of 
ND’s were expected to be have been produced by read errors, since they always 
occurred in the MACR in regions of 1 or 2X coverage with poor read quality. 
Moreover, the indels ≥ 10 nucleotides always involved poly- A and T sequence at the 
end of a read, which is usually unreliable.  
 
Identification and subsequent experimental verification of the mutations between 
the JH1, JH9, and N315 chromosomes. We formulated a Bayesian probabilistic 
model (BPM) to identify real ND’s in the MACR column by column. Thus, bona fide 
insertions or deletions ≥ 2 nucleotides in length and regions of non-homology that 
spanned multiple consecutive columns in the MACR were identified column by 
column. The BPM considered the coverage and Phred quality values of the JH1 and 
JH9 reads. If a real ND could be predicted or ruled out in a column with a probability 
P  > T  = 1−1/(3×10
6), then the column was said to be informative. The threshold T  
was selected so that the expected error rate (both false positive and false negative) was   106 
less than one per genome when calling a real ND in an informative column. Such 
confidence could not be achieved in uninformative columns, which occurred due to 
poor coverage (mostly 0-1X) and/or read quality. When a real ND was predicted in an 
informative column, the region containing the column in the MACR was always 
manually examined. The 10-20 columns with alignment errors in the MACR were 
checked. Anomalous predictions due to alignment errors were identified and not 
reported. It was also ensured that no real ND went unreported due to an alignment 
error. In the JH1 and N315 comparison, 97% of the columns in the MACR were 
informative, and only the real ND’s predicted in the informative columns were 
reported. Thus, no false ND between N315 and JH1 due to a read error in JH1 is 
expected to have been reported. In the JH1 and JH9 comparison, 94% of the columns 
in the MACR were informative. Every predicted real ND in the informative columns 
was confirmed by PCR sequencing, except for the deletion in the stretch of 14 
adenines that could not be sequenced (see Tables 3.1 and 3.2). Also considered were 
10 of the most promising predictions of real ND’s in the uninformative columns. All 
but two were shown to be false by PCR sequencing. One proved to be real, and the 
other was the deletion in the IS1811 insertion sequence that could not be PCR’d (see 
Tables 3.1 and 3.2). The real ND’s in the informative columns occurred at a rate of 
only 1:100,000 nucleotides. Assuming that the real ND’s occurred at the same rate in 
uninformative columns, the number of real ND’s expected to have gone unreported in 
the 6% of uninformative columns in the MACR can be estimated as 1/100,000 × 0.06 
× 3,000,000 = 1.8. When a second more rigorous estimate was done that considered 
the coverage and read quality in the uninformative columns, a number <2 was again 
obtained. 
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Transcriptome analysis. A previous study identified the open reading frames (ORF’s) 
(i.e. predicted genes) differentially expressed by ≥ 2-fold or more in JH9 compared to 
JH1 [11]. We in this study observed mutations in JH9 in loci encoding for the 
transcriptional regulators VraR, Agr, and YycF. Prior work had identified the ORF’s 
controlled directly or indirectly by these three regulators [15, 19, 38], as well as the 
positive transcriptional regulators TRAP [20] and ArlR [21] of the agr locus. We 
computed a P-score for the overlap of the list of ORF’s controlled by a regulator and 
the list of ORF’s differentially expressed in JH9 compared to JH1. The P-score was 
computed under a null model that assumed that the two lists were chosen 
independently.  
 
3.9.4. Available for download 
 
Table 3.3. Access to data and programs. 
Item 
Section 
first 
discussed 
Reference  How to obtain 
Sequence data 
raw JH1 and JH9 reads with base specific 
Phred quality values  3.9.6    NCBI’s trace archive
a. 
trimmed JH1 and JH9 reads with base 
specific Phred quality values  3.9.6   
complete JH1 and JH9 plasmid sequences  3.9.7   
full multi-alignment of JH1, JH9, and 
N315 chromosomal sequences and 
trimmed JH1 and JH9 reads with site 
specific Phred quality values (i.e. 
MACR) 
3.9.9   
Get a copy of data.tar.gz
b. 
Assembler 
recent version wgs-assembler-3.10 of the 
Celera assembler   3.9.6  [69] 
c 
Alignment programs 
clustalw, version 1.81  [63] 
dialign, version 2.2  [64] 
MGA, March 18, 2003 release 
3.9.5 
[65] 
q-gram filters  3.9.6  [70] 
blast programs  3.9.6  [71] 
See references. 
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Table 3.3 (Continued) 
Programs written for this study 
PERL script myalign.pl called by MGA 
to invoke clustaw and dialign  3.9.5    Get a copy of data.tar.gz
b. 
Previously sequenced genomes and lists of open reading frames (i.e. predicted genes) 
S. aureus strains N315, Mu50, MW2, 
COL, 476, and 252; E. coli K12; human.  6    NCBI’s genome database
d 
a. Go to the webpage: 
http://www.ncbi.nlm.nih.gov/Traces/trace.cgi?cmd=stat&f=xml_list_species&m=obtain&s=species. 
b. The sequence data and PERL script myalign.pl have been combined into a single compressed archive file data.tar.gz using 
the Unix tools tar and then gzip. The file data.tar.gz can be downloaded from the coauthor Siggia’s website:  
http://www.physics.rockefeller.edu/~siggia. 
Alternatively, you can request a copy of data.tar.gz by emailing the coauthor Mwangi at:  
mwangi@morel.rockefeller.edu. 
c. The current webpage for the wgs-assembler is:  
http://sourceforge.net/projects/wgs-assembler/. 
d. Go to the webpage:  
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?CMD=search&DB=genome. 
 
3.9.5. Multi-alignment programs used 
 
We used the following multi-alignment programs: 
a)  clustalw, version 1.81 [63]  
b)  dialign, version 2.2 [64] 
c)  MGA, March 18, 2003 release [65]   
 
Suitable for multi-aligning numerous small sequences at a time, clustalw and dialign 
were used frequently − always though on no more than several dozen sequences 
totaling no more than a few 100,000 nucleotides in length. When aligning S. aureus 
sequences that differed by isolated ND’s, clustalw produced better alignments than 
dialign, particularly for the more dissimilar sequences. When aligning S. aureus 
sequences that were nearly identical if not for large indels due to strain specific 
genomic islands or gaps in sequence, dialign produced better alignments than clustalw. 
Unless stated otherwise, clustalw and dialign were invoked as follows: 
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clustalw -type=DNA -dnamatrix=IUB -output=GDE -outorder=input                
-pwgapext=0 -gapext=0 -infile=[enter here input file name] 
  dialign2-2 -n -strict -thr 5 -fa [enter here input file name] 
 
Capable of globally multi-aligning several closely related bacterial chromosomes at a 
time, MGA was used to produce multi-alignments of large segments and/or whole 
chromosomes. To align regions between maximal exact matches, MGA calls external 
programs via a user specified script. A PERL script myalign.pl was written so that 
MGA would call clustalw when the regions differed in length by less than 10 
nucleotides and dialign otherwise. The program MGA was invoked as follows: 
 
mkvtree -dna -lcp -suf -tis -indexname [enter here index name] -db [enter here 
list of files each containing one of the sequences to be multi-aligned]  
mga.32seqs -v -l 1000 -always -gl 100000 -msascript myalign.pl -alignedseqs  
-gap -width 100 -o [enter here prefix of output files] [enter here index 
name specified in call to mkvtree above] 
 
The .align file produced by MGA proved to be especially useful since the file is a 
concise human readable list of all the differences between sequences in the MGA 
muli-alignment. The file therefore permitted the careful inspection by eye of large 
machine generated global muli-alignments. 
 
3.9.6. Sequencing and de novo assembly of the JH1 and JH9 genomes 
and mapping of the JH1 and JH9 reads onto respectively the JH1 and 
JH9 contigs 
 
3.9.6.1. Whole genome shotgun sequencing of JH1 and JH9 
 
For each of JH1 and JH9, the whole genome shotgun sequencing [66, 67] was carried 
out by the Joint Genomes Institute (JGI) [68] as follows:     110 
a)  Genomic DNA was sheered into random fragments, size selected, and cloned 
into an appropriate vector to produce three different sized libraries of clones:  
 
Genomic DNA was randomly sheared using a hydroshear device 
(Genemachines, San Carlos, CA), and the fragments were blunt-end 
repaired with T4 polymerase and Klenow fragment. Fragments were size 
selected by agarose gel electrophoresis, purified from the gel (Qiaquick, 
Qiagen Corporation, Valencia, CA), and ligated into pUC18 (small 
inserts), pMCL200 (medium inserts), or pCC1Fos (large inserts) 
(Epicentre, Madison, WI). Ligations were transformed into E. coli 
DH10B cells, and colonies were picked into 384-well plates containing 
LB and glycerol. 
 
b)  The ends of the clones were sequenced to generate over 40,000 single reads 
with a mean length between 500 to 1000 nucleotides: 
 
DNA for sequencing was produced by rolling circle amplification 
(Templiphi, GE Healthcare, Piscataway, NJ) or Sprintprep (Agencourt, 
Beverly MA) magnetic bead DNA purification. Subclone inserts were 
sequenced from both ends using universal primers and ET (GE 
Heathsciencies, Piscataway, NJ) or Big Dye (ABI, Foster City, CA) 
terminator chemistry. 
 
c)  Based on the trace data, each base call in each read was assigned its own Phred 
quality value Q, which was always an integer from 0 to 60 such that 
/10 10
Q -  is 
the probability the base call is incorrect [13]. 
d)  In most cases, both ends of a clone were sequenced, generating two single 
reads that formed a read pair. Two reads in a read pair are said to be mates. 
 
The sequencing protocols of the JGI are described in detail in [72] and at  
http://www.jgi.doe.gov/sequencing/protocols/index.html. 
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3.9.6.2. Trimming of the reads 
 
For each of JH1 and JH9:  
a)  The raw unprocessed reads were trimmed for both vector and quality using a 
specialized trimming pipeline.  
b)  The sum N of the lengths of the trimmed reads was between 26,000,000 to 
29,000,000 nucleotides.  
c)  Previously, it was established [10] by pulse field gel electrophoresis that the 
size L of the JH genome is similar to the size of the N315 genome, known to 
contain about 3,000,000 bp. Hence, the mean coverage N/L of the trimmed 
reads is estimated to be between 8.5 to 9.5X.   
 
3.9.6.3. Sizes of the libraries of clones and definition of a read pair’s 
mean and standard deviation 
 
Since MLST typing had suggested that the JH lineage differs from the sequenced S. 
aureus strain N315 by a point mutation rate as small as 1:3000 bp [10], the sizes of the 
three JH1 and three JH9 libraries of clones in Section 3.9.6.1 were determined using 
N315. For each library, the trimmed reads were mapped to the N315 genomic 
sequence using the q-gram technique [70], and the distance between the outermost 
ends of the trimmed reads in a read pair was found to be an approximately normally 
distributed random variable. For JH1, the distance had a mean of 3, 6, or 35 kbp and a 
standard deviation of 0.3, 0.5, or 3 kbp respectively, depending on which of the three 
libraries was considered. For JH9, the mean was 3, 6, or 36 kbp, and the standard 
deviation was 0.3, 0.5, or 4 kbp respectively. 
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For convenience, we speak of a read pair’s mean and standard deviation. By this, we 
are actually referring to the mean (3, 6, or 35-36 kbp) and the corresponding standard 
deviation (0.3, 0.5, or 3-4 kbp respectively) computed above for the library of clones 
containing the read pair.        
 
3.9.6.4. De novo assembly of the trimmed reads into contigs and 
scaffolds and verification of the sizes of the libraries of clones 
 
For each of JH1 and JH9, the de novo assembly of the trimmed reads was done using a 
recent version wgs-assembler-3.10 of the Celera assembler, the first version of which 
was developed by a team led by the coauthor Myers [69]. Invoked using standard 
parameter values, the assembler took as input: a list specifying the library and mate of 
each read (from Section 3.9.6.1), the trimmed reads (Section 3.9.6.2), and estimates of 
the sizes of the libraries of clones (Section 3.9.6.3). The assembler assembled the 
reads into contigs and grouped the contigs into scaffolds. A contig is a continuous 
segment of known sequence representing the consensus of overlapping staggered 
reads. A scaffold is a set of contigs ordered by position and all orientated to represent 
the same strand (Watson or Crick), plus estimates of the sizes of all the intra-scaffold 
contig gaps of unknown sequence between consecutive contigs. In a scaffold, the 
assembler can infer the contigs’ order and strands and can estimate the sizes of the 
contig gaps using read pairs bridging contigs and the estimates of the sizes of the 
libraries of clones. The assembler’s estimate of the size of a contig gap is a normally 
distributed random variable with a specified mean and standard deviation. As a 
consistency check, the assembler re-estimates the sizes of the libraries of clones using 
read pairs it maps to the same contig. The sizes computed in Section 3.9.6.3 and the 
assembler’s re-estimates agreed.      113 
3.9.6.5. First unambiguous mapping of trimmed reads to contigs 
 
Although rare, the Celera assembler can fail to group two contigs into a single scaffold 
even though the contigs are connected by read pairs. In the case of highly similar but 
non-identical repetitive regions, the assembler can also incorrectly map a read to the 
wrong region. For each of JH1 and JH9, we therefore felt it was prudent to also work 
with an unambiguous mapping of the trimmed reads to contigs, which was generated 
as follows: 
a)  The reads were locally aligned to the contigs using the q-gram technique [70].  
b)  For each read: All matches that had >97% nucleotide identity along their 
length were found. Then, matches that were <80% of the length of the longest 
match were eliminated. Afterwards, the best remaining match was identified, 
defined as the match with the smallest error rate. Finally, matches with an error 
rate >2 times the error rate of the best match were eliminated. 
c)  For each remaining match of each read: If for the match of the read it could be 
ruled out that there is a match of the read’s mate with a suitable orientation so 
that the two matches are a proper distance apart from each other on the genome, 
then the match of the read was eliminated. To be a proper distance apart, the 
two matches have to be separated on the genome by a distance that agrees with 
the read pair’s mean to within three of the read pair’s standard deviations (see 
Sections 3.9.6.3 and 3.9.6.4). 
d)  Reads still with multiple matches were eliminated. 
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3.9.6.6. Elimination of contaminant sequence by comparison with 
previously sequenced S. aureus strains 
 
Contigs arising from contaminant DNA were eliminated. Firstly, all the contigs were 
blasted against the completely sequenced genomes of the S. aureus strains N315, 
Mu50, MW2, COL, 476, and 252 using BLASTN with no filter [71]. A contig with no 
homology (E-score < 10
−5) to any of the S. aureus genomes was discarded, provided 
that the contig was not associated with another contig having homology to at least one 
of the S. aureus genomes. Two contigs were said to be associated with one another 
only if they were grouped together in a scaffold in Section 3.9.6.4 or connected by a 
read pair in the unambiguous mapping in Section 3.9.6.5. Thus, seemingly foreign 
sequence not in the previously sequenced S. aureus strains was eliminated only when 
there was no evidence connecting it to known S. aureus sequence. For each of JH1 and 
JH9, <2% of the contig sequence was gotten rid of. All the contigs that were discarded 
were 100-5000 nucleotides in length. About 10% of the eliminated sequence had 
>99% nucleotide identity to the sequenced E. coli K12 or human genomes. In the end, 
62 JH1 and 79 JH9 contigs remained. 
 
3.9.7. Determination of the JH1 and JH9 plasmid and chromosomal 
sequence and ordering of the JH1 and JH9 contigs using N315 
 
3.9.7.1. Preliminary comparison of JH1, N315, and Mu50 
 
In Section 3.9.6.3, the term MLST was defined. Previously, all the JH isolates JH1-
JH15 were found to have the MLST 1-4-1-4-12-1-28, and both of the sequenced S. 
aureus strains N315 and Mu50 were found to have the MLST 1-4-1-4-12-1-10 [10].   115 
To determine whether JH1 is more closely related to N315 or Mu50, we used MGA to 
multi-align several randomly chosen large JH1 contigs with the N315 and Mu50 
genomic sequences. By inspecting the .align file outputted by MGA (see Section 
3.9.5), we found that JH1 agreed in about three out of every four cases with N315 
rather than Mu50 when we examined over 50 isolated point mutations chromosome-
wide between N315 and Mu50. 
 
3.9.7.2. Determination of the plasmid and chromosomal sequence and 
ordering of the contigs using N315 
 
To order the scaffolds in Section 3.9.6.4, we blasted the scaffolds against the N315 
genomic sequence using BLASTN with no filter [71]. The N315 genome consists of a 
circular 24,653 bp plasmid and a circular 2,814,816 bp chromosome.  
 
One scaffold in each of JH1 and JH9 exhibited significant homology to the N315 
plasmid but little homology to the N315 chromosome. Each of these two scaffolds 
consisted of only one contig slightly greater than 30,000 nucleotides. It became clear 
that each of these two contigs represented the complete sequence of a circular plasmid 
for the following reasons. Each contig exhibited >99% nucleotide identity to the N315 
plasmid over a 15,000 nucleotide region. When each contig was inspected, it was 
found that the first roughly 1000 nucleotides at one end of the contig and the last 1000 
nucleotides at the other end were identical, suggesting the two ends were not distinct. 
For each contig, many read pairs in the unambiguous mapping in Section 3.9.6.5 
mapped to the contig such that the distance between a read and its mate on the contig 
could only be reconciled with the read pair’s mean and standard deviation (see   116 
Sections 3.9.6.3 and 3.9.6.4) if the contig represented a circular DNA molecule with a 
length of about 30,000 bp.  
 
It was determined that the remaining JH1 and JH9 scaffolds represented chromosomal 
sequence. The following applies to each of JH1 and JH9: Although dozens of large 
insertions and deletions 1000-50,000 bp were observed between the JH and N315 
chromosomes, the vast majority of the JH scaffolds exhibited enough homology over 
at least some of their contigs’ lengths that they could be mapped unambiguously to the 
N315 chromosome. These JH scaffolds could be ordered by position using N315. To 
make all scaffolds represent the Watson strand, scaffolds matching the Crick strand of 
the N315 chromosome were re-orientated by reverse complementation. The several 
small JH scaffolds that exhibited little or no homology to the N315 chromosome each 
consisted of only one contig < 10,000 bp,  representing novel chromosomal sequence 
in the JH lineage. The positions and suitable orientations of these small scaffolds 
could be inferred using read pairs in the unambiguous mapping in Section 3.9.6.5 that 
connected the small scaffolds to the scaffolds already ordered using N315. When the 
ordering of the contigs was complete, it could be seen that the JH chromosome was 
syntenous over its entire length with the N315 chromosome, except for several 
transpositions involving elements < 10,000 bp. 
 
3.9.7.3. Second unambiguous mapping of trimmed reads to contigs 
 
Since some of the scaffolds were re-orientated in Section 3.9.7.2, the unambiguous 
mapping of the trimmed reads to contigs in Section 3.9.6.5 was re-done just as before. 
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m1, s1
m2, s2
m3, s3
l2,1 l2,2
l1,1 l1,2
l3,1 l3,2
x contig 1 contig 2
 
Figure 3.2: Estimation of the size x in nucleotides of a contig gap. In this 
case, there are N  > 0 read pairs that span the gap and connect the two 
consecutive contigs 1 and 2 to the gap’s immediate left and right respectively. 
For simplicity, only three read pairs are shown. For the 
th i  read pair, several 
values are listed:  i m  and  i s  denote the read pair’s mean and standard 
deviation (see Sections 3.9.6.3 and 3.9.6.4), and  , i j l  denotes the distance in 
nucleotides from the outermost end of the read mapping to the contig  j = 1 or 
2 to the furthermost end of the contig. 
 
 
3.9.8. Estimation of the sizes of the JH1 and JH9 contig gaps, the 
ruling out of large differences between JH1 and JH9 in the contig 
gaps, and the editing of the MAC 
 
3.9.8.1. Our estimates of the sizes of the contig gaps from read pairs 
 
In Section 3.9.6.4, it was stated that assembler estimated the sizes of all intra-scaffold 
contig gaps from read pairs. Independently of the assembler, we estimated the sizes of 
contig gaps using read pairs in the unambiguous mapping produced in Section 3.9.7.3. 
To estimate the size of a contig gap, we used read pairs that span the gap and connect 
the two consecutive contigs to the gap’s immediate left and right. When such read 
pairs were not available, an attempt was made to use read pairs that span the gap and   118 
connect non-consecutive contigs. Regardless, the estimation was done using the same 
Bayesian approach. As an illustration, a contig gap is depicted in Figure 3.2. We 
would estimate the size of the contig gap as follows: 
a)  In the absence of prior information, we use an uninformative prior P( ) x  over 
x: 
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[ ] , L U -  and with zero probability elsewhere. Here, the values of L and U  are 
not particularly significant. We work in the limit of large  L and U . Thus, L 
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c)  By Bayes’ theorem, the posterior probability of  x given the configuration D 
of read pairs is: 
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Since we are working in the limit of large  L and U  and it is always observed 
that s  ≫ 1, the following approximation can be made: 
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Thus, the estimate of the size  x of the contig gap is a normally distributed random 
variable with a mean m  and standard deviation s . 
 
3.9.8.2. Estimating the sizes of the JH1 and JH9 contig gaps and 
ruling out large differences between JH1 and JH9 in the contig gaps    
 
By inspecting the .align file produced by MGA (see Section 3.9.5), we were able to 
very carefully examine by eye the entire MAC. Save for the few JH1 and JH9 contig 
gaps in new sequence specific to the JH lineage, it was possible to infer the sizes of all   120 
gaps from the corresponding sequence in N315. Thus, sometimes as many as three 
separate estimates of the size of a contig gap were available – one inferred from N315, 
another computed by the Celera assembler from read pairs (see Section 3.9.6.4), and 
yet another computed by us from read pairs (Section 3.9.8.1). Ultimately, at least one 
estimate was available for the size of every contig gap. For lists of all the estimates, 
see Tables 3.4 and 3.5.  
 
In several cases, contigs were found to overlap. To ensure that the apparent overlap 
was genuine and not the result of a tandem duplication, the read pairs spanning the 
putative region of overlap were carefully examined and in one case restriction digest 
and Southern analysis was even done (see the comments in Tables 3.4 and 3.5).  
 
When there was an indication of a large difference between JH1 and JH9 in a contig 
gap, the unknown sequence in the gap was determined by PCR sequencing. In each 
case, JH1 and JH9 were found to be identical (see the comments in Tables 3.4 and 3.5).   
 
Table 3.4: JH1 contig gaps. 
Preceding contig
a 
Estimates of the size of the contig gap in 
nucleotides
b 
Assembler
d  Us
e 
Unique 
identifier 
of contig 
Length in 
nucleotides
b 
N315
c 
mean  STD  mean  STD 
Comments 
1.1  404980  149  541  959  497  858   
1.2  34200  483  258  127  249  123   
1.3.1  211627    3010  520      This gap in JH1 is in a phage-like 
genomic island > 40,000 nucleotides 
specific to JH1 and JH9. 
1.3.2  75805  1797  1256  1119  1541  1357   
1.4  10562  532  878  302  887  297   
1.5  1551    1530  1598      This gap in JH1 overlaps an IS1811 
transposon insertion that is in N315 
but not JH9. Because the 
assembler’s estimate
d of the size of 
the gap has a large uncertainty ± 
1598 nucleotides, PCR sequencing 
was done to show that the sequence 
in the gap in JH1 does not contain 
the IS1811 insertion in N315 and is 
instead identical to JH9.      121 
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1.6  42793  75  -20  105  -35  100   
1.7  6739  953  -20  2723       
1.8  3783  349  -20  1073  3042  1919   
1.9  31687  46  166  155  73  135   
1.10  23352  281  1260  295  1360  297  The assembler’s and our estimates
d, e 
of the size of the gap in JH1 are 
respectively 1260 ± 295 and 1360 ± 
297 nucleotides. However, the 
corresponding regions in N315 and 
JH9 are both only 281 nucleotides 
long. The fact that the estimates of 
the size of the gap in JH1 differ by 
more than three standard deviations 
from the N315 and JH9 lengths 
suggests that there is an insertion 
specific to JH1. Nevertheless, PCR 
sequencing confirmed that the 
sequence in the gap in JH1 contained 
no insertion and is instead identical 
to N315 and JH9. 
1.11  10895  59  378  455  441  515       
1.12  1548  285         
2.1  1660  *See comments. 
1.13  1540    501  215  512  209 
1.14  1963  1409  440  332  1393  255 
*The assembler’s estimate
d of the 
size of the gap between contigs 1.12 
and 1.13 in JH1 is 3557 ± 453 
nucleotides. Thus, the size of the gap 
between 2.1 and 1.13 in JH1 is about 
3557−285−1660 = 1612 nucleotides. 
 
In all S. aureus strains sequenced 
thus far, there are several 
occurrences in the chromosome of a 
few thousand nucleotides long 
segment encoding for tRNA’s and 
rRNA’s. One occurrence is found in 
this region in N315, JH1, and JH9. 
However, the segment appears to be 
longer in JH1 and JH9, perhaps due 
to a tandem duplication. The 
additional sequence includes parts of 
contigs 1.13 and 1.13. That the 
additional sequence is not an artifact 
of the assembly is supported by 
reads spanning the novel juncture 
between the region common to 
N315, JH1, and JH9 and the 
additional region specific to JH1 and 
JH9. There is no evidence of a 
difference between JH1 and JH9. 
1.15  152230  110  -20  162  -90  117   
1.16  6428    452  215  455  209  This gap in JH1 is in an IS1181 
transposon insertion specific to JH1 
and JH9. 
1.17  972  372  1280  430       
1.18  229181  1651  1872  357  1964  364   
1.19  1299  1329  -20  1734       
1.20  59738  301  39  127  35  124   
1.21  78318  0           
3.1  1695  244  484  215  493  209 
3.2  1325  781         
The N315 estimate
c of the size of the 
gap between contigs 3.1 and 3.1 in 
JH1 is 2350 nucleotides, which 
agrees to within two standard 
deviations with our estimate
e of 
3036 ± 515 nucleotides. 
4.1  1562  2226             122 
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5.1.1  18211  0  -20  456       
5.1.2  46493  977  306  502  342  481   
5.2  26371  4730           
6.1  57445  0         
7.1  1160  916      1032  296 
8.1  1567  75         
The N315 estimate
c of the size of the 
gap between contigs 6.1 and 6.2 in 
JH1 is 3746 nucleotides, which 
agrees to within one standard 
deviation with the assembler’s 
estimate
d of 4081 ± 2350 
nucleotides. 
6.2  55053  1796      -2020  3324   
9.1  11552  314  -19  120  -19  117   
9.2  70828  103  324  140  324  137   
9.3  16186  113  112  131  112  128   
9.4  7955  497  681  242  897  296   
9.5  1187  160  122  224  267  257   
9.6  11020  563  -20  403  -169  364   
9.7  11802  272  472  198  456  194   
9.8  300702  289  295  163  251  170   
9.9  2868  292  347  220  229  256   
9.10  19351  900  917  303  926  296   
9.11  2349  310      248  257   
10.1  74807  185  -20  1345  -201  1002   
10.2  161502  451  317  147  408  109   
10.3  87353  55  210  158  207  154   
10.4  22559  203      112  104   
11.1  9097  0           
12.1  13517  78  216  165  206  162   
12.2  16205  208  191  173  183  170   
12.3  24143  446  1140  807  816  441   
12.4  126471  48  -20  172  -57  153   
12.5  56414  6595           
13.1  61722  598  227  1175  363  1108   
13.2  63541  350         
14.1  1075  416  338  264  377  162 
The N315 estimate
c of the size of the 
gap between contigs 13.2 and 14.2 in 
JH1 is 1842 nucleotides, which 
agrees to within two standard 
deviations with our estimate
e of 
2584 ± 515 nucleotides. 
14.2  27500  147  96  215  115  208   
14.3  40576  203  357  141  369  137   
14.4  9376  408           
15.1  7508  0           
a. The contig preceding the contig gap. b. In several cases, contigs were found to overlap. The redundant duplicate sequence was 
eliminated, and the lengths of the contigs and estimates of the sizes of the contig gaps had to be updated accordingly. This table 
lists not the initial but the adjusted lengths and estimates. c. The N315 inferred size of the contig gap. d. The Celera assembler’s 
estimate of the size of the intra-scaffold contig gap computed from read pairs (see Section 3.9.6.4). e. Our estimate of the size of 
the contig gap computed from read pairs (Section 3.9.8.1).          
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Table 3.5. JH9 contig gaps. 
Preceding contig
a 
Estimates of the size of the contig gap in 
nucleotides
b 
Assembler
d  Us
e 
Unique 
identifier 
of contig 
Length in 
nucleotides
b 
N315
c 
mean  STD  mean  STD 
Comments 
1.1  269456  633  531  1676  104  1417  It was observed that the first 7200 
nucleotides of contig 1.1 and the last 
7200 nucleotides of 23.3 in JH9 were 
identical. The duplicate sequence 
could have arisen two ways. Firstly, 
it may be an artifact of the assembly, 
arising because the assembler 
inexplicably failed to merge two 
highly overlapping contigs. 
Alternatively, the duplicate sequence 
may be the result of a genuine 
tandem duplication specific to JH9. 
Unfortunately, it was not possible to 
distinguish between the two 
possibilities by examining the reads 
or read pairs. Thus, restriction digest 
followed by Southern analysis was 
done to determine the length of the 
region. It was clear from the results 
that the duplicative sequence was 
indeed an artifact of the assembly and 
not the result of a tandem 
duplication. Thus, the redundant 
duplicate sequence in 1.1 was 
eliminated. The reported length of 
1.1 and the estimates of the sizes of 
the contig gap between 1.1 and 23.3 
were adjusted accordingly.       
1.2  115707  10  -20  252  -269  154   
1.3  128896    6726  1890  3922  386  This gap in JH9 is in a phage-like 
genomic island > 40,000 nucleotides 
specific to JH1 and JH9. 
1.4  3393  417  113  248  203  170   
1.5  44822  236  654  376  774  372   
1.6  27344  624  451  522  651  534   
1.7  13533  318  343  390  345  386   
1.8  1155  755  486  1601       
1.9  48602  4162  1733  2164  1729  2164   
1.10  24555  390  466  388  404  386   
1.11  1524  1782  1031  388  1937  273   
1.12  16045  959  775  2232       
1.13  23448  676      379  263 
2.1  1469  *See comments. 
1.14  2050    120  237  -131  263 
1.15  1406  1679  1444  218  1428  193 
*The assembler’s estimate
d of the 
size of the gap between contigs 1.13 
and 1.14 in JH9 is 4059 ± 378 
nucleotides. Thus, the size of the gap 
between 2.1 and 1.14 in JH9 is about 
4059−676−1469 = 1914 nucleotides. 
 
In all S. aureus strains sequenced 
thus far, there are several occurrences 
in the chromosome of a few thousand 
nucleotides long segment encoding 
for tRNA’s and rRNA’s. One 
occurrence is found in this region in 
N315, JH1, and JH9. However, the 
segment appears to be longer in JH1    124 
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              and JH9, perhaps due to a tandem 
duplication. The additional sequence 
includes parts of contigs 1.14 and 
1.15. That the additional sequence is 
not an artifact of the assembly is 
supported by reads spanning the 
novel juncture between the region 
common to N315, JH1, and JH9 and 
the additional region specific to JH1 
and JH9. There is no evidence of a 
difference between JH1 and JH9. 
1.16  22847  39  441  1699       
1.17  12619  292  220  274  133  188   
1.18  123025    776  167  767  162  This gap in JH9 is in an IS1181 
transposon insertion specific to JH1 
and JH9. 
1.19  86421  223  -20  240  -69  222   
1.20  18297  241  212  115  220  112   
1.21  31885  101  -20  150  5  138   
1.22  5386  94           
3.1  88657  2213  2158  1874  1615  1676   
3.2  77395  277  327  159  315  151   
3.3  57649  18  134  159  97  133   
3.4  3671  9083           
5.1  67985  211  244  113  200  110   
5.2  8869  160  241  159  242  157   
5.3  15073  1527           
6.1  1531  380           
7.1  4797  109  -20  133  -105  99   
7.2  27160  47  -20  130  -28  111   
7.3  25357  791         
8.1  1334  52  186  161  192  151 
8.2  3265  335  195  160  191  153 
The N315 estimate
c of the size of the 
gap between contigs 7.3 and 8.3 in 
JH9 is 5776 nucleotides, which 
agrees to within one standard 
deviation with our estimate
e of 8661 
± 3749 nucleotides. 
8.3  52445  4323  4990  2665       
8.4  3708  140  192  276  426  153   
8.5  13281  565           
9.1  48596  1308  1391  208  1388  206   
9.2  16592  100  -20  141  -67  118   
9.3  9190  491  702  225  704  222   
9.4  4092  1742  1560  276  1562  273   
9.5  3501  943      1384  546   
10.1  3604  0  81  318  83  315   
10.2  10832  886           
11.1  10349  303  448  184  8  244   
11.2  62638  285  271  152  270  150   
11.3  238542  415  588  196  597  186   
11.4  870  637  802  276  818  263   
11.5  47651  622  832  226  833  217   
11.6  1422  2655           
12.1  166625  202  246  276  244  273   
12.2  20228  542           
14.1  77858  21  110  120  109  117   
14.2  5300  18  -8  108  -8  105     125 
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14.3  49117  5343      6272  3749   
16.1  3682        2378  546   
17.1  50904  828  3620  1874  3303  1676   
17.2  30014  876  532  382  530  376   
17.3  88036  430  753  205  566  175   
17.4  1208  84  285  206  435  236   
17.5  48797  189  102  546  100  540   
17.6  9441  709      403  546 
18.1  1071  6         
The N315 estimate
c of the size of the 
gap between contigs 17.6 and 17.7 in 
JH9 is 1786 nucleotides, which 
agrees to within one standard 
deviation with the assembler’s 
estimate
d of 1692 ± 153 nucleotides. 
17.7  3784  4873           
19.1  62052  0           
20.1  1500  120           
19.2  62027  94           
21.1  28318  367  -20  568  -142  524   
21.2  34136  912  845  195  843  192   
21.3  5615  0  -20  568  -9  244   
21.4  9327  800           
22.1  1861  2  -20  165  -95  132  The sequence at the end of a read can 
be unreliable. When the sequence is 
unreliable, it is frequently clipped off 
in the trimming stage, but sometimes, 
it is retained, because of deceptively 
high quality values. Even when the 
sequence though unreliable is kept, it 
can often be identified, since it is 
typically poly- A or T sequence. 
 
When it was observed that the first 
14 nucleotides tctagaggatccca in 
contig 22.2 in JH9 are neither in 
N315 nor JH1, it was believed that 
the sequence was spurious, since it 
had a coverage of only 1X and was 
assembled from the end of a read. 
However, tctagaggatccca is not poly- 
A or T sequence, so it was confirmed 
by PCR sequencing that the sequence 
is indeed spurious. 
22.2  6174  103           
23.1  11440  121  191  160  187  153   
23.2  42258  0  -20   286  -64  267   
23.3  81629  0      160  131   
a. The contig preceding the contig gap. b. In several cases, contigs were found to overlap. The redundant duplicate sequence was 
eliminated, and the lengths of the contigs and estimates of the sizes of the contig gaps had to be updated accordingly. This table 
lists not the initial but the adjusted lengths and estimates. c. The N315 inferred size of the contig gap. d. The Celera assembler’s 
estimate of the size of the intra-scaffold contig gap computed from read pairs (see Section 3.9.6.4). e. Our estimate of the size of 
the contig gap computed from read pairs (Section 3.9.8.1).           
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3.9.8.3. The editing of the MAC 
 
The estimates of the sizes of the JH1 and JH9 contig gaps were used to edit the MAC. 
Each X marking a JH1 or JH9 contig gap was replaced by a string of N’s with a length 
equal to: 
a)  The estimate of the size of the contig gap from N315 where applicable. 
b)  Or the estimate computed by the assembler from read pairs as a second resort. 
c)  Or the estimate computed by us from read pairs as a last resort. 
Then, MGA was used to recompute the MAC, and the .align file produced by MGA 
(see Section 3.9.5) was used to carefully scrutinize the MAC by eye and fix the 
infrequent alignment errors manually. 
 
3.9.8.4. Third unambiguous mapping of trimmed reads to contigs 
 
Since some of the contigs were edited in Section 3.9.8.2, the unambiguous mapping of 
the trimmed reads to contigs in Section 3.9.7.3 was re-done just as before. 
 
3.9.9. Construction of the MACR 
 
We already had the MAC – that is the multi-alignment of the JH1, JH9, and N315 
chromosomal sequences, consisting of the ordered JH1 and JH9 contig sequences 
assembled from and therefore a consensus of the reads. We already had a mapping of 
the trimmed JH1 and JH9 reads onto respectively the JH1 and JH9 contig sequences 
(see Section 3.9.8.4).  
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We therefore were able to piecewise construct the MACR. We considered a window 
of W  columns in the MAC plus in this window the mapping of the JH1 and JH9 reads 
onto respectively the JH1 and JH9 contig sequences. We applied clustalw (Section 
3.9.5) to the window to produce a full-multi-alignment of the JH1 and JH9 contig 
sequences, N315 chromosomal sequence, and JH1 and JH9 reads. We then moved 
onto the next window of W  columns in the MAC and applied clustalw again and so 
on.  
 
The final MACR had a length of about 3,000,000 columns. In the MACR, an indel in 
a read was assigned the Phred quality value of the previous base (Section 3.9.6.1). To 
identify alignment errors in the MACR, we for each of JH1 and JH9 searched for and 
manually examined columns in which the symbol in the JH contig sequence disagreed 
with a symbol in a JH read that had a Phred quality value ≥ 30. Through a process of 
trial and error, we were able to find optimal values for the parameters of clustalw that 
produced alignment errors at a rate of only about 1:200,000 columns, with no error 
spanning more than several columns.  
 
To achieve this alignment error rate, the program clustalw was used as follows. It was 
applied to successive windows of the MAC, each containing 500 columns. When 
applied to a given window, it was invoked as follows:   
 
 
clustalw -type=DNA -pwdnamatrix=bestfit_dna_matrix_less_priority_to_degenerate 
-dnamatrix=bestfit_dna_matrix_less_priority_to_degenerate -profile1=all.txt  
-profile2=JH.txt -sequences -outfile=all.txt 
 
The file bestfit_dna_matrix_less_priority_to_degenerate contains the following DNA 
scoring matrix: 
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      A   C   G   T   N     
A   10  -9  -9  -9  5    
C   -9  10  -9  -9  5     
G   -9  -9  10  -9  5      
T   -9  -9  -9  10  5      
N   5   5   5   5   5 
  
The scoring matrix places less emphasis on matches to the strings of N’s representing 
contig gaps in the MAC. Initially, the file all.txt contains only the N315 chromosomal 
sequence, and the file JH.txt contains the JH1 and JH9 contig sequences and reads.  
 
3.9.10. Identification and subsequent experimental verification of the 
mutations between the JH1, JH9, and N315 chromosomes. 
 
3.9.10.1. Bayesian probabilistic model for identifying mutations 
between the JH1, JH9, and N315 chromosomes 
 
The Bayesian probabilistic model (BPM) for identifying real ND’s considered in each 
column in the MACR in Section 3.9.9 the symbols in the trimmed JH1 and JH9 reads 
and their Phred quality values. A symbol in a trimmed JH1 or JH9 read could be an A, 
C, G, T, N, or −, where N represents any of the four bases and − is an indel that was 
inserted during the multi-alignment. In each of JH1 and JH9, the four-fold degenerate 
symbol N occurred in the trimmed reads with a frequency of about 1:5000 nucleotides, 
and there was no instance in any trimmed read of a two-fold degenerate symbol 
representing any of two of the bases (e.g. W = A or T) or a three-fold degenerate 
symbol representing any of three of the bases (e.g. H = A, C, or T). Since a N serves 
as a placeholder and is otherwise uninformative, instances of N’s were ignored. If for 
example a column contained six reads for JH1 and two of these reads contained a N, 
then the coverage in the column for JH1 would be reported as 4X, and only the four   129 
reads containing a non-N would be considered. As described in Section 3.9.9, a − in a 
read was assigned the quality value of the previous base in the read.     
 
3.9.10.2. Use of the unambiguous mapping of the trimmed reads to 
contigs 
 
The MACR in Section 3.9.9 was generated using the unambiguous mapping of the 
trimmed reads to contigs in Section 3.9.8.4, which excluded reads that matched more 
than one region. The omission of these reads was actually considered to be 
advantageous for the following reasons. While the exclusion of the reads ultimately 
reduced the coverage, the affect was confined to only repetitive sequence. When the 
reads were included, the coverage in JH1 and JH9 increased in only 2.2 and 1.4% 
respectively of the columns in the MACR, all of which were found to fall in highly 
repetitive regions. In these columns, the mean coverage rose from 6X to 16X in JH1 
and from 8X to 17X in JH9. However, cursory examination of these columns 
suggested that the extra coverage was unreliable due to unresolved repeats. In some of 
the columns, the symbols in the reads for JH1 and/or JH9 were found be a mixture (e.g. 
Seven reads for JH1 contained an A, and another six reads for JH1 contained a C.). 
Such mixtures are a sign of unresolved repeats. For instance, a segment of a 
chromosome may have an A at some position along its length whereas a near-identical 
copy of the segment elsewhere in the chromosome may have a C at the position. 
Reads from the first copy mapping to the second copy might produce a mixture of A’s 
and C’s in the column in the MACR corresponding to the stated position. Depending 
on the relative coverage of the two copies, a probabilistic model may therefore 
incorrectly call an A instead of C in the second copy at the stated position. Due to   130 
incorrectly mapped repeats, the Celera assembler is known to make errors more 
frequently in repetitive regions.    
 
3.9.10.3. Read error rates 
 
For S  = JH1 or JH9,  X  Î { } A,C,G,T,- , and Y  Î { } A,C,G,T,- , we define 
E ( | ; ) S Y X Q  as the probability in the isolate S  that the base calling program will call 
a symbol Y  in a read given that the correct symbol is  X  and the call will be assigned 
a Phred quality value Q. Note that each of  X  and Y  can take on five values: one of 
the four bases or an indel. The case  X  ¹  Y  represents a read error. 
 
As described in Section 3.9.6.1, the Phred quality value Q assigned to a symbol Y  in 
a read is an integer from 0 to 60 defined such that 
/10 10
Q -  is probability that Y  is an 
incorrect call. Extensive work has shown that the Phred quality value tracks the read 
error reasonably well [13]. Let P ( | ; ) S X Y Q  denote the probability in the isolate S  
that the correct symbol is  X  given that the symbol called in a read was Y  and was 
assigned a Phred quality value Q. In terms of P ( | ; ) S X Y Q , the definition of Q is 
equivalent to 
 
 
/10
   
P ( | ; ) 10
Q
S
X
X Y
X Y Q
-
¹
º ∑ .  (4.8) 
 
Using Bayes’ theorem, E ( | ; ) S Y X Q  can be related to P ( | ; ) S X Y Q : 
 
 
E ( | ; )P( )
= P ( | ; )
E ( | ; )P( )
S
S
S
X
Y X Q X
X Y Q
Y X Q X ∑
  (4.9) 
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where P( ) X  is the prior probability over  X . In the absence of prior information, we 
took an uninformative prior P( ) 1 5 X = , so Eq. 4.9 reduced to 
 
 
E ( | ; )
=P ( | ; )
E ( | ; )
S
S
S
X
Y X Q
X Y Q
Y X Q ∑
.  (4.10) 
 
Summing over  X Y ¹ , it can be seen using Eq. 4.8 that the definition of Q is 
tantamount to the statement 
 
 
   
E ( | ; )
10
E ( | ; )
S
X
X Y Q
S
X
Y X Q
Y X Q
¹ - º
∑
∑
.  (4.11) 
 
Initially, we computed E ( | ; ) S Y X Q  not using the definition of Q but directly from 
the MACR by enumerating read errors. We considered only columns in the MACR in 
which there was high coverage for S  and all but a small percentage of the symbols in 
the reads for S  agreed. The anomalous symbols were assumed to be the result of read 
errors. Unfortunately, the computed E ( | ; ) S Y X Q  were unreliable for Q ≥  about 30 
due to insufficient counts for  X  ¹  Y . Several techniques were tried to improve the 
estimates of the E ( | ; ) S Y X Q  at higher Q: columns with lower coverage for S  were 
also considered to increase counts; curves were fit to the E ( | ; ) S Y X Q  at lower Q, and 
the curves were then extrapolated to estimate the E ( | ; ) S Y X Q  at higher Q; counts 
were binned to compute the E ( | ; ) S Y X Q  at higher Q; etc. However, each approach 
that was tried seemed to introduce sizable errors.  
 
Although the E ( | ; ) S Y X Q  computed directly from the MACR were unreliable, 
several trends did emerge: E ( | ; ) S Y X Q  seemed to be independent of S ; E ( | ; ) S Y X Q    132 
for  X  ¹  Y  appeared to be roughly independent of  X  and Y  over most of the range 
of Q; and finally, E ( | ; ) S Y X Q  was observed to a good approximation to satisfy Eq. 
4.11. In accordance with these observations, we made the approximation 
 
 
1 E( ),         
E ( | ; )
E( ) 1 4,      
S
Q Y X
Y X Q
Q Y X
- = 
= 
´ ¹ 
  (4.12) 
 
where the probability E( ) Q  that  X  is called incorrectly in a read as Y X ¹  depends 
only on Q. We then substituted Eq. 4.12 into Eq. 4.11 to yield 
 
  E( ) 10
Q Q
- = .  (4.13) 
 
Thus, Eq. 4.12 could be written as 
 
 
/10
/10
1 10 ,         
E ( | ; ) .
10 1 4,      
Q
S Q
Y X
Y X Q
Y X
-
-
 - =
= 
´ ¹ 
  (4.14) 
 
We computed E ( | ; ) S Y X Q  using Eq. 4.14. 
 
3.9.10.4.  The i
th column in the MACR  
 
We considered in the MACR the 
th i  column. Like every column in the MACR, the 
th i  
column contains a single symbol from N315 and symbols from the JH1 and JH9 reads. 
Let  N315 Z  Î { } A,C,G,T,-  denote the symbol from N315, which we assumed to be 
correct. Using the reads, we wished to evaluate the probability that the correct symbols 
in JH1 and JH9 are  JH1 X  Î { } A,C,G,T,-  and  JH9 X  Î { } A,C,G,T,-  respectively. 
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3.9.10.5.  Priors 
 
We worked with two priors over  JH1 X  and  JH9 X : 
 
 
( )
JH1 JH9
JH1,JH9 JH9 JH1
1
,                                       1 (uniformative) 
25 P( , ; ) .
1
M | ,       2 (phylogenetic)
5
X X
X X
a
a
a
 =   = 
 =
 
  (4.15) 
 
In the uninformative prior a  = 1, each of the 25 combinations of values of  JH1 X  and 
JH9 X  are equally likely. The phylogenetic prior a  = 2 reflects the phylogeny between 
JH1 and JH9, as defined by the point mutation rate  JH1,JH9 M ( | ) Y X . 
 
We defined  JH1,JH9 M ( | ) Y X  to be the probability that a symbol  X  in the isolate JH1 
was changed to the symbol Y  in the isolate JH9 by a point mutation. In the special 
case  X Y = ,  JH1,JH9 M ( | ) Y X X =  is defined as the probability of no point mutation 
occurring. We computed  JH1,JH9 M ( | ) Y X  as follows: 
 
 
JH1,JH9
JH1,JH9
JH1,JH9
1 ,         
M ( | ) 1
,          
4
m Y X
Y X
m Y X
- = 
 = 
¹  
  (4.16) 
 
where  JH1,JH9 m  is some estimate that needs to be determined of the overall point 
mutation rate between JH1 and JH9 that includes insertions, deletions, and 
substitutions. It is assumed that the point mutation rate  JH1,JH9 M ( | ) Y X  is independent 
of  X  and Y  when  X Y ¹ . A more refined model is not possible for two reasons. 
Firstly, the dependence of  JH1,JH9 M ( | ) Y X  on  X  and Y  when  X Y ¹  may vary widely 
from locus to locus. The strong selective pressures due to antibiotic chemotherapy can 
select for a particular type of point mutation in one locus and a different type of point   134 
mutation in another locus. Secondly, the dependence cannot be reliably computed 
since the mutations between JH1 and JH9 are so rare. 
  
In both priors a  = 1 or 2, we did not consider the phylogeny between N315 and the 
JH lineage because N315 and the JH lineage differ by large regions of non-homology 
(including one replacement > 40,000 nucleotides) and large inserts and deletions 
(including three > 40,000 nucleotides). Thus, the phylogeny between N315 and the JH 
lineage cannot be characterized by a simple prior that assumes a single mutation rate 
and ignores spatial correlations by assuming all differences are due to independent 
point mutations. Because the mutations between JH1 and JH9 are so rare, we could 
not a priori reliably estimate the mutation rate between JH1 and JH9, so we used the 
uninformative prior a  = 1 to predict real ND’s. Once we had a reliable estimate of the 
mutation rate between JH1 and JH9 in the regions of high coverage and good quality, 
we used the phylogenetic prior a  = 2 to estimate the number of mutations in the 
regions of low coverage and poor quality.     
 
3.9.10.6. Conditional probabilities 
 
We computed the conditional probability  JH1 JH9 P( | , ) i X X  of observing in the 
th i  
column the reads given that the correct symbols in JH1 and JH9 are  JH1 X  and  JH9 X  
respectively:  
 
  JH1 JH9 JH1 JH1 JH9 JH9
         ,          ,
over JH1 reads over JH9 reads
P( | , ) E ( | ; ) E ( | , ) .
Y Q Y Q
i X X Y X Q Y X Q
  
   =   
     
Õ Õ  (4.17) 
 
We used the read error probabilities in Eq. 4.14.   135 
 
3.9.10.7. Posterior probabilties 
 
Using Bayes’ theorem, we computed the posterior probability  JH1 JH9 P( , | ; ) X X i a  that 
the correct symbols in the 
th i  column in JH1 and JH9 are  JH1 X  and  JH9 X  respectively  
given the observed reads: 
 
 
{ }
{ }
JH1 JH9 JH1 JH9
JH1 JH9
A,C,G,T,
A,C,G,T,
P( | , )P( , ; )
P( , | ; )
P( | , )P( , ; )
U
V
i X X X X
X X i
i U V U V
a
a
a
Î -
Î -
=
∑
.  (4.18) 
 
We used the prior a  in Eq. 4.15 and the conditional probabilities in Eq. 4.17. We then 
computed the posterior probability P(JH1 N315| ; ) i a ¹  of a real ND in the 
th i  column 
between JH1 and N315: 
 
 
JH1 JH9
JH1 N315
JH1 JH9
      
P(JH1 N315| ; )   P( , | ; ).
X X
X Z
i X X i a a
¹
¹ = ∑ ∑   (4.19) 
 
We also computed the posterior probability P(JH1 JH9| ; ) i a ¹  of a real ND in the 
th i  
column between JH1 and JH9: 
 
 
JH1 JH9
JH9 JH1
JH1 JH9
     
P(JH1 JH9| ; )   P( , | ; ).
X X
X X
i X X i a a
¹
¹ =∑ ∑   (4.20) 
 
3.9.10.8. Identification of real ND’s and informative columns 
 
For ( ) 1 2 , S S  = (N315, JH1) or (JH1, JH9), we compared the two strains  1 S  and  2 S . In 
the absence of prior information, we used the uninformative prior a  = 1 (see Eq. 
4.15). The posterior probability  1 2 P( | ; 1) S S i a ¹ =  of a real ND in the 
th i  column   136 
between  1 S  and  2 S  (see Eq.’s 4.19 and 4.20) must satisfy one and only one of the 
three following conditions: 
 
                     1 2 P( | ; 1) S S i T a ¹ = >                  (case 1, informative, real ND)  (4.21) 
or 
                     1 2 1 P( | ; 1) T S S i T a - £ ¹ = £     (case 2, uninformative, no call)  (4.22) 
or 
                     1 2 P( | ; 1) 1 S S i T a ¹ = < -            (case 3, informative, no real ND)  (4.23) 
where  
  ( )
6 1 1/ 3 10 T = - ´ .  (4.24) 
In case 1, we labeled the 
th i  column informative and predicted a real ND; in case 2, 
we labeled the column uninformative and made no call either way about a real ND; 
and in case 3, we labeled the column informative and ruled out a real ND. The 
threshold  ( )
6 1 1/ 3 10 T = - ´  was selected so that the expected error (both false 
positive and false negative) for calling a real ND is less than one for the entire MACR. 
 
When a real ND was predicted in an informative column, the region containing the 
column in the MACR was always manually examined. The 10-20 columns with 
alignment errors in the MACR were checked (see Section 3.9.9). Anomalous 
predictions due to alignment errors were identified and not reported. It was also 
ensured that no real ND went unreported due to an alignment error.  
 
3.9.10.9. Reported mutations between the JH1 and N315 
chromosomes 
 
In the comparison of JH1 and N315, 97% of the columns in the MACR were    137 
informative, and we reported only the predicted real ND’s in informative columns. 
Runs of real ND’s occurring in regions of non-homology or arising due to large inserts 
and deletions were identified as such. The results are summarized in Figure 3.1(a).  
 
3.9.10.10. Reported mutations between JH1 and JH9 chromosomes 
 
In the JH1 and JH9 comparison, 94% of the columns in the MACR were informative. 
PCR sequencing was done to check all the predicted real ND’s in the informative 
columns. As already stated, all of the predicted real ND’s were confirmed except one. 
In the sole exceptional case, the PCR sequencing method failed, and the result was 
inconclusive. Also, PCR sequencing was done to check the 10 uninformative columns 
with the highest P(JH1 JH9| ; 1) i a ¹ = , that is the 10 uninformative columns most 
likely to contain a real ND. This amounted to checking all uninformative columns 
with a P(JH1 JH9| ; 1) i a ¹ =  ≥ 
4 1 10
- - . In eight of these columns, a real ND was ruled 
out. For one column, the PCR sequencing method failed, and the result was 
inconclusive. In the remaining column, a real ND was found. See Table 3.6 for a 
summary of the P(JH1 JH9| ; 1) i a ¹ =  scores. 
  
Table 3.6. An overview of the P(JH1 JH9| ; 1) i a ¹ =  scores. Here, 
P(JH1 JH9| ; 1) i a ¹ =  is denoted simply by P. 
34 informative columns with a predicted real ND [P > 1 − 1/(3×10
6)] 
·  P ranges from 1−10
−80 to 1−10
−11. 
 
·  PCR sequencing was done to check all columns. All were confirmed to contain a 
real RND except one. In the sole exceptional case, the PCR sequencing method 
failed, and the result was inconclusive.   
Uniformative columns [1/(3×10
6) ≤ P  ≤ 1 − 1/(3×10
6)] 
10 uniformative columns for which P ≥ 1−10
−4     
·  PCR sequencing was done to check all columns. In eight of these columns, a real 
ND was ruled out. For one column, the PCR sequencing method failed, and the 
result was inconclusive. In the remaining column, a real ND was found. 
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Table 3.6 (Continued) 
Remaining 176,994 uniformative columns for which P < 1−10
−4 
·  Shown in bold are the three columns with the highest P’s (i.e. the 3 columns most 
likely to contain a real ND). Also shown are adjacent columns. Differences in the 
two columns with the highest P’s occurred in the same run of five T’s at the end of 
a read. Poly-A and -T sequence at the end of a read is known to be unreliable. 
  
two columns with highest P’s 
A  G  A  G  A  T  C  A  T  T  T  A  T  T  G  − 
A  G  G  G  A  T  C  A  T  T  T  A  T  T  G  − 
A  G  G  G  A  T  C  A  T  T  T  A  T  T  G  − 
A  G  G  G  A  T  C  A  T  T  T  A  T  T  G  G 
A  G  G  G  A  T  C  A  T  T  T  A  T  T  G  − 
JH1 
6X 
coverage 
A  G  G  G  A  T  C  A  T  T  T  A  T  T  G  − 
                                 
JH9 
1X 
coverage 
A  G  G  G  A  T  T  T  T  T  read ended 
now 0X coverage 
              P = 1-
10
−3.9 
P = 1-
10
−3.9                 
 
third column 
T  C  A  A  A  A  G  A  T  T  G  JH1 
2X coverage  T  C  A  A  A  A  G  A  T  T  G 
                       
JH9 
1X coverage  T  C  A  A  A  −  G  A  T  T  T 
            P = 1-10
−3.8           
 
·  90,115 columns have 0X coverage, 64,169 columns have 1X coverage, and the 
remaining 176,994 −90,115−64,169 = 22710 have almost exclusively poor quality 
2X coverage in JH1 or JH9 or both. Thus, there is insufficient read information to 
discriminate between read ND’s and read errors. 
 
·  Of course, the 90,115 columns with 0X coverage in JH1 or JH9 or both all have a 
P = 4/5, corresponding to the a priori probability of a real ND. 
 
·  Only 458 columns have a P > 4/5. The vast majority of the differences in these 
columns are expected to be read errors. Many of the differences occur in 1X. 
coverage in poly-A or –T sequence at the end of a read, which is known to be 
unreliable. A read error rate between 10
−2 and 10
−3 could easily generate in 1X 
coverage on the order of 500 read errors in regions totaling 60,000 bases 
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Table 3.6 (Continued) 
Informative columns for which a real ND was ruled out [P < 1/(3×10
6)] 
·  P ranges from 10
−6.5 to 10
−110 
 
·  Shown in bold is the column with the highest P (i.e. the column most likely to 
contain a real ND). Also shown are adjacent columns. 
 
T  A  A  A  T  G  A  C  A  C  A 
T  A  A  A  T  G  A  C  A  C  A 
T  A  A  A  T  G  A  C  A  C  A 
JH1 
4X coverage 
T  A  A  A  T  G  A  C  A  C  A 
                       
T  A  A  A  T  G  A  C  A  C  A  JH9 
2X coverage  T  A  A  A  T  G  A  C  A  C  A 
            P = 10
−6.5             
 
3.9.10.11. Estimation of number of unreported mutations between 
JH1 and JH9 chromosomes  
 
In the JH1 and JH9 comparison, only point mutations were found in the 94% of the 
informative columns in the MACR. Moreover, the point mutations were observed to 
occur at a rate of 1:100,000 bp. To estimate the number  unreported N  of unreported 
mutations between the JH1 and JH9 chromosomes, we assumed that only point 
mutations occurred in the remaining 6% of uninformative columns, also at a rate of 
1:100,000 bp. We estimated  unreported N  as follows:  
 
  unreported
1
0.06 3,000,000 1.8
100,000
N = ´ ´ = .  (4.25) 
 
However, this estimation assumed that we have no information in the uninformative 
columns as to whether there is or is not a real ND. This is true only in the regions of 
0X coverage. The regions of 1-2X coverage offer some discriminatory power. To 
produce a more rigorous estimate of  unreported N , we chose  JH1,JH9 m  = 1/100,000 in Eq. 
4.16, used the phylogenetic prior a  = 2 in Eq. 4.15, and compute  unreported N  as follows: 
   140 
 
4
unreported
                         
uniformative columns for which 
P(JH1 JH9| ; 1)  1 10
P(JH1 JH9| ; 2)        1.5
i
i
N i
a
a
- ¹ = < -
= ¹ = = ∑   (4.26) 
 
where the sum is over the uninformative columns not checked by PCR sequencing for 
which P(JH1 JH9| ; 1) i a ¹ =  < 
4 1 10
- - . 
 
3.9.11. Transcriptome analysis 
 
We generated a list of putative operons by grouping any two consecutive tandemly 
transcribed ORFs on the N315 chromosome into the same putative operon if the two 
ORFs were separated by less than 50 bp of intergenic sequence. For each list X0 of 
ORF’s in Table 3.7, we generated a new list X50 consisting of the putative operons 
each with at least one ORF in X0.  
 
For n = 0 or 50, we assessed the overlap between the list Xn for a transcription factor 
and the list JH9/JH1n as follows: 
a)  Each locus (ORF when n = 0 and operon when n = 50) in Xn that is positively 
(negatively) regulated by the factor was assigned a +1 (-1), if the mutation in 
JH9 was expected to increase the activity of the factor. Alternatively, each 
locus in Xn that is positively (negatively) regulated by the factor was assigned a 
-1 (+1), if the mutation in JH9 was expected to decrease the activity of the 
factor. 
b)  Each locus in JH9/JH1n that is upregulated (downregulated) in JH9 compared 
to JH1 was assigned a +1 (-1). 
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Table 3.7. Lists of ORFs considered. The activity of the Agr qorum sensing 
system is believed to be growth dependent [20, 22]. Therefore, it is important 
to note that the lists JH9/JH10 and ARLR0 were both determined in mid-
exponential phase and that AGR0 and TRAP0 were both determined in post-
exponential phase.   
Name of list  Description  Ref. for 
data set 
Expected affect of mutation in 
JH9 on transcriptional regulator 
ALL0  all 2588 ORFs on N315 chromosome  [73]   
JH9/JH10 
224 ORFs found to be upregulated or 
downregulated by ≥ 2-fold in JH9 
compared to JH1 (determined in mid-
exponential phase) 
[11]   
VRAR0  46 ORFs identified to be induced directly 
or indirectly by VraR 
[15] 
Expectation. There is a 
nonsynonymous substitution in 
SA1702, which is in the vraSR 
operon [14]. It increases the 
activity of VraR. Reason. In 
JH9/JH10, the genes vraSR are 
over-expressed in JH9 compared to 
JH1. 
AGR0 
138 ORFs identified to be positively or 
negatively regulated directly or indirectly 
by the Agr qorum sensing system 
(determined in post-exponential phase) 
[19] 
Expectation. Frameshift in agrC 
decreases activity of Agr. Reason. 
Loss of Agr function. See [22]. 
TRAP0 
78 ORFs identified to be positively or 
negatively regulated directly or indirectly 
by TRAP, a positive regulator of the agr 
locus (determined in post-exponential 
phase) 
[20] 
Expectation. Frameshift in agrC 
decreases activity of TRAP. 
Reason. Loss of Agr function. See 
[20, 22]. 
ARLR0 
114 ORFs identified to be positively or 
negatively regulated directly or indirectly 
by ArlR, a positive regulator of the agr 
locus (determined in mid-exponential 
phase) 
[21] 
Expectation. Frameshift in agrC 
decreases activity of ArlR. Reason. 
Loss of Agr function. See [21, 22]. 
AGR_ALL0  list of 244 ORFs produced by the union of 
AGR0 + TRAP0 + ARLR0 
  See entries for AGR0, TRAP0, and 
ARLR0. 
YYCF0  32 ORFs predicted to be directly regulated 
by YycF  [38] 
Expectation. Truncation of yycH 
increases activity of YycF. Reason. 
Deletion of yycH has been shown 
to lead to increase in YycF-
dependent gene expression [58]. 
 
c)  We determined the overlap between Xn and JH9/JH1n, defined as the number N 
of loci that not only appear in both Xn and JH9/JH1n but are assigned 1’s with 
the same sign in the two lists. 
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Table 3.8. The P-score of the overlap of 
Xn with JH9/JH1n. The highlighted P-scores 
are those reported in the main paper. 
List  P-score  List  P-score 
VRAR0  10
−13  VRAR50  10
−11 
AGR0  10
−0.7  AGR50  10
−0.5 
TRAP0  10
−4  TRAP50  10
−4 
ARLR0  10
−3  ARLR50  10
−2 
AGR_ALL0  10
−3  AGR_ALL50  10
−2 
YYCF0  10
−2  YYCF50  10
−2 
 
d)  Under a null model that assumed the two lists Xn and JH9/JH1n were picked 
independently, we computed the expected overlap m  of the two lists: 
 
 
n
JH9/JH1 1
ALL 2
n
n X m =   (4.27) 
 
  where  i  denotes the size of the list. 
e)  Assuming Poisson statistics, a P-score P for the observed overlap N was 
computed: 
 
 
e
!
k
k N
P
k
mm
-
³
=∑ .  (4.28) 
 
The P-scores are summarized in Table 3.8. 
 
The P-scores for the lists of lists of ORFs were considered less reliable than for the 
putative operons. When regarding ORFs as independent, there is a danger of over-
estimating the significance of overlap when a large operon consisting of many ORFs 
happens to make it into both lists. Note that the lists for Agr do not have good P-scores   143 
even though the lists for Trap and AlrR do. This may have to do with the fact that the 
lists for Agr were determined in post-exponential phase whereas the transcriptome 
profile of JH9 versus JH1 was determined in mid-exponential phase.   
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